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A B S T R A C T
The European Cooperation in Science and Technology (COST) provides an ideal framework to establish multi-
disciplinary research networks. COST Action BM1203 (EU-ROS) represents a consortium of researchers from
different disciplines who are dedicated to providing new insights and tools for better understanding redox
biology and medicine and, in the long run, to finding new therapeutic strategies to target dysregulated redox
processes in various diseases. This report highlights the major achievements of EU-ROS as well as research
updates and new perspectives arising from its members. The EU-ROS consortium comprised more than 140
active members who worked together for four years on the topics briefly described below. The formation of
reactive oxygen and nitrogen species (RONS) is an established hallmark of our aerobic environment and
metabolism but RONS also act as messengers via redox regulation of essential cellular processes. The fact that
many diseases have been found to be associated with oxidative stress established the theory of oxidative stress as
a trigger of diseases that can be corrected by antioxidant therapy. However, while experimental studies support
this thesis, clinical studies still generate controversial results, due to complex pathophysiology of oxidative stress
in humans. For future improvement of antioxidant therapy and better understanding of redox-associated disease
progression detailed knowledge on the sources and targets of RONS formation and discrimination of their
detrimental or beneficial roles is required. In order to advance this important area of biology and medicine,
highly synergistic approaches combining a variety of diverse and contrasting disciplines are needed.
1. Introduction
Andreas Daiber and Fabio Di Lisa.
1.1. Mission, structure and major achievements of EU-ROS consortium
The COST Action BM1203 (EU-ROS) is a research consortium of
networking supported by the European Cooperation in Science and
Technology (COST), which is embedded within the Biomedicine and
Molecular Biosciences Domain. It covers areas of basic, preclinical and
clinical research in biology, chemistry, physics and medicine, not only
on mammalian cells but also plants, bacteria and other organisms. The
mission of EU-ROS is to advance the field of redox biology and
oxidative stress research by bringing together multi-disciplinary experts
by organizing scientific meetings and providing funds for the exchange
of researchers between laboratories (for more details see www.eu-ros.
eu or www.cost.eu/COST_Actions/bmbs/Actions/BM1203). During the
active funding period of EU-ROS (2013–2016) we organized ten major
scientific meetings, supported 29 short-term scientific missions for
research visits of postdoctoral fellows and Ph.D students, and co-
organized three scientific symposia at European conferences of the
Society for Free Radical Research Europe (SFRRe). In order to foster the
next generation of redox biology scientists we also supported numerous
early-stage researchers and invited them either to the six training
schools that we (co)organized or to the young investigator sessions at
our meetings. Among the major achievements of EU-ROS are three
major successful grant applications within the European H2020 funding
scheme as well as three major coordinated collections of position
papers, reviews and original articles published by our members
[1–4]. The “small to medium sized enterprises” (SME) participating in
EU-ROS filed three patents with the help of research collaborations
established within our consortium. In order to disseminate the collected
knowledge to a broader audience of non-expert scientists and the public
we also opened a EU-ROS YouTube channel (https://www.youtube.
com/channel/UCXFnyGD4uVFUTcLshvDtxcQ). The present collection
of research updates and perspectives represents the final dissemination
of COST Action BM1203 (EU-ROS).
In order to achieve the scientific objectives, as laid down in the
memorandum of understanding of COST Action BM1203, we defined 6
working groups (WG) with elected leaders, each representing a
taskforce for a specific area of research or organization/management:
WG1 Sources of ROS (Ulla Knaus), WG2 Molecular Mechanisms (Agnes
Görlach), WG3 Drugs & Tools (Tamara Seredenina), WG4 Biomarkers
(Pietro Ghezzi/Paul Winyard), WG5 Imaging (Yves Frappart) and WG6
Technology Transfer & Funding (Vincent Jaquet).
1.2. Redox biology and oxidative stress: the EU-ROS approach
The fact that life requires oxygen, which per se represents a
1 These authors contributed equally and should be considered joint first or senior
authors.
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chemically aggressive molecule [5], bears the risk that biomolecules in
all aerobic living species on earth are targets of oxidative modifications
resulting from uncontrolled formation of reactive oxygen species
(ROS2) and reactive nitrogen species (RNS3). In order to prevent
oxidative damage, all aerobic organisms have developed highly effi-
cient antioxidant strategies during evolution. However, these highly
reactive species may be generated accidentally as a result of altered
metabolism (e.g. during mitochondrial respiration) or can be formed
deliberately (e.g. by professional ROS-producing enzymes at sites of
inflammation). Hence, it is not surprising that most metabolic diseases,
as well as those pathologies associated with low-grade inflammation,
display increased patterns of biomarkers of oxidative stress [6]. It is
well established that cardiovascular [7–9], neurodegenerative [10,11],
metabolic [12,13] and inflammatory diseases [14–16] are associated
with increased oxidative stress (some rare immune diseases are linked
to insufficient ROS formation [17]). Despite the large body of evidence
linking oxidative stress with many common diseases, which is sup-
ported by the significant correlation of redox biomarkers with cardio-
vascular and all-cause mortality [18–20], direct clinical proof is still
lacking that oral therapy with antioxidants, such as vitamin C and E,
helps to prevent the development or progression of these diseases. Most
large-scale antioxidant clinical trials yielded disappointing results
regarding all-cause mortality and in some cases oral antioxidants had
detrimental effects [21–23] and to this date no “antioxidant” is
admitted as a drug for clinical use [24]. More recent reports in
publication channels dedicated to the non-expert or public readership
highlighted the potential risks associated with excessive oral consump-
tion of antioxidants (see online publications by Mustain [25] and Riley
[26]). Antioxidant therapy was also mentioned among “the science
myths that will not die” [27]. In contrast, a large number of small to
intermediate size cohort studies with short-term and parenteral vitamin
C therapy showed highly beneficial effects in various cardiovascular
disease settings, and, for vitamin D, positive reports on oral therapy
exist [9,19,28]. The most likely explanation for the antioxidant
/oxidative stress paradox may be that reactive oxygen and nitrogen
species (RONS) are not only injurious (oxidative stress) but also
modulate important biological functions (redox signaling). Accord-
ingly, chronic, systemic oral therapy with antioxidants will likely
interfere with important ROS-mediated cellular processes, such as
stress adaptation by ischemic preconditioning [19,21,28]. Additional
reasons for the failure of large trials on oral antioxidant therapy might
comprise the pro-oxidant effects of vitamin C and E radicals, reaction
kinetics that are too slow, or lack of effective concentrations at sites of
RONS formation. It is also possible that the patients included in these
trials had already been exposed to drugs with pleiotropic antioxidant
effects (e.g. ACE inhibitors or statins) (all reviewed in [19,21,28]). In
addition, as shown by the EPIC Norfolk study, large antioxidant clinical
trials suffer from suboptimal control of their potential efficacy, such as
not measuring the patients’ plasma levels of antioxidants to verify
compliance [29]. This study also showed that vitamin C concentrations
in the blood inversely correlate with all-cause mortality in healthy
volunteers. The inherent problems of vitamin C and E, that were mostly
used in clinical trials, were also highlighted by Darley-Usmar and
colleagues by a previous review [30]. Moreover, Forman, Davies and
Ursini postulated that the nucleophilic tone and para-hormesis (para-
doxic oxidative activation of intrinsic defence mechanisms such as the
NRF2 pathway) is more important than free radical scavenging proper-
ties of antioxidants for their beneficial effects in vivo [31].
This obvious paradox in antioxidant therapy efficacy warrants
better understanding of the role of RONS in physiology and pathophy-
siology. Our consortium put forward the concept that the failure of the
traditional antioxidants such as vitamin C and E was predictable
considering the above-mentioned limitations, but that excessive forma-
tion of RONS (mostly termed “oxidative stress”) plays a role in disease
development and progression or, at least, leads to stable biomarkers
(e.g. oxidatively modified biomolecules) that can be used for diagnostic
aspects in various diseases (reviewed in full detail in the Forum issue by
EU-ROS members [2]). In brief, we believe that activation of intrinsic
antioxidant processes (e.g. NRF2-dependent pathways), inhibition of
disease-relevant sources of RONS (e.g. isoform-specific NOX inhibitors),
scavenging of disease-triggering RONS by site- and time-specific
antioxidants or even repair of oxidatively inactivated enzymes (the
most prominent examples being sGC activators) represent recently
clinically established or promising future antioxidant strategies. The
main concept of our biomedical approach and working scheme is shown
in Fig. 1.1.
The present overview is an interdisciplinary forum of opinions from
various experts in the field of redox biology and oxidative stress
research participating in EU-ROS. We have separated the present work
into 11 sections since the contributions cover a wide range of scientific
topics (mammals, worms, bacteria, plants) and even the terminology of
RONS varies substantially depending on whether they belong to rather
theoretical and basic science oriented disciplines or biomedical and
clinical research areas. RONS regulate not only hydrogen sulfide (H2S)
but also nitric oxide (•NO) and carbon monoxide (CO), thereby affecting
all major gasotransmitter systems [33,34]. Also the concept of ROS-
induced ROS formation (the crosstalk of different ROS-producing
systems) is highlighted in the subsequent sections [35,36]. These direct
and indirect mechanisms based upon redox modifications or direct
reactions with other messengers (e.g. •NO and H2S) underlie RONS
involvement in receptor-dependent signaling pathways, also due to the
modulation of expression and activity of transcription factors. The
contributions below also highlight how RONS contribute to established
signaling pathways by their redox modulation. The interactions of
RONS with microparticles [37–39], protein aggregates [40,41] and the
gasotransmitter H2S [33,42] represent important examples that illus-
trate how RONS as messengers indirectly influence other signaling
systems. Therefore, far from being merely biological waste products,
RONS represent highly active and tightly regulated signaling molecules.
2. Conceptual and mechanistic aspects of ROS and oxidative stress
Ulla G. Knaus (ulla.knaus@ucd.ie).
2.1. Background and terminology
“ROS is over”, a statement at the ESF-EMBO meeting (Spain 2015)
by Fulvio Ursini, should probably be extended to “Oxidative Stress is
over” (Ulla G. Knaus). There is no doubt that ROS exist and that the
concept of oxidative stress summarizes certain conditions connected to
a variety of diseases. However, the unspecific usage of these blanket
terms, especially during recent years, does not adequately reflect the
diversity of reactive oxygen metabolites being produced, the intricate
regulation of redox signaling and the oxidant-antioxidant balance, or
2 Throughout this report, the term ROS refers almost exclusively to hydrogen peroxide
and superoxide anion radical since both species are involved in redox signaling and are
formed by a number of enzymatic sources. Other ROS include the hydroxyl radical or
singlet oxygen, which however have most likely no specific roles in redox signaling but
rather contribute to unspecific oxidative damage and oxidative stress. A large number of
organic peroxides (e.g. lipid peroxides) are also covered by the term ROS but these species
are only marginally discussed in the present overview. Other ROS such as hypochlorite
are also not in the focus of the present work.
3 Throughout this report, the term RNS refers almost exclusively to peroxynitrite,
peroxynitrous acid and derived free radicals (e.g. hydroxyl radicals and nitrogen dioxide
radicals). Peroxynitrite anion has a high specificity for activated thiols and readily reacts
with carbon dioxide (the latter supports radical reactions). Peroxynitrous acid also has a
high specificity for activated thiols but also reacts with transition metal complexes. RNS
also comprises nitric oxide, which upon reaction with oxygen can form nitrogen dioxide
radicals or nitrosating species such as N2O3 and has a high affinity for transition metal
complexes such as iron(II), all of which contributes to the potent redox signaling
properties of nitric oxide. However, in the context of “oxidation of biomolecules” the
term RNS does not refer to nitric oxide due to its weak reactivity towards biomolecules in
general.
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the causality of oxidative modifications versus detrimental outcome in
biological systems. “ROS” is discussed below in detail, while oxidative
stress is usually defined as an imbalance between production of ROS
and antioxidants and the ensuing pathophysiological consequences of
increased, unspecified ROS. If the term oxidative stress is used retro-
spectively via determination of oxidative modifications of proteins,
lipids or DNA, it might instead be oxidative damage. Direct measure-
ments of oxidative stress often use oxidized glutathione as readout, but
Morgan et al. identified immediate glutathione disulfide removal
pathways and antioxidant backup systems that ensured redox home-
ostasis [43]. In some circumstances oxidative stress is correlated with
the presence or upregulation of an enzyme that can (but might not)
generate superoxide or hydrogen peroxide, or the presence of cell types
that produce these species when activated. However, the outcome in
redox biology will always be dependent on the type of oxygen species
generated over a certain time period at a certain location. One example
is wound healing which requires ROS [44], but may progress to fibrosis
when deregulation of the process occurs [45]. Another example is
hypoxic tissue reconstitution facilitated by the neutrophil oxidative
burst [46] versus neutrophil-mediated tissue injury in other circum-
stances [47]. What happens when the predominant superoxide source is
missing is evident in chronic granulomatous disease (CGD), an inher-
ited immunodeficiency caused by inactivating variants of the NOX2
NADPH oxidase complex. CGD patients present not only with life-
threatening infections, but also with hyperinflammation, and Cybb-/-
(Nox2) knockout mice show an increase in proinflammatory mediators
and tissue damage in disease models [48–50].
As Carsten Berndt and Marcus Conrad note, ROS, a widely used
umbrella term, urgently needs specification. Its use is misleading, as
just some of the molecules encompassed under this term are indeed
reactive species. This is especially true for the non-radical species, and
it is another common misunderstanding that all ROS are radicals.
Unlike the hydroxyl radical (HO•) or the superoxide anion radical (O2•-)
singlet oxygen (1O2) or hydrogen peroxide (H2O2) are not radicals,
which is underlined by the different reactivities (second order rate
constant M−1 s−1) of ROS with a given substrate (methionine) that
range from 2×10−2 (H2O2) to 7x109 (HO•) [51]. Another often
neglected fact is the continuous formation of certain reactive species
by enzymes under physiological conditions. Ero1α, for instance, gen-
erates one H2O2 molecule following each disulfide bridge formed in the
endoplasmic reticulum. Therefore, reactive species cannot be consid-
ered solely a phenomenon of damage and disease. These species formed
under physiological conditions can contribute to diverse cellular
functions. For instance, reversible oxidative posttranscriptional thiol
modifications are important during several processes in cells or even
whole organisms including embryonic development [52,53]. Moreover,
the formation of reactive species at different subcellular sites distin-
guishes between cellular functions, such as stem cell maintenance or
differentiation [54]. Not only posttranslational oxidative modifications,
but also damage by certain types of reactive species can be a trigger for
specific cellular functions: Ferroptosis after lipid peroxidation was
recently shown to specifically impede reprogramming into neurons
[55]. For these reasons, it is impossible to measure “ROS”, to induce
“ROS”, to inhibit “ROS”, or to accumulate “ROS”. Besides scientific
recognition, limited experimental tools are a problem to move research
forward (or back) to the specific investigation of specific species.
Promising in vivo tools are highly sensitive genetically encoded
fluorescence probes [56] and genetic cell and animal models with
targeted deficiencies in professional redox enzymes dealing with a
select subset of distinct reactive species, such as the ferroptosis
regulator glutathione peroxidase 4 [57]. Several research communities
focus or have focused on ROS molecules, e.g. the Oxygen Club of
California, the Society for Free Radical Research (SFRR), and EU-ROS.
Hence, researchers working in the field of redox biology must,
whenever possible, discriminate among the different partially reduced
forms of oxygen being studied as this will allow us to acknowledge their
different chemical features and/or biological functions as well as
ultimately help to provide strong and solid mechanistic data on
important biological processes.
2.2. ROS sources and their activation
There are circumstances where the term “ROS” is unavoidable,
mainly due to our inability to exactly measure the species generated in
a spatiotemporal manner or to correctly identify or discriminate
between species responsible for a certain biological event. Sometimes
a mixture of oxygen metabolites is produced as several sources are
stimulated or interact with each other. Thus, ROS sources should not be
considered isolated enzymatic systems, and biological processes may
involve ROS-induced ROS (Andreas Daiber and Matthias Oelze). There
is increasing evidence that they can crosstalk with each other via
reactive oxygen and nitrogen species signaling [35,58]. The theory of
so-called “kindling radicals” or also the “bonfire” hypothesis is based on
the formation of a few primary ROS that “inflame” a cascade of ROS
RONS 
sources
Beneficial redox signaling Detrimental in specific disease
Should be preserved by redox
drugs
Should be specifically inhibited in 
specific disease
Possible strategies: Repair of proteins, source specific inhibitors, acvators of
endogenous anoxidant systems, inhibion of toxifiers, cell- ,organelle-, or species-
specific direct RONS scavengers
Requires advanced imaging and biomarkers to verify successful therapy
RONS 
targets
Fig. 1.1. The main concept of our biomedical approach and working scheme within the EU-ROS consortium as explained in detail previously [32].
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amplification by stimulating the sources of secondary ROS (Fig. 2.1A).
This was first described for mitochondria [59] and involves several
mitochondrial pores that are required for the release of mitochondrial
ROS such as the mitochondrial permeability transition pore, aquaporins
or the inner membrane anion channel as well as sources of oxidants
(e.g. respiratory complexes, p66shc, monoamine oxidases) [18]. This
crosstalk concept can be extended to almost all kinds of sources of
oxidants. We have described “redox switches” that lead to uncoupling
of endothelial nitric oxide synthase (eNOS), redirecting this enzyme
from nitric oxide to superoxide production and thereby changing the
entire vascular phenotype from a dilated, anti-thrombotic, anti-inflam-
matory state to a constricted, thrombotic and inflammatory state
(Fig. 2.1B) [18,20,60]. Likewise, initially formed “kindling” ROS easily
activate xanthine oxidase by a thiol oxidation-dependent and proteo-
lytic conversion of xanthine dehydrogenase to the oxidase form [60] or
activate NADPH oxidases (NOX), either by redox-sensitive activation of
protein kinase C and translocation of cytosolic subunits (for NOX1 and
NOX2) or by upregulation of all NOX isoforms by redox-sensitive
transcription factors or changes in mRNA stability [60]. The most
important crosstalk between different sources of oxidants was described
for mitochondria and NOX, which was reviewed in full detail by us and
others [18,58]. We have observed this kind of crosstalk in nitroglycerin-
induced endothelial dysfunction and oxidative stress [61], in models of
aging-induced vascular dysfunction and oxidative stress [62], as well as
Fig. 2.1. (A) Crosstalk between different sources of ROS and RNS (mitochondria, NADPH oxidases, xanthine oxidase and NO synthase). Xanthine oxidase (XO) originates from oxidative
stress-mediated conversion of the xanthine dehydrogenase via oxidation of critical thiols in cysteine535/992. NO synthases (mainly eNOS) are uncoupled upon oxidative depletion of
tetrahydrobiopterin (BH4), S-glutathionylation (-SSG) and other redox switches. Mitochondrial superoxide/hydrogen peroxide formation may be triggered by oxidative stress from all
ROS sources (including other damaged/activated mitochondria) via redox-activation of PKC, MAPK, other kinase pathways and potential involvement of redox-sensitive mitochondrial
ATP-sensitive potassium channels (mtKATP) with subsequent p66Shc, monoamine oxidase (MAO), respiratory complex activation or impairment of mitochondrial antioxidant defence.
Mitochondrial superoxide/ hydrogen peroxide is released to the cytosol via mitochondrial pores and channels (e.g. redox-sensitive mitochondrial permeability transition pore (mPTP),
inner membrane anion channel (IMAC) or aquaporins) or by diffusion due to increased mitochondrial permeability under pro-inflammatory conditions. In the cytosol these species (along
with released calcium) cause activation of redox-sensitive protein kinases (PKC) and tyrosine kinases (cSrc) with subsequent activation of NADPH oxidases and amplification of the
cellular oxidative stress. Modified from [35, 64]. With permission of Elsevier. Copyright 2010 & 2015. (B) Redox switches in endothelial nitric oxide synthase (eNOS). X-ray structure of
human eNOS with the ironporphyrin (blue), the substrate L-arginine (green), the P450-forming axial iron-thiolate ligand from a cysteine residue (yellow), the cofactor
tetrahydrobiopterin (BH4) (purple), the zinc-thiolate complex forming cysteines (red, two from each subunit), and the zinc ion (brown). The boxes represent the ‘‘redox switches’’ in
eNOS, such as S-glutathionylation, PKC- and protein tyrosine kinase-2 (PYK-2)–dependent phosphorylation, oxidative BH4 depletion, disruption of the zinc-sulfur cluster, as well as
asymmetric dimethylarginine (ADMA) synthesis/degradation, all of which contribute to the regulation of its enzymatic activity. GSH, glutathione; GSSG, glutathione disulfide. The crystal
structure was rendered from the protein database entry 3NOS (DOI:10.2210/pdb3nos/pdb) using the PyMOL Molecular Graphics System Version 1.2r1 (DeLano Scientific LLC). Adapted
from [60]. With permission of Mary Ann Liebert, Inc. Copyright 2014 .
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in angiotensin-II induced hypertension and immune cell activation
[63]. In conclusion, the redox crosstalk between different sources of
oxidants may explain why multiple publications describe different ROS
sources as the major pathological trigger in a certain disease (e.g. for
the hypertension mitochondrial respiratory chain, NOX1, NOX2, NOX4
and xanthine oxidase) and that pharmacological or genetic blockade of
one of these sources was enough to prevent the adverse phenotype [18].
If this concept can be translated to patients, it may be enough to target
one specific source of ROS to prevent or retard the progression of a
certain disease.
Determination of the ROS source(s) and their interactions is still
challenging. The multitude of potential inputs range from NADPH
oxidases (NOX1-5, DUOX1-2) and the mitochondrial electron chain, to
xanthine oxidase, monoamino oxidase(s), cyclooxygenase(s), lipoxy-
genase(s), lysyl oxidase(s), cytochrome P450, or MICAL family mem-
bers, to name a few. In all of the cases, the oxygen metabolite
superoxide (O2•-) or H2O2 is primarily generated as a by-product of
key enzymatic reactions of a particular enzyme. NADPH oxidases are
the only enzymes solely dedicated to regulate O2- (NOX1-3, 5) and
H2O2 (NOX4, DUOX1-2) production [65]. How certain NADPH oxidases
can internally convert O2•- to H2O2 when using NADPH as the electron
donor for the one-electron reduction of molecular oxygen is still
unresolved. This feature discriminates the signaling input of NOX4
and DUOX1-2 from other family members due to the diffusibility and
longer half-life of H2O2 versus O2•- or secondary reactive metabolites.
2.3. ROS sources in microbiota
O2•-/ H2O2 generation by enzymes and their consequences are
mainly considered in the context of plant or animal hosts. However,
hosts are colonized by an ecological community of commensal,
symbiotic and pathogenic microorganisms, collectively termed micro-
biota. The presence and composition of the microbiota, which includes
bacteria, fungi and viruses and resides in biofluids or on epithelial
surfaces, is critical for health and disease. Bacteria represent the
majority of the human microbiota (1014 bacterial cells) with estimates
of 1000 or more bacterial species. Bacteria-host interactions in redox
biology have been mostly defined by infections, where host defense
relies on NOX2-mediated oxidative destruction of pathogens.
Yet an immediate and close relationship exists between commen-
sals, pathogens and host epithelial surfaces, which is best characterized
in the intestine. In the gut, feedback communication ensues with
bacteria as inducers, targets and producers of ROS (Ulla G. Knaus and
Gratiela G. Pircalabioru). The association of germ-free mice with
microbiota induced the expression of epithelial DUOX2 [66]. Intestinal
pathogens such as C. jejuni, K. pneumoniae, or L. monocytogenes
triggered by a yet unknown mechanism the activation of NOX1 and
DUOX2, resulting in O2•- generation and H2O2 release into the gut
lumen [67,68]. Enteropathogenic E. coli stimulated a NOX1-mediated
pathway that included ASK1, p38 and AFT-2 and culminated in an over
20-fold upregulation of the DUOX2 complex [69]. Others reported that
Lactobacillaceae activate NOX1, thereby promoting intestinal stem cell
proliferation and wound healing responses [70]. While pathogens and
segmented filamentous bacteria can gain access to the epithelium,
lactobacilli usually colonize the further removed, loose mucus layer.
However, any disruption of the barrier including changes in perme-
ability or mucus composition/density will permit the interaction of
commensals with host cells and may result in ROS signaling via NOX
and/or mitochondria. For example, mitochondrial ROS is required for
NLRP3 inflammasome activation by bacteria or bacterial products, and
subsequent IL-1β and IL-18 production [71]. The bacteria-host inter-
action will also initiate release of H2O2 from the mucosal surface.
Uptake of H2O2 by extracellular bacteria alters their transcriptional
program and intrabacterial signaling. Although antioxidant defense
genes will be upregulated, Fenton reaction-associated oxidations will
decrease phosphotyrosine signaling and alter pathogenicity gene reg-
ulation [68,69]. These oxidative modifications reduce the virulence of
extracellular bacteria, which can then be eliminated more efficiently by
the host.
Certain commensals, in particular Lactobacillus and Lactococcus
strains, use endogenous H2O2 production as their own means of
communication. The bacterial enzymes capable of generating H2O2
are largely unknown except for L. acidophilus [72], although the
consequences to host physiology and niche protection have been
reported. The antiinflammatory effects of lactobacilli are multifaceted,
but lactobacilli-mediated killing of pathogens (e.g. S. enterica, E. coli)
has been firmly associated with their H2O2 production [73]. Even some
catalase-negative pathogens use endogenous H2O2 production for intra-
and inter-bacterial signaling. Aerobic growth of Streptococcus pneumo-
niae leads to pyruvate oxidase (SpxB)-mediated H2O2 generation, which
was required for fatty acid metabolism and inhibited replication of
other microorganisms competing for the same environmental niche
[74,75]. In conclusion, bacteria need to be considered as endogenous
sources and exogenous inducers of H2O2, thereby propagating intra-and
interkingdom signaling.
This connection between bacteria and the host has been studied
extensively in the nematode worm Caenorhabditis elegans [76–79], but
as Elizabeth A. Veal and Antonio Miranda-Vizuete comment, C. elegans
can serve as a general model for redox biology and has already provided
significant new insight into the interplay between ROS, ROS signaling
and aging. Notably, genetic studies have failed to show that the ROS-
detoxifying activities of any of C. elegans’ array of ROS-metabolizing
enzymes protects against aging. However, these studies have revealed
specific roles for several of these proteins in redox signaling, protein
homeostasis or regulation of normal physiology. For example, glu-
tathione reductase is essential for cell division during embryonic
development [80], thioredoxin reductase or glutathione reductase
activity for larval development to reduce disulfide bonds of cuticle
components prior to molting [81] and the peroxiredoxin PRDX-2 for
regulation of feeding behavior [82] and normal levels of insulin
secretion [83]. The causative role of ROS-induced damage in animal
aging has also been challenged by the unexpected discovery that
increases in ROS can actually promote C. elegans longevity (for review
see [84]). Nevertheless, stress-activated transcription factors DAF-16
and SKN-1 (orthologous to the mammalian FOXO and NRF2 transcrip-
tion factors), which promote the expression of a range of defenses,
including ROS-detoxifying and phase 2 metabolism enzymes, are vital
for survival under stress conditions, during infection and the extended
lifespan associated with inhibition of a variety of pathways. As the
primary tissue encountering xenobiotics and pathogens that trigger
increases in ROS, intestinal levels of these proteins seem particularly
important for survival under stress conditions. However, studies with
tissue-specific transgenes and RNAi have indicated that cell non-
autonomous signals from neurons and germline cells play an important
part in regulating these stress defenses (for reviews see [85,86]).
Moreover, there is increasing evidence that maintaining C. elegans on
different strains of E. coli can profoundly influence ROS production,
redox signaling, metabolism and longevity [87]. C. elegans transparency
throughout its entire life cycle has enabled the development of a variety
of fluorescent redox-sensitive probes that can be employed to monitor
in vivo changes in redox status. For example, analysis of animals
expressing a genetically encoded peroxide sensor has suggested that
peroxide levels are higher during larval development than in adults but
rise again following the reproductive period [88]. Recent advances in
genome editing tools, NGS approaches to identify mutations obtained
by traditional mutagenesis screens, redox proteomics, including OxIC-
AT, metabolomics, and high throughput techniques for genome-wide
and tissue-specific RNAi-screening and lifespan analyses have all added
to the C. elegans toolbox that enhance the power of C. elegans as a model
to advance the redox biology field. The simplicity, ease of manipula-
tion, microscopic examination, short lifespan and vast range of genetic
and post-genomic tools have established C. elegans as a powerful model
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for providing mechanistic insight into the role of redox changes in
normal physiology and disease.
2.4. Redox regulation via redox modifications of biomolecules and altered
phosphorylation
ROS, in particular H2O2, participate in redox regulation and
signaling responses by modifying proteins, lipids and DNA. An emer-
ging concept is redox control of protein-protein interactions (Andrew R.
Pitt and Corinne M. Spickett). Signal transduction via proteins contain-
ing redox-sensitive cysteine residues is now a well-established concept,
and the list of such proteins is growing rapidly [89]. The cysteine
residues involved are most commonly ones with unusually low pKas,
which therefore exist as thiolates under physiological conditions [90].
The oxidation of these residues to form a disulfide by reaction with a
second, resolving cysteine alters the structure and activity of the
protein. A fundamental requirement of redox regulation in signaling
is that it must be reversible, and thioredoxin is a central enzyme that
mediates the reduction of protein disulfides via formation of an
intermolecular disulfide with the target protein. Covalent and non-
covalent protein-protein interactions are known to be critical in
signaling pathways and are thought to contribute to the commonly
observed pleiotrophic effects of ligands and crosstalk between signaling
pathways [91]. Advances in proteomic technologies have facilitated
studies of the interactomes of an expanding number of proteins. Not
surprisingly, these approaches have also been applied to redox proteins,
and much attention has focused on members of the thioredoxin family.
The covalent interactomes of thioredoxin from Plasmodium falciparum
and tryparedoxin from Trypanosoma cruzi have been reported, driven by
the need to identify novel drug targets for protozoan parasites, and in
Escherichia coli, 268 substrates for Trx were reported from experiments
involving strains engineered to optimize trapping of the covalent
interaction [92]. The human glutathione-S-transferase P interactome
has also been reviewed recently, and includes known key players in
redox sensing such as STAT3 and NRF2 [93]. There are many reports of
interactions of other redox proteins, and in an attempt to bring together
all the available information, an “oxidative status interactome map” has
been created of known interactions of human cellular-level oxidative
status proteins [94]. Although all of these articles report the general
interactions of redox-active proteins, the effect of the redox status of the
individual proteins on their interactome, especially the non-covalent
interactome, has largely been ignored. One study that has addressed
this issue investigated the differential interactome of the tumor
suppressor PTEN in native (reduced) and reversibly oxidized forms,
and reported a number of proteins whose levels changed significantly
depending on the redox state, including Anxa2, Trx and Prdx1 [95].
More studies of this kind would help to understand cell redox
regulation, and would provide an additional dimension to oxidative
status protein mapping.
Oxidative regulation of protein phosphorylation is not only an
important part of efficient and essential signal propagation, but can also
promote a deregulated state when the reversibility of the oxidation is
compromised. This can happen by irreversible overoxidation of cy-
steines or by irreversible oxidative modification of other amino acids
such as methionine or tyrosine. In balanced conditions H2O2 is required
in the endoplasmic reticulum (ER) for oxidative protein folding, while
overproduction of ROS results in ER stress. This two edged sword is
discussed by Andreas Petry and Agnes Görlach using ER-localized
NADPH oxidases as example [96,97]. ER stress activates the unfolded
protein response (UPR) in three main steps (or phases). Activation of
the Protein Kinase RNA-like Endoplasmic Reticulum Kinase (PERK),
which phosphorylates eIF2alpha, results in general inactivation of CAP-
dependent translation, despite some specific exceptions such as the
transcription factor ATF4. Then, ER stress activates the inositol requir-
ing element 1 (IRE1) – which splices the mRNA of XBP1 – and the
transcription factor ATF6. ATF4, ATF6 and XBP1 induce the expression
of genes involved in protein folding and degradation in order to
reestablish proper protein folding and to remove protein debris. In
the later ER stress response, pro-apoptotic proteins are upregulated
such as CHOP in order to activate programmed cell death if the cell
cannot resume physiological function.
ROS act especially on the phosphorylation status of eIF2alpha since
protein phosphatase 1 (PP1), which controls together with GADD34 the
dephosphorylation of eIF2alpha, is redox sensitive. H2O2 is able to
oxidize a cysteine close to the catalytic core in a reversible manner
resulting in the inactivation of PP1. Sources for ROS in ER stress are
Ero1 in the ER or mitochondria, but also NADPH oxidases play a role.
NOX1, NOX4 and p22phox were shown to interact with ER proteins such
as PDI [98], and NADPH oxidase derived ROS were involved in the ER
stress response [99–102]. In response to ER stress due to inhibition of
N-glycosylation, NOX4 associated with GADD34 thereby oxidizing PP1,
extending eIF2alpha phosphorylation and promoting survival of cardi-
omyocytes [101]. However, other reports showed that 7-keto-choles-
terol-induced ER stress in human arterial smooth muscle cells induced
NOX4, resulting either directly in cell death [100] or in increased
autophagy [99], which demonstrated a pro-apoptotic role for NOX4. In
addition, NOX1 and NOX2 can play a pro-apoptotic role in cardiomyo-
cytes [102] and renal cells [103] in response to ER stress. In summary,
ROS derived from NADPH oxidases participate in the ER stress
response. However, the subsequent outcome seems to be dependent
on the cellular context, the stimuli used, the spatial distribution and the
type of ROS. It is important to take these parameters into account when
analyzing the role of ROS in ER stress and other pathophysiological
conditions.
Another enzyme connected to ER stress is neutral sphingomyelinase
(N-SMase). Sphingomyelinases (SMases) are categorized into neutral,
acid and alkaline subtypes and hydrolyze sphingomyelin to ceramide
[104]. Mutay Aslan discusses the accumulating evidence that ceramide
induces oxygen species production via the mitochondrial respiratory
chain [105,106] and stimulates inducible nitric oxide synthase (NOS2)
expression [107]. Indeed, activation of neutral sphingomyelinase (N-
SMase) is reported to be involved in various disease pathologies
connected to “oxidative stress”. Studies have shown that ischemia
reperfusion (IR) injury leads to activation of N-SMase in rat cardiac
myocytes [108] and rat liver [109]. Repletion of glutathione (GSH) via
N-acetylcysteine (NAC) treatment in post-myocardial infarction rat
hearts resulted in inhibition of N-SMase and decreased oxidative stress
resulting in improved left ventricular function [110]. Similarly, inhibi-
tion of N-SMase reduced elevated levels of nitrative and oxidative stress
markers in liver IR injury [111].
Neutral SMase is localized in sphingolipid-rich membrane fractions
[111], establishing the structural basis for its functional interaction
with NOS [112]. Cellular stress responses, which increase N-SMase
activity, also affect NOS2 expression and nitric oxide bioavailability. It
has been reported that ceramide production by N-SMase is a key
mediator in the induction of NOS2. Other studies showed that
exogenous ceramide induces NOS2 expression in rat primary astrocytes
[113] and reported positive modulation of NOS2 gene expression by
SMase and/or ceramide in vascular smooth muscle cells and microglia
[114,115]. Neutral SMase inhibition decreased both NOS2 and nitro-
tyrosine levels in an experimental model of glaucoma [116] and liver IR
injury [109]. In summary, studies reveal that cellular stress responses
significantly increase N-SMase activity and sphingomyelin/ceramide
levels, leading to increased nitrative and oxidative modifications.
Inhibition of N-SMase significantly reduced oxidant and nitrative stress
markers, which emphasizes the need for future studies evaluating
agents blocking N-SMase activity that can facilitate the development
of treatment strategies to alleviate inflammation and oxidative injury.
The close relationship between bacteria and host is evident in
bacterial toxin production that alters redox regulation in the host and in
the response of bacteria to host-derived secondary oxygen metabolites
generated as an innate immune response by post-translationally
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modifying bacterial proteins for protection and survival. Amanda J.
Edson and Kari E. Fladmark discuss how cyanotoxins induce oxidative
modifications in the host. The overabundance of cyanobacteria in
aquatic ecosystems may result in a large increase in the manufacture
and release of cyanotoxins into the aquatic environment, which cause
human health implications through biomagnification [117]. A variety
of cyanotoxins are produced by a wide range of cyanobacteria includ-
ing: microcystins [118,119] (MC), nodularin [120] (NOD), and β-N-
methylamino-L-alanine [121,122] (BMAA). Microcystins and nodularin
are potent inhibitors of Ser/Thr protein phosphatases (PP), specifically
PP1 and PP2A [118,120] through direct interaction at the catalytic site
[123]. Both toxins are cyclic peptides containing several non-proteino-
genic amino acids [118,120]. BMAA has been shown to indirectly target
PP2A by inhibitory phosphorylation mediated through BMAA activa-
tion of the glutamate receptor mGluR5 [124]. However, unlike MC and
NOD, BMAA is a non-proteinogenic amino acid with a high degree of
structural similarity to simple amino acids allowing it to be misincor-
porated into proteins leading to an additional toxic effect [121]. MC,
NOD, and BMAA exposure of cells has been found to promote protein
hyperphosphorylation, increase ROS production, and induce apoptosis
[118,120,121,124].
Phosphorylation of proteins including ROS scavenging enzymes
may be one of the major mechanisms of ROS induction by cyanotoxins.
PP inhibitory action of cyanotoxins will result in broad protein
hyperphosphorylation. In addition to ROS induction through PP
inhibition, BMAA may also increase ROS through a non-glutamatergic
mechanism [122]. H2O2 accumulation occurs within minutes in MC and
NOD-exposed hepatocytes followed by cytoskeletal rearrangement and
apoptosis [119,120]. Ca2+/calmodulin-dependent protein kinase II
(CaMKII) has been shown to be essential in MC- and NOD-induced
apoptosis and acts up-stream of H2O2 accumulation. Inhibition of PP by
toxin exposure prevents the dephosphorylation of CaMKII autopho-
sphorylated on Thr287/286 [123] leading to kinase hyper-activation.
Rather surprisingly, CaMKII seems to be responsible for all observed MC
and NOD-induced phosphorylation supporting its role as a key actor in
cytotoxicity. Toxin-induced H2O2 generation may also amplify CaMKII
activity and thereby also H2O2 generation through specific methionine
oxidation of CaMKII [123]. The role of CaMKII in BMAA-induced
toxicity remains to be elucidated, however CaMKII is shown to bind to
and regulate the directly BMAA targeted mGluR5 receptor [125]. The
converging signaling pathways of BMAA, MC and NOD suggest that co-
existence of these toxins may increase the environmental risk factor to
human health.
2.5. Oxidative stress and adaptation processes
Hypochlorous acid (HOCl) is a strong oxidant produced by activated
neutrophils that kills pathogenic bacteria. Thus, bacteria have to defend
against hypochlorite to maintain the reduced state of their cytoplasm.
Gram-negative bacteria utilize glutathione (GSH) as their major thiol-
redox buffer, but most Gram-positive bacteria do not produce GSH.
Melanie Hillion and Haike Antelmann study redox modifications in
Gram-positive bacteria under oxidative stress. Actinomycetes utilize
mycothiol (MSH; AcCys-GlcN-myoinositol), which functions in protec-
tion against reactive oxygen, nitrogen and electrophilic species, anti-
biotics and heavy metals [126,127]. Firmicutes bacteria, including
Bacillus and Staphylococcus species produce the redox buffer bacillithiol
(BSH; Cys-GlcN-malate). BSH-deficient Staphylococcus aureus isolates
were more sensitive to antibiotics (fosfomycin and rifampicin) and
showed reduced survival in macrophage infection assays [127]. Thus,
BSH biosynthesis genes could be drug targets for the development of
novel antibiotics to treat S. aureus infections. Under conditions of
NaOCl stress, BSH plays an important role in the protection and redox
regulation of proteins by formation of BSH mixed protein disulfides,
termed S-bacillithiolation [127]. In Bacillus subtilis, S-bacillithiolation
controls the activity of the organic hydroperoxide repressor OhrR and
the methionine synthase MetE [127,128]. S-bacillithiolation of the
OhrR repressor leads to derepression of the OhrA peroxiredoxin that
confers NaOCl resistance. S-bacillithiolation of MetE in its Zn-binding
active site leads to methionine auxotrophy under oxidative stress. Two
bacilliredoxins (BrxA and BrxB) with unusual CGC active site motifs
were characterized that function in the reduction of S-bacillithiolated
OhrR and MetE [129]. De-bacillithiolation results in the formation of
bacillithiolated Brx (Brx-SSB) that requires BSH and an uncharacterized
BSSB reductase for recycling. However, the bacilliredoxin pathway is
redundant with the thioredoxin pathway in vivo for reduction of BSH
mixed protein disulfides.
In Corynebacterium glutamicum, about 25 S-mycothiolated proteins
were identified under hypochlorite stress conditions [130]. These
include many metabolic enzymes, such as the methionine synthase
MetE, the glycogen phosphorylase MalP, the myoinositol-1-phosphate
synthase Ino1 and antioxidant enzymes (Tpx, Gpx, MsrA). S-mycothio-
lation of MalP is required for the oxidative stress resistance of C.
glutamicum and could prevent glycogen degradation under NaOCl stress
to save the energy and carbon source. Redox regulation of the thiol
peroxidase Tpx, the MSH peroxidase Mpx and the methionine sulfoxide
reductase MsrA was recently studied. The mycoredoxin (Mrx1) and
thioredoxin (Trx) pathways are both involved in reduction and
regeneration of S-mycothiolated Mpx and MsrA to restore their enzyme
activities for detoxification of peroxides and reduction of methionine
sulfoxides [131,132]. In conclusion, S-bacillithiolation and S-mycothio-
lation are widespread redox modifications in Gram-positive bacteria
that function in redox regulation and thiol-protection under oxidative
stress conditions.
Acclimatization of an organism to stress or so-called precondition-
ing is a modulating response that prevents pathophysiological damage.
In plants, waves of calcium and ROS are generated as response to
abiotic stress, pathogen infection and mechanical injury. These waves
mediate long-distance signaling and systemic cell-to-cell communica-
tion [133]. Khrystyna Semen and Olha Yelisyeyeva propose mitochon-
drial ROS oscillations as a balancing factor in mammalian metabolism.
The development of a hormetic reaction (preconditioning or mild
stress) represents one approach to increase resistance to oxidative
damage and eliminate signs of oxidative stress (OS), which is involved
in multiple pathological processes and aging [134,135]. A hormetic
reaction is triggered by a mild energy deficit, which precludes some
increase in ADP/ATP and NAD+/NADH ratios leading to activation of
redox processes and energy function of mitochondria. As a result,
mobilization of various metabolic pathways, especially PUFA oxidation,
takes place which promotes the flow of succinate into the Krebs cycle,
activation of succinate oxidation and monopolization of the respiratory
chain by succinate dehydrogenase. Such a metabolic state promotes
more diverse shunting of the Krebs cycle with activation of glutamine/
glutamate metabolism, the glyoxalate cycle, peroxisomal oxidation and
accumulation of succinate. At the same time, activation of transaminase
and alcohol dehydrogenase (ALDH2) reactions causes an increased flow
of alpha-ketoglutarate and its more efficient oxidation [30,136,137].
Simultaneous activation of pathways related to these two reciprocal
mitochondrial substrates serves as an important mechanism involved in
the hormetic response. At the cell level that is reflected by the improved
interactions between catabolism and anabolism, while excessive flow of
electrons in the respiratory chain can be controlled by several
mechanisms of “mild uncoupling” including reverse electron transport
from Complex II to Complex I, activation of sirtuins (especially SIRT1)
and uncoupling proteins. The fine-tuned leak of electrons that occurs
with an increase in membrane and ATP potentials is further involved in
production of a certain amount of superoxide, hydrogen peroxide and
nitric oxide [30,60]. Subsequently these reactive oxygen/nitrogen
species function as signaling molecules for multiple pathways, mainly
HIF/NRF2/NF-κB and their crosstalk, rather than promote excessive
oxidative damage to macromolecules.
Mild prooxidant activity accompanying the formation of a hormetic
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response gives rise to the production of metabolic “endogenous”
oxygen, which can be readily used either for oxygenase or oxidase
reactions, maintenance of pO2 and elimination of hypoxia. Under such
circumstances the activity of oxygen dependent enzymes, including
those involved in H2S/NO/CO synthesis, is optimized, which promotes
activation of K+ATP, BK and TRP channels. In fact, more frequent
oscillation of ROS and metabolism dependent O2 promote sustained
efficient function of mitochondria, which in turn leads to prolongation
of free radical reactions (FRR) and membrane lipid peroxidation in the
cell. The oscillatory nature of ROS/O2 and related regulatory substances
is the least studied aspect in free radical biology. In our opinion, the
most important outstanding questions include the mechanisms of
fluctuations of ROS/O2, transcriptional factors and other regulatory
substances derived from oxidative modifications of lipid and proteins,
their pattern and localization in cell compartments. A better under-
standing of these mechanisms will promote therapeutic manipulation of
ROS generation and thus, the dynamic association of respiratory
complexes (supercomplex formation) to maintain optimal energy
function of the mitochondria. Energy produced during FRR may play
a crucial regulatory role to achieve better self-organization of the
metabolism, improved stress resistance and sustained hormetic reac-
tions.
For some diseases, including cardiovascular disease, cancer, or
metabolic and neurological pathologies, the involvement of redox
deregulation is unquestionable. Fernando Antunes and Paula M. Brito
discuss how systems quantitative redox biology may bring us closer to
an in depth understanding of “ROS”, their effects and therapeutic
intervention in disease. Deregulation of reactive oxygen, nitrogen, and
sulfur species (RONSS) affects cellular and organismal well being.
RONSS target selected proteins either by binding to, or oxidizing metal
centers or cysteine residues at the level of specific organs, tissues, cell
types, and cellular organelles. These selected proteins constitute redox
switches. Most of them are controlled by reversible oxidation and are
key players in many signal transduction pathways [138]. The identifi-
cation of hundreds of redox switches by large scale proteomic analysis
[138] has provided new potential therapeutic targets and biomarkers
that are yet to be explored. Thus, a critical mass has been reached to
implement an ambitious translational redox biomedicine program.
Perhaps the most important barrier to the development of such a
program is the complexity of RONSS effects, including biphasic curves
with narrow concentration ranges that often lead to contradictory
conclusions. Such complex behavior is caused by the highly interactive
molecular network formed by redox switches. A promising approach to
deal with this issue is systems quantitative redox biology [139,140] that
integrates the network of redox-regulated pathways and has the
potential to predict the behavior of redox networks when interrogated
with a pharmaceutical drug. This will help identify redox circuits that
are amenable to redox therapeutic interventions without triggering
undesired responses by pathways that share the same redox mediators.
RONSS generation is tightly controlled with respect to kinetics,
concentration and subcellular location [141]; the implications of these
observations are that highly targeted redox therapies, as opposed to
systemic antioxidant interventions, are key for a viable pharmacologi-
cal strategy. Recent advances in nanotechnology have provided new
tools to deliver drugs to specific therapeutic target locations and have
the potential to generate new classes of drugs that contain redox-active
molecules or molecules that modulate the levels of RONSS as active
pharmaceutical ingredients.
2.6. Microparticles and reactive oxygen species
According to Rhian M. Touyz, microparticles, also termed micro-
vesicles, are cell membrane-derived fractions, which are generated
from activated cells that undergo stress or injury [37]. Theoretically all
cell types are able to generate microparticles, which are detectable in
biological fluids. In the circulation the major microparticle subtypes are
derived from platelets, neutrophils, erythrocytes and endothelial cells
and are measured and phenotyped by specific markers and flow
cytometry [37,142]. Microparticles have distinct characteristics: they
are 100–1000 nm in diameter, contain features of their parent cells and
do not contain nuclear material. Microparticles were first considered as
‘plasma dust’ representing cell debris; however, it is now clear that
these elements are biologically functional and that they are signatures
of the cells from which they are derived. Accordingly, microparticles
have been considered as biomarkers of various pathologies
[37,142,143]. Many pathological states including cardiovascular dis-
eases, kidney disease, cancer, diabetes, thrombosis among others are
associated with increased levels of circulating microparticles. In addi-
tion, increasing evidence indicates that microparticles themselves can
contribute to pathophysiological processes, because they contain
proteins, enzymes, nucleic acids, cytoskeletal machinery, specialized
lipids and microRNAs, that can be transferred to other cells, thereby
initiating signaling events and changes in target cell function
[144–146]. Through this mechanism, microparticles also play an
important role in cell-cell communication and cross-talk. As such
microparticles are now considered not only biomarkers of diseases,
but also biovectors. In addition, because microparticles transfer their
‘cargo’, they have been considered as novel delivery systems for
therapeutics [147]. Increased circulating levels of microparticles are
found in conditions associated with oxidative stress, including hyper-
tension, diabetes, kidney disease and cancer. Moreover, many of the
mechanisms underlying the generation of microparticles involve ROS
and many of the effects of microparticles are redox sensitive [148,149].
Formation of microparticles involves lipid oxidation, mitochondrial
activation, caspases, calcium signaling and Rho kinase activation,
processes linked to increased intracellular ROS bioavailability. Micro-
particles can possess the enzymatic machinery responsible for ROS
formation, including NOX subunits and/or nitric oxide synthase (NOS)
and there is growing evidence that microparticles can generate ROS and
nitric oxide (•NO) [148,149]. Microparticles are supposed to transfer
O2•-, H2O2 and •NO to neighboring cells, and they can stimulate
production of ROS in target cells by stimulating cellular oxidases
[150]. These processes can be inhibited by ROS scavengers, NOX
inhibitors, NOS inhibitors and antioxidants. Hence microparticles are
influenced by redox processes and can themselves modulate redox-
sensitive signaling pathways [37,148,149]. While it is clear that
oxidative stress and microparticle formation are closely linked and that
microparticles can act as biovectors influencing cellular redox pro-
cesses, many of the studies were performed under in vitro conditions in
cell-based systems. The pathophysiological significance of these pro-
cesses in vivo awaits further clarification.
2.7. Conclusions
To tackle these questions a multipronged approach is necessary. In
depth understanding of the spatiotemporal role of a particular ROS
source in vivo can only be achieved by scientific endeavors that
combine basic discovery with appropriate animal models. But these
studies depend on the development of improved tools for visualization
and quantification of the oxygen metabolite generated. In addition, a
combination of the expertise of redox biologists, systems biologists,
nanotechnologists and clinical scientists will be required to support the
successful translation of redox biology knowledge into viable pharma-
cological treatments and novel diagnostic biomarkers of diseases, which
will have a major scientific and socio-economic impact.
3. ROS as signaling molecules
Agnes Görlach (goerlach@dhm.mhn.de) and Andreas Petry (petry@
dhm.mhn.de).
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3.1. Introduction
Reactive oxygen species (ROS) in high concentrations have dama-
ging actions, but in lower concentrations they can act as signaling
molecules (Fig. 3.1). ROS generated by the activation of enzymes such
as NOX, xanthine oxidases, uncoupled NO synthases and other sources
such as arachidonic acid metabolizing enzymes, lipoxygenases and
cycloxygenases, the cytochrome P450s, peroxidases and other hemo-
proteins, as well as ROS generated by mitochondria seem to play
various roles in the cellular signaling network under different physio-
logical and pathophysiological conditions. Various cellular antioxidant
systems oppose ROS load thereby limiting not only cellular damage, but
also contributing to ROS-dependent signaling.
3.2. Role of ROS in VEGF and TGF signaling
The dual role of ROS as either damaging or signaling molecules is
well illustrated in the vascular system. For example, as discussed by
María Monsalve and Ignacio Prieto, ROS have been demonstrated to be
central in the control of angiogenesis and are required for the induction
of endothelial cell migration and proliferation. VEGF-A is the most
potent and primary endothelial cell specific angiogenic growth factor
and stimulates vascular permeability, endothelial cell proliferation,
migration and tube formation, primarily through the VEGF-A receptor 2
(VEGFR-2). ROS work both upstream and downstream of VEGF-A.
Exogenous ROS administration induces VEGF-A levels and promotes
endothelial migration and proliferation, which can lead to diabetic
retinopathy, development of vasa vasorum in atherosclerosis and tumor
angiogenesis [151]. ROS-sensitive transcription factors and coactiva-
tors have been identified that can directly regulate VEGF-A mRNA
levels, such as the hypoxia-inducible factors 1α and 2α (HIF-1α, HIF-
2α) [152–154], the transcriptional coactivator peroxisome proliferator
γ coactivator 1α (PGC-1α) [155], but also Ref-1, p53, NF-κB and Ets-1
[156].
ROS have also been shown to regulate VEGFR-2 activity and
signaling [157]. The antioxidant protein peroxiredoxin II (PrxII) has
been found associated with VEGFR-2 and is necessary to prevent its
oxidation. VEGFR-2 oxidation renders the receptor insensitive to VEGF-
A stimulation [158]. Following VEGFR-2 stimulation and tyrosine
phosphorylation, the receptor can be dephosphorylated by several
phosphatases such as protein tyrosine phosphatases (PTPs) and den-
sity-enhanced phosphatase-1(DEP-1)/CD148 which can be inactivated
by ROS [159,160]. Downstream of VEGFR-2, several signaling nodes
have also been shown to be ROS sensitive such as PI3K/AKT [161].
Importantly, VEGFR-2 activation can induce ROS production by
endothelial cells (EC), and abrogation of VEGFR-2-dependent induction
of ROS levels abolishes VEGF-A effects on EC migration and prolifera-
tion. It has been amply demonstrated that VEGF-A stimulates ROS
production through the activation of NOX enzymes in EC [156]. VEGF-
A/VEGFR2-dependent activation of NOX1 has been related to increased
angiogenic tube formation of EC [162]. NOX2 knockout mice display
impaired neovascularization in hind limb ischemia and their ECs have
much reduced VEGF-A induced proliferation and migration [163,164].
In addition, NOX4 siRNA inhibited VEGF-induced EC migration and
proliferation [165]. Upon VEGF-A-stimulated receptor phosphoryla-
tion, TSAd-dependent Src activation recruits the scaffold protein IQG-
AP1 that promotes the recruitment of Rac1 and NOX2 to initiate ROS
production [166,167]. Furthermore, inhibition of mitochondrial ROS
production was sufficient to abrogate VEGF-A and EC migration
independent of NOX enzymes [168]. One possible mechanism could
be inactivation and transcriptional downregulation of PGC-1α follow-
ing PI3K/AKT activation in response to growth factor stimulation that
results in the enhanced production of mitochondrial ROS required to
promote endothelial cell migration [169]. Furthermore, several lines of
evidence suggest that NOX enzymes can function downstream of
mitochondria. Hence, depletion of mtDNA reduces NOX activity, while
induction of mitochondrial dysfunction increases mitochondrial ROS
production resulting in the activation of NOX enzymes [58]. Enhanced
mitochondrial ROS production was sufficient to recapitulate most if not
all the features of diabetic retinopathy, and the underlying mechanism
involved was associated with ROS-dependent constitutive activation of
VEGFR-2, and reduced sensitivity to VEGF-A stimulation. Importantly,
both a mitochondrial targeted antioxidant and a general NOX inhibitor
effectively normalized VEGF-A signaling and endothelial tube forma-
tion, indicating that both NOX and mitochondrial ROS are functionally
co-regulated in this context [170,171].
Other factors that have been identified as potent inducers of ROS
belong to the TGF-β family. These cytokines play essential roles in the
maintenance of tissue homeostasis, regulation of cell growth, migration
and invasion, extracellular matrix remodeling and immune suppression
[172]. As Isabel Fabregat points out, deregulation of TGF-β signaling is
frequently observed in disease states, such as fibrosis, inflammation and
cancer, being considered responsible for part of the sequence of events
leading to the end-stage of these diseases [173]. Initial studies in the
middle of the 1990s indicated that TGF-β mediates ROS production
[174,175] and a NOX activity was suggested to be responsible for the
release of H2O2 [174,176]. Nowadays, NOXs are considered as relevant
mediators of TGF-β actions in different cells, contributing to the
regulation of growth, death and activation of myofibroblasts, key
executers of the fibrotic process. Although different NOXs have been
proposed to be modulated by TGF-β, NOX1 and NOX4 appear to be the
NOXs most frequently involved in its actions. Under physiological
circumstances, NOX4 is transcriptionally upregulated by TGF-β in a
Smad-3-dependent manner and is considered a mediator of TGF-β-
mediated suppressor effects. In particular, NOX4 is required for TGF-β-
induced apoptosis in epithelial cells [177,178]. In contrast, NOX1,
activated by TGF-β in a caveolin-1-dependent manner, plays opposite
roles, stimulating anti-apoptotic signals and preventing cell death
[179]. Deciphering the specific roles of NOX1 and NOX4 in TGF-β
actions during tumorigenesis will require further investigations, but
current data indicate that overactivation of growth factor signals favor
activation of NOX1 and inhibit NOX4 up-regulation, which would
prevent cell death [180]. Once cells overcome apoptosis, NOX4 might
Fig. 3.1. Summary scheme of ROS acting as signaling molecules in different disease
settings but also in physiological processes.
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promote pro-tumorigenic actions of TGF-β, such as epithelial-mesench-
ymal transitions (EMT), that induce cell migration and invasion [181].
Strong evidence supports a role of NOX4 in mediating TGF-β-induced
myofibroblast activation in different models of fibrosis [182,183], as
well as in the maintenance of the phenotype of myofibroblasts [184].
NOX4 also mediates TGF-β-induced apoptosis in epithelial cells
[178,184], which contributes to the inflammatory process that concurs
with increased activation of myofibroblasts and extracellular matrix
deposits. These studies provide proof of concept for therapeutic
targeting of NOX4 to inhibit TGF-β-induced fibrogenesis. However,
further research is required to validate the safety of these inhibitors, at
least in those tissues where TGF-β acts as a tumor suppressor factor. In
this sense, recent results indicate that knockdown of NOX4 increases
proliferation and tumorigenic properties of liver tumor cells [185].
3.3. Redox regulation of fundamental cellular processes such as cell death
In a more general way, the dual role of ROS has been associated
with different cancer types. As Guia Carrara and Geoffrey L. Smith
explain, elevated levels of ROS have been a well established property of
most cancers where they contribute to many aspects of tumor devel-
opment and progression, including cell proliferation, genomic instabil-
ity, resistance to apoptosis, cell adhesion and motility, and a metabolic
shift to glycolysis [186,187]. On the other hand, excess ROS is
deleterious to the survival and proliferation of cancer cells. Hence,
endogenous antioxidants are also upregulated to detoxify the cell and
maintain a delicate balance of elevated intracellular ROS that is
beneficial to malignant cells [186,187]. Recently, the Transmembrane
Bax Inhibitor-1 Motif-containing (TMBIM) protein family has received
increasing attention in relation to its role in cancer, which is supported,
for instance, by dysregulation of expression being associated with many
cancer types and by the characterization of its multiple functions that
constitute important hallmarks of malignancy [188]. The Golgi anti-
apoptotic protein (GAAP) is a member of the TMBIM family and is
projected by phylogenetic analyses to have originated before the
divergence of plants and protozoa about 2000 million years ago
[189]. Orthologues of the human GAAP are remarkably conserved at
the protein level (e.g. amino acid sequence, length and hydrophobicity
profile) throughout eukaryotes, prokaryotes and some poxviruses, in
agreement with a highly conserved ancestral structure and function
[190–192]. Since the first discovery of this gene in 2002 in camelpox
virus [193], several cellular functions and structural properties of
GAAPs from various origins have been described. Within eukaryotes,
GAAPs regulate Ca2+ levels and fluxes from the principal intracellular
stores (Golgi and ER), confer resistance to a broad range of apoptotic
stimuli and promote cell adhesion and migration via the activation of
store-operated Ca2+ entry (SOCE) [193-195]. Importantly, these multi-
transmembrane proteins were shown recently to form cation-selective
ion channels, potentially forming the basis for the modulation of the
diverse functions of GAAPs [191]. In view of these functions as
important hallmarks of cancer, the effects of human GAAP on ROS
homeostasis in the context of cancerous cells were investigated.
Significantly greater overall basal ROS levels, and more specifically
basal H2O2, were detected intracellularly in cells over-expressing
GAAP. In addition, cells over-expressing GAAP displayed greater
invasive capabilities in tissue culture, which was confirmed by the
opposite effect upon GAAP knock down by siRNA. Furthermore, the
activity of secreted matrix metalloproteinases 2 and 9, which are
sensitive to regulation by ROS and play a key role in migration and
invasion, was dysregulated in these cells. Although both the mechan-
istic links between these observations and the contribution of Ca2+
remain to be established, ROS appear to be a common factor of
importance and relevance in understanding the contribution of GAAP
in cancer development. Furthermore, the diverse multifunctional
properties of GAAP provide a useful common starting point from which
the complex interplay between ROS homeostasis with other important
hallmarks of cancer such as cell invasion, migration, and resistance to
apoptosis can be studied.
Other cellular structures with a putative relation to ROS are
centrosomes. Centrosomes are the microtubule organizing centers
(MTOCs) that nucleate and organize microtubules. They have critical
roles in various processes, including cell division and polarity. Over 100
years ago, it was claimed that centrosome aberrations may lead to
genomic instability and consequently to cancer [196]. As Lokman
Varisli and Serap Ilikay summarize, it was reported that genetic
manipulations that lead to centrosome amplification can cause tumor
development [197]. Consistently, centrosome abnormalities have been
observed in many human cancers and in premalignant lesions [198].
Increased centrosome numbers can arise from various mechanisms,
such as centrosome overduplication, cell fusions or failures during
cytokinesis [199]. However, the causes and mechanisms leading to
these effects are not fully understood. In recent years, it was suggested
that ROS may be involved in the regulation of centrosome organization.
Indeed, various researchers reported that oxidative stress may lead to
increases in the number of centrosomes. However, there are contra-
dicting reports in this area. While some researchers reported that
oxidative stress can trigger hyperamplification of centrosomes and
consequently may promote progression of cancer [200], others sug-
gested that centrosomal abnormalities may contribute to the entry of
the cells into senescence, thus preventing proliferation of damaged
cells. Consequently, centrosome abnormalities are a part of the defense
mechanism that inhibits carcinogenesis [201,202]. On the other hand,
it is known that centrosomes are shielded from oxidative stress through
their association with peroxiredoxin I (PRX1) during interphase, while
this enzyme is inhibited by cyclin-dependent kinase 1 (Cdk1) in mitosis
[203]. Moreover, it was reported that the local concentration of H2O2
around centrosomes is involved in the regulation of centrosomal levels
of some cell/centrosome cycle related proteins and also in the regula-
tion of mitotic entry [203]. In concordance, it was shown that reduction
of peri-centrosomal H2O2 by centrosome-targeted catalase inhibits entry
of cells into mitosis [203]. Consistently, treatment of mitotic cells with
H2O2 causes mitotic slippage and consequently formation of hyperte-
traploid cells [204]. Although the mechanisms of H2O2 induced mitotic
slippage have not been entirely elucidated, this effect is probably
related to exposure of naked centrosomes to H2O2 without a Prx1 (and
probably other antioxidants) shield during mitosis.
3.4. Redox regulation involving mitochondria
In mitochondria, the thiol redox conditions are essentially con-
trolled by glutathione and thioredoxin systems. In the latter, a reducing
sequence starting with NADPH allows the transfer of electrons to
thioredoxin in a process mediated by the mitochondrial selenoenzymes
thioredoxin reductases (TrxR2). NADPH is maintained in a reduced
form by specific dehydrogenases and by the membrane-bound transhy-
drogenase. Alberto Bindoli and Maria Pia Rigobello discuss, that TrxR2
is able to reduce, in addition to its specific substrate thioredoxin (Trx2),
a large number of different molecules. Thioredoxin is a key component
of the thioredoxin system acting as a wide-ranging protein-disulfide
reductase and therefore controlling the redox state of different factors
[205]. In particular, Trx2 reduces Prx3, which therefore controls the
levels of H2O2. The mitochondrial isoform of cyclophilin (CypD) plays a
relevant role in regulating the mitochondrial permeability transition
pore [206] and is endowed with redox properties due to the presence of
specific cysteine residues [207]. In isolated rat heart mitochondria, the
inhibition of TrxR2 with the gold compound auranofin leads to a
concomitant oxidation of Trx2, Prx3 and CypD as demonstrated by the
redox Western blot technique [208]. Similarly, CEM-R cancer cells
incubated with auranofin or other inhibitors of thioredoxin reductase
such as ATO (arsenic trioxide) and CNDB (1-chloro-2,4-dinitrobenzene)
show also a concurrent oxidation of Trx2, Prx3 and CypD. Both in
mitochondria and cancer cells, the addition of H2O2 leads to an
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oxidation pattern similar to that observed after treatment with inhibi-
tors of TrxR2 [208]. In addition, CypD co-immunoprecipitates with
both Trx2 and Prx3 [208] indicating a potential cooperation involving
these proteins. These results indicate that CypD can act as a redox
protein able to modulate the mitochondrial functions such as mem-
brane permeability and that the redox conditions of CypD may be
controlled by the thioredoxin system. Of note, Prx3 can act as a sensor
of hydrogen peroxide and transduce this oxidation to CypD. This view is
further supported by a molecular modeling approach showing a
potential interaction of CypD both with Trx2 and Prx3 [208].
As Carlos M. Palmeira and Anabela P. Rolo point out, mitochondria
play also an essential role in energy production and cellular home-
ostasis. Their highly dynamic nature, based on alterations in biogenesis,
mitophagy, fusion and fission, allows adjustment of the sequential
oxidoreductive reactions in the electron transport chain (ETC) and
dissipation of the membrane potential by ATP synthase in response to
different environmental cues [209]. Such adaptive processes may
involve signaling by ROS and explain how mild levels of mitochon-
drial-derived ROS trigger a hormetic response resulting in extended
lifespan. As ROS are an inevitable by-product of oxidative phosphor-
ylation, alterations in the mitochondrial oxidative rate with a conse-
quent excessive load of ROS, have been traditionally associated with
pathological processes such as cancer, diabetes and neurodegeneration.
Although in mammals the exact signal released by mitochondria that
triggers a hormetic response is still uncertain, more and more studies
are addressing ROS as promoters of mitohormesis, as opposed to their
pro-aging action due to persistently induced oxidative damage. The
concept of mitohormesis proposes that a mild increase in mitochondrial
ROS may act as a sublethal trigger of cytoprotective long-lasting
metabolic and biochemical changes against larger subsequent stresses
[210]. Caloric restriction (CR) has been repeatedly shown to decrease
risk- actors for major age-related diseases and to increase lifespan in
various organisms. Early on, work in C. elegans [211] has shown that
reduced glucose availability was linked to an increase in both ROS and
catalase activity, ultimately culminating in increased survival rates.
Several other studies have further demonstrated that many strategies
promoting longevity share a common downstream aspect, that is:
increased mitochondrial ROS. Inhibition of the mitochondrial ETC by
certain mutations or inactivation of mitochondrial superoxide dismu-
tase increases C. elegans lifespan, as reviewed by Dancy et al. [212].
Low doses of rotenone, an inhibitor of complex I, have also been shown
to extend the lifespan of C. elegans [212] as well as to induce hormesis
in primary human fibroblasts, an effect not possible in older cells or
with higher concentrations of rotenone [213]. Inhibition of mTORC
signaling and the consequent induction of autophagy by caloric
restriction or by pharmacological agents has also been found to
promote longevity in yeast, worms, flies and mice, as recently reviewed
[214]. Further, it has been shown that hearts with impaired mitophagy
and consequent accumulation of damaged ROS-forming mitochondria
develop cardiomyopathy, which can be surprisingly improved by the
ROS-dependent activation of compensatory autophagic pathways of
mitochondrial quality control, preventing a vicious cycle of ROS
formation and mitochondrial dysfunction [215].
3.5. Role of ROS in hypoxia
When oxygen availability is reduced (hypoxia), eukaryotic cells
sense this reduction and trigger a series of cellular and systemic
responses that facilitate adaptation to hypoxia, including the optimiza-
tion of oxygen consumption. As Pablo Hernansanz-Agustín and Antonio
Martínez-Ruiz explain, some of these responses are mediated through
transcriptional regulation by the stabilization of hypoxia-inducible
factors (HIFs); however, this mechanism requires at least several hours
for activation, and there is crosstalk with ROS signaling (for a recent
review, see [216]). Several acute responses operate in minutes in
specialized organs in which local temporal changes in the redox state
have been implied. One example is the carotid body, which senses
variations in blood oxygen to activate the respiratory center. The search
for the molecular mechanisms of oxygen sensing in carotid body cells
has recently led Fernández-Agüera et al. to propose a fundamental role
for mitochondrial complex I in the production of a ROS signal in
response to hypoxia [217]. For a long time there has been a debate on
whether hypoxia increases or decreases ROS production, with appar-
ently contradictory reports in the literature. This controversy might
arise from the ROS source studied, from the cell type, tissue or organism
examined, from the techniques used to measure different ROS, and/or
from the duration of hypoxia applied in each study. It has recently been
shown that several cell types respond to acute hypoxia with a transient
increase in superoxide production at the beginning of hypoxia, which
has been called a superoxide burst in acute hypoxia [218]. This may
explain in part the apparently divergent results found by different
groups that have not taken into account the time frame of acute hypoxic
ROS production. Molecular mechanisms in acute hypoxia might involve
mitochondrial complex I and the mitochondrial sodium/calcium ex-
changer (NCLX) (Hernansanz-Agustín et al., manuscript under evalua-
tion). Superoxide production in acute hypoxia seems to be a common
mechanism for different cell types, but it would elicit different
responses in specialized cells and tissues where the adequate compo-
nents for signal transduction may be present such as cysteine residues
sensitive to reversible oxidation. Examples of this are the carotid body
cells where localized ROS production inhibits K+ channels [217,219];
or the pulmonary arteries where mitochondrial ROS production may
elicit a signal cascade including ceramide production, further ROS
production by NADPH oxidases and alterations in ion channel activity
[220]. In endothelial cells, by using specialized thiol redox proteomics
methods, the reversible oxidation of a range of protein cysteine residues
has been observed that could mediate acute responses to hypoxia in
these cells [221]. Another molecular example of a hypoxia signal
transducer is the Na+,K+ ATPase, with cysteine residues that are
sensitive to variations in the oxygen concentration, and that alter the
function of the protein (recently reviewed in [222]). In conclusion, ROS
production is being increasingly considered as a key signaling event in
acute hypoxia, and the molecular mechanisms and functional conse-
quences of this event are currently an active field of research, with
implications for molecular physiology and pathology.
An enzyme family that requires oxygen for function, and is thus
related to oxygen availability, are •NO synthases. As Damir Kračun and
Agnes Görlach discuss, all three family members, endothelial NOS
(eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS), catalyze the
reaction of •NO production by binding a number of cofactors such as
flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN),
heme, 5,6,7,8-tetrahydrobiopterin (BH4) and calmodulin to convert L-
arginine and O2 to L-citrulline and •NO.
The flow of electrons within NOS is tightly regulated. If disturbed,
the chemical reduction of oxygen and the generation of •NO are
uncoupled and O2•- is generated from the oxygenase domain. In
particular, failure of adequate provision of the cofactor BH4 shifts
electrons to molecular oxygen rather than to L-arginine, thus transform-
ing NOS into a pro-oxidant superoxide anion-generating enzyme [223].
Conditions of low oxygen availability have differential effects on
•NO levels: decreased, increased and unchanged levels were reported. In
some cases, the differences might have been due to different detection
methods. Moreover, in several cases, NOS expression levels did not
match the •NO levels measured. While several reports showed that NOS
expression increased under hypoxia, there was no concomitant increase
in •NO levels [224]; recent data indicate that hypoxia leads to
uncoupling of NOS, which might explain this observation [225].
Mechanistically, a decrease in BH4 levels observed under hypoxia in
vitro and in vivo has been related to this effect. BH4 levels in the
endothelium are controlled through de novo BH4 synthesis by GTP
cyclohydrolase I (GTPCH-1), loss of BH4 by oxidation to 7,8-dihydro-
biopterin (BH2), and regeneration of BH4 from BH2 by dihydrofolate
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reductase (DHFR) [226]. While GTPCH-1 downregulation under hy-
poxia was not clearly demonstrated, recent data show that hypoxia can
decrease the levels of DHFR, thus diminishing the capacity to recycle
BH2 to BH4 [225]. In support of this finding, treatment with folic acid
(FA), which has been shown to upregulate DHFR levels under normoxic
conditions [227], restored DHFR, BH4, and •NO levels in hypoxic cells
[225]. Decreased levels of BH4 and DHFR together with diminished •NO
bioavailability were also observed in vivo in mice suffering from
chronic hypoxia-induced pulmonary hypertension. While treatment
with the biopterin precursor sepiapterin, which needs to be converted
to BH4 by DHFR, only marginally affected this disease [228], treatment
with FA not only enhanced •NO and BH4 bioavailability but also
diminished pulmonary hypertension [225]. Since a decline in DHFR
has also been reported to promote angiotensin-II induced hypertension
[227], preservation of DHFR levels appears to be an important
mechanism to combat uncoupling of NOS and its associated patholo-
gies.
3.6. Redox regulation of gene expression via modulation of transcription
factors and epigenetic pathways
Conditions of low oxygen are also favorable for stem cell main-
tenance. As Holger Steinbrenner and Lars-Oliver Klotz point out, adult
mammals harbor multipotent somatic stem cells that are capable of
replenishing terminally differentiated functional cells for maintenance
and regeneration of tissues as well as for adaptation to metabolic
demands. Examples include hematopoietic stem cells (HSCs) located in
bone marrow, epithelial stem cells in intestinal crypts, and mesench-
ymal stem cells in adipose tissue and bone marrow. Somatic stem cells
in adults are often quiescent but they may temporarily re-enter the cell
cycle and proliferate rapidly in response to the appropriate signals. In
recent years, it has become increasingly evident that even slight
variations in intra- and extracellular levels of ROS may exert a profound
impact on the fate and function of stem cells [229,230]. ROS serve as
signaling molecules that affect the balance between self-renewal and
differentiation of stem cells, their commitment, differentiation and
maturation to specialized cell types, and their survival and aging. ROS
involved in these processes, such as superoxide and hydrogen peroxide
(H2O2), derive for the most part from the mitochondrial respiratory
chain and from membrane-bound NADPH oxidases [229,230]. Tran-
scription factors of the forkhead box, class O (FoxO) family participate
in regulating and fine-tuning ROS-modulated cellular differentiation
processes, as illustrated by the following examples. FoxOs stimulate the
biosynthesis of ROS-reducing proteins located in mitochondria [super-
oxide dismutase 2 (SOD2), peroxiredoxins 3 and 5], in peroxisomes
(catalase), and extracellularly [selenoprotein P (SelP)] [231]. Elevated
Fig. 3.2. (A) Reactive oxygen species can display their regulatory effect on the classical gene regulatory machinery and on epigenetic processes. One of the prominent pathways attributed
to oxidative stress is thiol oxidation, which is involved in OxyR, NF-κB and KEAP1 signaling. Oxygen sensing prolyl hydroxylases represent another class of redox-dependent enzymes. For
example, epigenetic involvement of ROS has been attributed to oxidative conversion of 5-mC to 5-hmC. (B) ROS impact on mRNA stability at the cytosolic level. Reactive oxygen species
are involved in GAPDH signaling by directly altering its structure with the help of GSH or S-nitrosoglutathione (GSNO), and thus activate translation of endothelin-1 (ET-1) mRNA (i). AP-
1 thiol redox regulation directly affects the gene regulating factor HuR by stability of its target mRNAs (ii). ROS have been implicated in the regulation of miRNA pathways, altering
mRNA stability and their transport inside the cytosol. HRE means hormone response element. With permission of Elsevier and the authors. Copyright 2015.
Adapted from [238].
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circulating levels of SelP may then result, by means of its function as a
plasma selenium transporter, in increased biosynthesis and cellular
activity of antioxidant and redox state-modulating selenoenzymes such
as glutathione peroxidases and thioredoxin reductases [231]. Thus,
FoxOs are crucial for cellular stress resistance and longevity. Tightly
controlled increases in FoxO expression and activity may balance ROS
generation in differentiating cells through an adaptive up-regulation of
antioxidant enzymes, which has been well documented for adipogen-
esis; committed mesenchymal stem cells (preadipocytes) of the sub-
cutaneous adipose tissue may undergo clonal expansion in response to
high nutrient intake. This is followed by growth arrest and terminal
differentiation into mature lipid-accumulating adipocytes. Adipogenic
differentiation of human adipose tissue-derived stem cells has been
shown to be associated with elevated ROS generation, and it was
stimulated both by exogenous application of H2O2 and by overexpres-
sion of Nox4. During adipogenesis, expression of FoxO1 and FoxO3
genes as well as the FOXO target genes coding for catalase and SOD2
were upregulated; silencing of FoxO1 suppressed adipogenesis [232].
The continuous renewal of the intestinal epithelium represents another
example that illustrates the importance of ROS for differentiation
processes: stem cells located at the bottom of intestinal crypts are
capable of proliferating and differentiating into absorptive and secre-
tory cell types. The switch between cell proliferation and differentia-
tion/growth arrest is typically associated with changes in the intracel-
lular glutathione (GSH/GSSG) and in the extracellular cysteine/cystine
redox potentials in the gut: proliferation is fostered in a reducing redox
environment, whereas a modest shift towards the oxidation side of the
two redox couples favors differentiation. A highly oxidized glutathione
redox status, however, associates with cell death [233]. Human
intestinal epithelial Caco-2 cells, a commonly used in vitro model for
intestinal differentiation, stop proliferation and undergo differentiation
into enterocytes/colonocytes following confluency. Differentiation of
Caco-2 cells is associated with induction of FoxO1 and SelP [234], an
antioxidant protein that was identified as a FoxO1 target gene [235].
Thus, FoxO1-mediated up-regulation of antioxidant enzymes might
limit the severity and duration of the redox shift during enterocyte
differentiation.
Stem cell differentiation has been also associated with epigenetic
alterations. As Alina Hanf and Andreas Daiber summarize, there is a
growing body of evidence that ROS/RNS contribute to the regulation of
gene expression and genome stability not only by modulation of
transcription factors, mRNA stability and DNA damage/repair, but also
influence epigenetic pathways by affecting the function or expression of
histone and DNA modifying enzymes (Fig. 3.2) [236–238]. For
instance, it was shown that oxidative stress alters global histone
methylation by attenuating Fe(II)- and α-ketoglutarate-dependent
histone demethylase activity of Jumonji C (JmjC) domain-containing
enzymes and TET DNA hydroxylases [237,238]. Furthermore, it is well
established that levels of HDAC2 are decreased due to inflammation-
induced ROS/RNS production in chronic obstructive pulmonary disease
(COPD) [239]. Another example is the generation of reactive halogen
compounds, such as 5-chlorocytosine, by ROS/RNS, leading to inaccu-
rate methylation by DNA methyltransferase (DNMT) [240]. Adverse
redox regulation of epigenetic processes may ultimately result in
pathological consequences such as dysfunctional energy metabolism
or increased oxidative stress that are associated with cardiovascular
pathologies. For instance, hydrogen peroxide (H2O2) alters the binding
of DNA methyl-transferases (DNMTs) to chromatin leading to hypo-
methylation in atherosclerosis [241,242]. Furthermore, epigenetic
silencing of superoxide dismutase 2 (SOD2) by selective hypermethyla-
tion of CpG islands in the SOD2 gene is associated with pulmonary
arterial hypertension [242,243], and oxidation of HDAC4 by NOX4-
mediated ROS production was observed in cardiac hypertrophy [244].
There is experimental evidence that cardiomyocytes of failing hearts
undergo significant changes in epigenetic profiles of H3K4 and H3K9
methylation marks that go hand in hand with ROS-induced changes in
histone demethylase activity [242,245,246]. This has also been ob-
served in humans with heart failure [247]. Not only histone modifying
enzymes but also histone proteins themselves can be directly affected
by oxidizing and nitrating agents since exposure to peroxynitrite
induces dityrosine formation in histone H2A and H2B leading to
structural changes by intra-molecular cross-linking [248,249]. Dityr-
osine bridge formation represents an irreversible oxidative modification
and it may be speculated that histones carrying this modification
account for the persistent changes in gene expression observed in
various disease states. In conclusion, epigenetic regulation by ROS/RNS
in the setting of various oxidative stress-associated disorders may
become an attractive target for redox medicine in the near future.
In addition to histone- and DNA-modifying enzymes, microRNAs
(miRNAs) have an important impact on the epigenetic landscape. They
comprise a large family of conserved, small (19–25 nucleotides (nt)
long), non-coding RNAs that regulate gene expression at the post-
transcriptional level. miRNAs bind to the 3′-untranslated region (3′-
UTR), coding sequences or 5′-untranslated region (5′-UTR) of target
messenger RNAs, thus leading to the inhibition of translation or mRNA
degradation [250,251]. As Verónica Miguel and Santiago Lamas
explain, it has recently been found that miRNAs are able to “fine-tune”
the regulation of redox signaling. This may occur by direct interaction
with NRF2, the major transcriptional regulator in the defense against
ROS [252,253], or its co-regulators Kelch-like ECH-associated protein 1
(KEAP1) and CNC homolog 1 (Bach1), or by controlling the generation
of ROS [254]. This new subset of miRNAs, that either regulate redox
pathways or are themselves regulated by the cellular redox state, has
been termed “redoximiRs” [255]. As pointed out above, fibrosis is an
aberrant repair process that results from chronic inflammation and
leads to excessive extracellular matrix (ECM) deposition that ultimately
impairs organ function [256]. Myofibroblasts are considered the
quintessential cell type responsible for ECM accumulation [257].
Fibrosis of major organs including liver, lung, heart, skin and kidney
share common molecular mechanisms regarding the genesis of the
fibrotic process such as the essential role of the TGF-β pathway [258].
However, major differences exist regarding the cellular origin of
myofibroblasts and the role of epithelial-mesenchymal transitions
(EMT) in each particular organ [259]. The lack of effective and specific
therapeutic alternatives for fibrosis prevention or cure remains a
fundamental clinical challenge in all organs. In the last decade, miRNAs
have been shown to be modulators of pro- and anti-fibrotic processes in
human diseases and this subset of miRNAs are called “fibromiRs”
[260,261]. Aberrant expression of fibromiRs drives the initiation and
progression of the fibrotic process in response to persistent tissue injury.
Moreover, TGF-β signaling through Smad proteins can regulate the
transcription of miRNAs by DNA binding or miRNA maturation by
associating with the Drosha/DGCR8 complex [262], suggesting a
possible link between miRNAs and fibrogenesis. The overlap between
the sets of fibromiRs and redoximiRs is now becoming evident and is of
potential importance for both mechanistic and translational purposes
[263]. Currently several miRNAs pertaining to this intersection have
been described and are the objects of intense research, including miR-
21 [264–266], miR-29 [267,268], miR-9 [269,270], miR-199 [271] and
miR-433 [272]. Of interest, some of these miRNAs, such as miR-21, may
regulate metabolic pathways related to fatty acid oxidation, a process
that has been proven crucial for the pathogenesis and perpetuation of
fibrosis in the kidney [273–275]. Overall, the crosstalk regulation
between redox balance and miRNA function appears to be an exciting
avenue of research, which may lead to a more profound comprehension
of fibrosis and eventually to provide effective therapeutic alternatives.
3.7. Redox signaling via RONS-derived electrophiles such as oxidized lipids
Fibrosis and inflammatory diseases have been also associated with
lipid oxidation. As Catarina B. Afonso and Corinne M. Spickett discuss,
oxidized phospholipids (OxPLs) have a known role in several inflam-
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matory diseases such as atherosclerosis and diabetes, but also in
neurodegenerative diseases including Alzheimer's and Parkinson's dis-
ease. Although they mostly have a pro-inflammatory role, as reviewed
recently [276,277], their capacity as anti-inflammatory agents has also
been described. The anti-inflammatory activity of OxPLs has been
shown to involve several pathways (reviewed in [278]). The mechan-
isms by which they act include the inhibition of nitric oxide synthesis in
macrophages; activation of peroxisome proliferator activated receptors
(PPARs), leading to inhibition of major inflammatory pathways (such as
the NF-κB and AP-1 signaling pathways); attenuation of dendritic cell
activation and maturation, and inhibition of T-cell proliferation and
cytotoxicity, which are important in the adaptive immune system. One
of the most studied anti-inflammatory mechanisms by which OxPLs act,
however, involves the regulation of Toll-like Receptors (TLRs). These
receptors are responsible for innate immune responses by recognizing
pathogen-associated molecular patterns (PAMPs). The presence of
oxidized phospholipids appears to selectively inhibit some proteins of
this family (such as TLR2 and TLR4), possibly through binding to
assessory proteins important for their activity [278]. However, much
research has been performed using specific oxidized phospholipids, and
the different phospholipid species could alter the response observed
[279]. Also, their anti-inflammatory activity is known to depend on
several factors. For example, low concentrations (< 25 µM) of the oxPL
are thought to be anti-inflammatory, whereas higher concentrations
(> 50 µM) tend to be pro-inflammatory and cytotoxic [276]. The
effects of cell type [280] and the presence of endotoxin [281] have
also been reported. The potential of OxPLs for the diagnosis and
treatment of inflammatory diseases is evident, but further research is
necessary to characterize the relationships fully.
ROS, RNS and lipid peroxidation (LPO) products are not only crucial
in regulating cellular signaling processes under physiological and
pathophysiological conditions, they are also crucial in the cellular
response to materials, acting in turn as chemo-attractants, signaling
molecules and agents of degradation [282]. As Pierre-Alexis Mouthuy
and Neven Žarković point out, such interactions between cells, materi-
als (or ‘scaffolds’), and bioactive molecules can be observed in tissue
engineering in order to improve or replace biological tissues in
regenerative medicine. In this context, modulation of ROS may have
the potential to improve the quality of the engineered constructs. So far,
approaches in tissue engineering that target ROS in order to improve
cell-material interactions have focused on antioxidant therapies to
minimize oxidative stress in cells. However, it is challenging to provide
antioxidant concentrations that are physiologically relevant and re-
spond to variations of oxidative stress levels, which may occur during
new tissue formation. Thus, recent strategies aim to develop polymeric
scaffolds that undergo oxidative degradation and/or release bioactive
molecules such as antioxidants in response to the oxidant concentra-
tions [283–285]. On the other hand, considering the multiple roles that
oxidants play during the response to biomaterials, pro-oxidant thera-
pies are also becoming attractive for tissue engineering applications.
The LPO products, like 4-hydroxynonenal (HNE) known as a "second
messenger of free radicals", are particularly interesting candidates to be
supplemented as bioactive molecules. Namely, despite being biomar-
kers of pathological oxidative stress, LPO products have been shown to
stimulate cell proliferation and matrix synthesis [286,287]. Compared
to ROS and RNS, the LPO products have the advantage of forming
rather stable protein adducts. Moreover, their hydrophobicity suggests
that their incorporation into a hydrophobic polymer matrix (such as
biodegradable polyesters) could lead to a slow and prolonged release,
which is desirable for tissue engineering applications. Overall, the
existing evidence supports the idea of providing LPO products during
tissue engineering in order to stimulate cell infiltration and new tissue
formation. Such a novel approach has been proposed as a supplement
for a bone regeneration strategy, which is currently being tested using
HNE.
Moreover, proteins can be modified by covalent reactions on the
nucleophilic residues cysteine, histidine, arginine and lysine, leading to
the formation of a wide variety of adducts with oxidized products of
lipids. As Bebiana C. Sousa and Corinne M. Spickett explain, even
though protein lipoxidation can occur under basal conditions, it is
increased and thought to be relevant in pathophysiological conditions
[288]. In order to understand their impact on a complex matrix like
cells, tissues or body fluids, potentially important protein-lipid adducts
are often generated in vitro under controlled conditions [289]. This
approach has the advantage of potentially decoding the reactivity of
each specific electrophilic lipid species and specific fragmentation
patterns of lipoxidation adducts, allowing a targeted analysis in
complex biological samples. On the other hand, this strategy also
presents some disadvantages, as previously reported by other authors
[290,291]. Mass spectrometry (MS)-based analytical approaches are
one of the most popular methodologies to study biological systems and
are used extensively in the study of protein-lipid adducts. The adducts
are detected by MS analysis, often involving liquid-chromatography
followed by top-down or bottom-up proteomic strategies. Because the
top-down approach requires expensive mass analyzers with high mass
accuracy and resolution, the bottom-up approach is the most commonly
used. However, it also involves disadvantages; for example, when the
aldehydes react with lysine and arginine, this leads to additional
difficulties since these modifications may interfere with trypsin diges-
tion, which is typically used in proteomics. Furthermore, stabilization
of adducts is required prior to the enzymatic digestion and MS analysis
due to their labile nature. Certain MS/MS conditions can cleave labile
post-translational modifications during peptide fragmentation, result-
ing in the neutral loss of the modification. For these reasons, it is
advantageous to use enrichment procedures and chemical labeling in
order to improve sensitivity and selectivity. Western blot immunoassay
using specific or non-specific antibodies can also be performed,
followed by in-gel digestion and MS analysis for protein identification.
However, the cross-reactivity of some antibodies with different lipids is
a major disadvantage. The development of new MS approaches could
provide tools to identify and quantify lipid-protein adducts and under-
stand their effects upon oxidative stress and related pathophysiological
conditions [292].
3.8. Interaction of the gasotransmitter H2S with ROS and RNS
In recent years, H2S biology has attracted a lot of attention by
unraveling multiple physiological roles for this gasotransmitter, linking
it to disease conditions and offering novel translational opportunities,
as summarized by Andreas Papapetropoulos (Chair of the COST Action
BM1005 (ENOG)). Hydrogen sulfide is generated in mammalian cells by
three distinct enzymes: cystathionine-β synthase (CBS), cystathionine-γ
lyase (CSE) and 3-mercaptopyruvate sulfotransferase (3MST)
[293,294]. Although the exact levels of H2S in cells remain unknown,
they are most likely in the nM range. In addition to free H2S, acid-labile
and protein-bound sulfane sulfur pools exist [295]. H2S is a weak acid
and readily ionizes at physiological pH, with 70% of H2S existing in the
anionic sulfide (HS-) form [293]. H2S is a weaker reductant than
cysteine and glutathione. This, in addition to its much lower concen-
tration compared to glutathione and protein thiols, argues against a role
for H2S as a “professional” direct reducing agent in a cellular context.
H2S most likely acts as a signaling molecule boosting endogenous
antioxidant mechanisms.
Low levels of H2S are neuroprotective, cardioprotective, anti-
apoptotic and anti-inflammatory [293]. Many of its biological actions
have been attributed to its antioxidant properties [293,296]. H2S
impacts on the cellular redox state as it reacts with ROS, inhibits ROS
production, activates antioxidant enzymes and upregulates the expres-
sion of antioxidant genes. H2S reacts with ROS/RNS including HOCl,
O2•─, H2O2 and ONOO─ [297]. With the exception of HOCl, the reaction
rate constants of H2S with the above-mentioned oxidants are low,
suggesting that they are most likely of little biological significance
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[295]. The reaction of H2S with free radicals can give rise to a number
of novel species. Of particular interest is the reaction between H2S and
•NO, which generates S/N hybrid species and HNO• [298].
NRF2 is a transcription factor that acts as a major regulator of the
cellular defense response to oxidative stress since it is the master
transcription factor regulating antioxidant genes [299,300]. NRF2 is
found in a complex with Kelch-like ECH-associated protein 1 (KEAP1)
in the cytosol that facilitates its degradation through the proteasome
pathway. Following exposure to oxidative stress, KEAP1 dissociates
from NRF2 allowing it to escape from ubiquitination and enabling
translocation to the nucleus where it binds to antioxidant response
elements in the promoter region of several genes. Treatment of cells or
animals with H2S donors causes persulfidation of KEAP-1 on cysteine-
151, which in turn causes a conformational change in KEAP1 allowing
it to dissociate from NRF2 [301]. In addition to NRF2 activation, H2S
donor administration up regulates NRF2 expression [294].
Treatment with H2S has been shown to be protective against a
variety of oxidative stress-related injuries and ROS-induced toxicity
[296]. From a mechanistic point of view the protective effects of H2S, in
addition to NRF2, have been linked to increased activity of antioxidant
enzymes such as superoxide dismutase, catalase and glutathione
peroxidase, inhibition of superoxide generation and lipid peroxidation
and reduction of NOX expression [296,301]. Moreover, treatment with
H2S donors increases the cellular concentration of reduced glutathione
by promoting cysteine and cystine uptake and by upregulating the level
of the GSH biosynthetic enzyme γ-glutamylcysteine synthase and GSH
reductase; H2S also increases thioredoxin-1 gene expression [296].
4. Redox biomarkers
Paul Winyard (E-mail: p.g.winyard@exeter.ac.uk) and Pietro Ghezzi
(E-Mail: P.Ghezzi@bsms.ac.uk).
4.1. Introduction
This section will deal with selected redox biomarkers. As the
causative molecules of oxidative damage are ROS, one might expect
most studies would be performed by measuring ROS, such as the
superoxide radical or the hydroxyl radical, (among others) in patients’
fluids, just as inflammation researchers measure the level of inflamma-
tory cytokines in disease. However, most ROS are extremely unstable,
with half-lives of 10−6 −10−9 s. Also “more long-lived” ROS, such as
hydrogen peroxide, have a half-life of less than a millisecond [302].
Therefore, it is difficult to measure them in biological fluids. ROS can be
measured during their production in vitro using chemicals (e.g. “spin
traps” and “fluorescent probes”) to detect them while they are
produced, but they cannot be measured in stored plasma or stored
culture supernatants. Therefore, we do what is done in high energy
physics. Not being able to detect subatomic particles, we can only have
a clue of their presence by the traces they leave. The main feature of
ROS is their high reactivity, hence the name, and measurement of
oxidized macromolecules that can arise by interaction with endogenous
ROS can give us an estimate of the production of ROS (Fig. 4.1) [6].
Likewise, upregulation of ROS enzymatic sources or so-called toxifiers
(e.g. myeloperoxidase) can also work as biomarkers of oxidative stress.
Measurement of these oxidized molecules can provide three types of
biomarkers. Some can be indicators of the production of ROS. An
example is S-thiolated hemoglobin (whose oxidation, to our knowledge,
has no pathogenic role). This is similar to the situation with glycated
hemoglobin (HbA1c) in diabetes, a good and stable indicator of how
much the organism has been exposed to high blood glucose, but which,
unlike blood glucose, has limited functional consequences in vivo.
Others are, in effect, biomarkers of oxidative stress, that is, they reflect
oxidative damage that may have biological consequences. An example
of this type is oxidized DNA metabolites, as they may potentially be
responsible for oxidative stress-induced mutagenesis and cancer. A
third group of biomarkers consists of oxidized products that have an
Fig. 4.1. Redox pathways associated with putative biomarkers of oxidative stress. The processes that lead to oxidative modifications of proteins, lipids, and nucleotides are highly
complex. Enzymes, such as XO, NOX, and NOS, can produce ROS and RNS. These ROS can furthermore serve as substrates for other enzymes to generate additional types of ROS, such as
the generation of HOCl from H2O2 by MPO. Cellular systems and enzymes, including the GSH and thioredoxin system, together with peroxiredoxins (T/Prx), counterbalance the
production of ROS. In addition, increased levels of ROS activate NRF2 to transcribe genes that are involved in counteracting these ROS. Oxidative stress affects cGMP signaling through its
effects on nitric oxide (•NO) production, scavenging, and on the •NO receptor sGC. cGMP, cyclic guanosine monophosphate; GSH, glutathione; H2O2, hydrogen peroxide; HOCl,
hypochlorous acid; MPO, myeloperoxidase; NOS, nitric oxide synthase; NOX, NADPH oxidase; RNS, reactive nitrogen species; ROS, reactive oxygen species; sGC, soluble guanylate
cyclase; XO, xanthine oxidase. Adpated from [6]. With permission of Mary Ann Liebert, Inc. Copyright 2015.
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intrinsic biological activity, which may propagate some of the con-
sequences of oxidative stress – such as hydroxynonenal, an aldehyde
generated by lipid oxidation [303].
This review will deal with different types of stable redox biomarkers
that can be used in biological samples from clinical or population-based
studies. The biomarkers have been grouped in the subsections below
according to their identity as oxidation products of proteins, lipids, or
DNA.
4.2. Protein oxidation products as redox biomarkers
The following section was composed by Serge P. Bottari, Stuart P.
Meredith and Corinne M. Spickett. Biological systems are exposed to
various endogenous and exogenous oxidants capable of modifying
proteins, which, among other processes, may affect cell signaling
pathways [304] and contribute to inflammatory diseases [302]. A
number of acute and chronic diseases have been reported to cause, be
accompanied by, or be due to, "oxidative stress". This stress can be
considered as a deregulation of redox signaling resulting in an excess of
ROS, which may be responsible for further complications.
Since the major substrate of the primary ROS, O2•-, in terms of
kinetics is •NO (the reaction with O2•- has a rate constant which is 3–4
times greater than the rate constant for the dismutation of O2•-
catalyzed by SOD), oxidative stress is generally preceded – and
accompanied by – an increased generation of RNS, essentially perox-
ynitrite (ONOO-), which, in the case of excessive concentrations, can
cause nitro-oxidative stress [305]. Since RNS can, like ROS, alter
proteins, lipids and nucleic acids, RNS may also be involved in
pathological mechanisms [306,307]. Interestingly, however, most
posttranslational protein modifications due to RNS appear to often be
reversible in vivo. Therefore, nitro-oxidation should be considered as a
potential therapeutic target, as the modifications involved are modu-
lated primarily by the redox status, •NO and O2•- fluxes [308], the
former being easily manipulable.
The major pathophysiological nitro-oxidative protein modifications
elicited by ONOO- are glutathiolation and S-nitrosation of Cys and
nitration of Tyr residues. Other modifications are zinc finger oxidation
and methionine sulfoxidation. •NO by itself is a major neurotransmitter
and an activator of soluble guanylate cyclase. Its reaction with O2•-
therefore has dual consequences: primarily the generation of novel
messengers (RNS) and a decreased bioavailability of •NO with direct
consequences on its targets [305,307].
Antibody-based methods are among the most common techniques
for identifying and quantifying these oxidative post-translational
modifications to amino acid residues. The most common techniques
(Table 4.1) include ELISA, Western blotting (WB) and immunostaining
techniques, such as immunohistochemistry (IHC) and immunocyto-
chemistry (ICC). The accuracy of these techniques relies on the
specificity of the available antibodies, but not all antibodies are
validated for all procedures [309]. The majority of antibodies against
oxidative posttranslational modifications are primarily validated for
Western blotting (~75%), with smaller numbers suitable for the other
techniques (IHC ~40% and ELISA ~35%), and they are not necessarily
interchangeable. Searching on databases such as CiteAb and Biocom-
pare suggests there are more than 500 commercially available anti-
bodies to modified residues (Table 4.1), but on average less than 15% of
these have been specifically cited in scientific publications. Some
antibodies are more extensively cited and used in different techniques,
so selecting the appropriate one is important.
An important issue is the specificity of the antibodies, which may
vary according to the immunogen used to generate them, including the
carrier. The most commonly used approach is conjugation of the
modified residue to either keyhole limpet hemocyanin (KLH) or bovine
serum albumin (BSA), but others were produced by immunizing
directly with proteins treated with oxidizing, chlorinating or nitrating
agents. A limitation of using modified BSA or other proteins is that it
generates antibodies to a variety of epitopes on the antigen that may
lead to cross reactivity upon translation, especially as most nitrating
and chlorinating agents are also oxidizing, so a wide range of oxidative
posttranslational modifications result. Even using synthetic modified
residues conjugated to a carrier protein, there are likely to be several
antibodies to epitopes that do not include the modification site, so
purification is required. Thus the resulting polyclonal sera are semi-
specific at best; while monoclonal products are better, some cross-
reactivity is still possible. For example, limitations of antibodies and
antibody-dependent assays for methionine sulfoxide have been re-
ported [310,311]. This indicates the importance of understanding the
nature of the antibody being used in order to interpret results correctly,
but unfortunately, often little information is available from the
supplier. It also suggests the benefit of producing better characterized
antibodies, possibly with known sequence specificity in addition to
modification specificity.
Among the applications of the above antibodies to immunochemical
assays, it is of primary interest to be able to detect and quantify nitro-
oxidative "stress" in pathophysiological situations before irreversible
oxidative cell damage occurs. Among the nitro-oxidative protein
modifications, the most stable and therefore easiest one to investigate
is Tyr nitration. Indeed, glutathiolation and S-nitrosation, being heavily
dependent upon the redox state, can easily be artifactually generated or
reduced in biological samples.
In order to achieve monitoring of nitro-oxidative "stress" in patho-
physiological situations, Rocha et al. developed an ELISA assay for the
quantitative determination of nitrated albumin in plasma. Indeed,
assaying free or peptide-bound nitroTyr does not reflect nitro-oxidative
stress as most of it is of dietary origin [312].
This test allowed Bottari's group to monitor the occurrence of
systemic nitro-oxidative "stress" under two conditions which can lead
to severe long-term psychomotor retardation: perinatal asphyxia and
Table 4.1
Summary of the types of antibodies currently available against oxidatively modified residues.
Modification Number of
Antibodies
Antibodies Cited Clonality (mAb:
pAb)
Most Common Antigen Range of Validated
Techniques
3-Chlorotyrosine 1 1 0:1 3-Chlorotyrosine (no details) IA, IHC
3-Nitrotyrosine 439 15 129:310 3-Nitrotyrosine conjugated to KLH WB, ELISA, ICC, IF, IHC, IP
S-nitrosocysteine 1 0 0:1 Recombinant protein ELISA, WB
Cysteine sulfenic Acid 3 3 0:3 Sulfenic acid-cysteine (2-thiodimedone-specific Ig) WB
Cysteine sulfinic acid 1 0 0:1 Cysteine sulfinic acid adducts ELISA, IHC
Cysteine sulfonate 3 3 0:3 Dimedone-modified cysteine conjugated to KLH WB
5-Hydroxytryptophan 17 1 8:9 Conjugated to bovine serum albumin via a
glutaraldehyde linkage
WB, ELISA, ICC, IHC, IF
Methionine sulfoxide 3 2 0:2 Protein with methionine sulfoxide modifications WB
Hydroxyproline 19 3 0:19 Conjugated to bovine serum albumin ELISA, IHC, ICC, WB
Carbonyl 43 41 27:16 Conjugated to bovine serum albumin ELISA, IHC, ICC, WB
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neonatal hypoglycemia [313,314]. Whereas the clinical significance
and importance of perinatal asphyxia on neurodevelopmental outcome
of severely and even moderately affected newborns is now generally
accepted, this has not been the case for neonatal hypoglycemia whose
clinical significance is still a matter of intense debate [315–319].
Interestingly, animal models of these two conditions invariably show
cerebral insult associated with increased tyrosine nitration both in vitro
and in vivo. These observations have been confirmed in postmortem
cerebral and medullar tissues of asphyxiated neonates [320,321].
Since high peroxynitrite flux generation has been reported to cause
neuronal apoptosis, Wayenberg et al. investigated potential correlations
between plasma nitroalbumin levels and other biological and clinical
parameters in asphyxiated and hypoglycemic neonates [313]. In
perinatal asphyxia, it was found that plasma nitroalbumin concentra-
tions at day 1 to be strongly correlated with the severity of neonatal
encephalopathy (χ2 =7.23; p<0.05) indicating the occurrence of
systemic nitro-oxidative stress in these infants. Nitroalbumin levels
were also inversely correlated (p< 0.05) with Apgar score (a marker
for the health of newborns) and arterial blood pH and directly with
creatinemia, arterial base deficit and lactacidemia. The latter correla-
tion indicates a correlation between the degree of hypoxia and albumin
nitration, whereas the increase in creatinemia is indicative of a
decreased glomerular filtration rate, which may reflect afferent arter-
iolar vasoconstriction. Nitroalbumin levels were back to control levels
at day 4 suggesting that this stress was transient [313].
It has been well documented that moderate and severe neonatal
encephalopathy are often associated with subsequent periventricular
leucomalacia and cerebral palsy, often leading to impaired neurodeve-
lopmental outcome. The data of Wayenberg et al. therefore suggest that
increased RNS generation may play a role in hypoxic-ischemic brain
injury. Further studies are required to verify whether plasma nitroal-
bumin may serve as a marker of nitro-oxidative stress in neuroprotec-
tive trials.
In neonatal hypoglycemia [314], Wayenberg et al. found an inverse
correlation between glycemia and plasma nitroalbumin as early as the
first hour of life (r=−0.35; p<0.02) and through day 1. Lactacidemia
was inversely correlated with nitroalbumin suggesting that lactate may
serve as an alternate fuel. Another interesting finding is the strong
correlation between nitroalbumin levels and the severity and duration
of the hypoglycemic events determined as area-under-the-curve. Simi-
larly, in neonates who had more than 2 hypoglycemic episodes during
the first 24 h of life, nitroalbumin levels were still significantly elevated
at day 4.
Whereas, as mentioned earlier, the impact of neonatal hypoglyce-
mia on neurodevelopmental outcome is still a matter of debate, our
data clearly indicate that severe and repeated hypoglycemic events
during the first 24 h of life induce an important and long-lasting
systemic nitro-oxidative stress both in preterm and term infants, which
may be involved in the cerebral insult responsible for the psychomotor
retardation reported by several authors. These observations therefore
provide grounds for timely and appropriate management of neonatal
hypoglycemia and call for further studies on careful metabolic mon-
itoring and long-term follow-up of the neurodevelopmental outcome of
these infants.
In conclusion, plasma nitroalbumin determination provides a highly
sensitive and robust marker, which may prove useful for monitoring
nitro-oxidative stress and for understanding the involvement and role of
redox deregulations and RNS in various pathophysiological conditions.
4.3. Lipid oxidation products as redox biomarkers
The following section was composed by Opeyemi S. Ademowo,
Irundika Dias and Helen Griffiths. Malondialdehyde (MDA) is the best
known and most abundant (10–20 µM in plasma) end-product of the
autocatalytic lipid peroxidation chain reaction. In addition to alde-
hydes, other common cholesterol, phospholipid and polyunsaturated
fatty acid peroxidation biomarkers that are formed include ketones
such as 4-hydroxynonenal, alcohols such as isoprostanes, hydroper-
oxides such as 1-palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phospho-
choline (POVPC) and cyclic endoperoxides. Polyunsaturated fatty acids
(free or in phospholipids) with methylene interrupted unconjugated
olefinic bonds are highly susceptible to free radical oxidation and yield
hydroperoxide species in situ, which in the case of membranes, are
released by phospholipases. Commonly reported examples of oxidized
cholesterols (oxysterols) include 6-cholesten-5α-hydroperoxide, 7-ke-
tocholesterol, 7-dehydrocholesterol and 25-hydroxycholesterol [322].
The suitability of these molecules as biomarkers is dependent on their
stability, ease of enrichment or separation and accurate detection
methods in the presence of several orders of magnitude higher
concentrations of the parent lipid. The commonly used thiobarbituric
acid-reactive substances (TBARs) assay lacks specificity for MDA
measurement in biological materials and is not a method of choice
for MDA quantitation [323].
Lipid peroxidation analysis by absorption spectrometry has been
superseded by the accurate determination of unmodified or derivatized
lipids using chromatographic separation followed by mass spectrometry
(MS) methods. Gas and liquid chromatography have been used
successfully according to equipment availability, but LC is easier as it
does not require the samples to be volatilized. The precision of such
methods is achieved by: 1) stability of the analyte; 2) enrichment of the
analyte; 3) specific detection by multiple reaction monitoring transi-
tions; 4) the sensitivity of the MS method including variation in dwell
time; and 5) the availability of stable isotope standards for the species
of interest.
For MDA, the commercial deuterated standard is available to
support stable isotope dilution methods; successful derivatization and
stabilization in acetone has been achieved using pentafluorobenzylbro-
mide followed by extraction using toluene to remove matrix followed
by GC separation to enrich for species of interest [324], and using 3-
nitrophenylhydrazine to derivatize followed by LC separation using
stable isotope dilution methods to compensate for matrix effects during
electrospray ionization [325].
Quantification is typically achieved by selected ion monitoring
(SIM) after MS (e.g. of m/z 251 for MDA and m/z 253 for its stable
isotope after neutral loss of PFB) and selected reaction monitoring
(SRM) by MS/MS of the mass transition (e.g. m/z 251→ m/z 175 for d0-
MDA and m/z 253→ m/z 177 for d2-MDA) [324]. By derivatizing MDA,
these methods capture the reactive carbonyl prior to sample processing.
Similar to MDA, 4-HNE is highly reactive and MS methods of
analysis typically rely on derivatization using PFB to stabilize the
reactive carbonyl. After GC separation and analysis by the SIM method,
the deuterated analog, HNE-d11, has been successfully used for
quantitation [326]. Plasma concentrations of 4HNE are ~100 nM.
Isoprostanes (IsoPs) are stable products of polyunsaturated fatty
acid peroxidation. F2-isoP, the most common, is derived from arachi-
donic acid with a concentration< 0.5 nM in the plasma of healthy
human subjects. One LC-MS method using deuterated standardization
has been described, despite this method having the potential to be the
most sensitive and specific for many different isomeric forms. Solid
phase extraction was adopted to remove contaminants and following
LC-MS, two MRM transitions were acquired per analyte for quantifica-
tion and confirmation of IsoPs [327]. The recovery of the spiked
standard was 70–120%.
Oxidized cholesterols have biological activity [328] although they
are found at very low concentrations in plasma (7-ketocholesterol: <
75 nM). They are often esterified. Some methods describe saponifica-
tion to release the free oxidized cholesterol as an index of oxidative
stress whereas other authors prefer to analyze the biologically active
free oxidized forms. Solid phase or liquid-liquid extraction and protein
precipitation during sample preparation has proved to be important for
sample enrichment. The incorporation of deuterated standards using
stable isotope dilution enables absolute recovery to be reported. Using a
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monolithic column, efficient chromatographic separation of isomeric
oxysterols was achieved; MRM transitions of m/z 369/287 enabled
specific detection for 7-ketocholesterol with 81–108% recovery [329].
In order to highlight the innovations in the field of lipid peroxida-
tion product analysis by LC, a recent approach for detection of the
oxidized phospholipid POVPC has been described that relies on a
nanoparticle-based strategy for successful trapping and enrichment of
aldehyde-containing oxidized phospholipids [330]. After derivatization
of carbonyl containing phospholipids with a bifunctional reagent
containing a thiol moiety to bind onto nanoparticles, the derivative
and enriched moieties can be released by a reducing agent for analysis
by LC-MS/MS. The authors highlight a two-fold improvement in the
sensitivity of POVPC detection using nanoparticles.
As LC-MS/MS with SRM methods and deuterated standards become
more widely available, a new era of reliable lipid peroxidation analysis
will dawn enabling researchers to understand the concentration and
species produced in different biological contexts. Improved enrichment
techniques that minimize the risk of artefactual oxidation and novel
chromatographic materials that can offer improved separation of
amphipathic molecules are key to further development in this field.
4.4. Nucleic acid oxidation products as redox biomarkers
The following section was composed by Marcus S. Cooke, Mahsa
Karbaschi and Henrik E. Poulsen. Nucleic acid oxidation has attracted
attention since it was shown that it was one of the most abundant DNA
modifications [331]. It also is a pre-mutagenic lesion that induces CG:
TA transversion mutations. The guanine moiety is particularly prone to
oxidation and is studied as a prototype for both DNA and RNA
oxidation. In DNA it can be measured as the nucleoside upon digestion
and hydrolysis. The gold standard for measurement is now ultra-high-
performance liquid chromatography with tandem mass spectrometry
for quantification. The optimum method includes extensive chromato-
graphy, isotope dilution with the use of both quantifier and qualified
ions [332]. The oxidized nucleosides from both DNA and RNA are
excreted into urine and are used as non-invasive biomarkers [6].
Biomonitoring such damage, both in vitro and in vivo, is therefore
critical to understanding the mechanisms linking damage with disease,
but achieving this can present technical challenges. Blood is a poten-
tially problematic matrix to measure oxidatively generated DNA
damage, as it is necessarily invasive (typically ~5 mL is needed);
peripheral blood mononuclear cells need to be isolated before analysis
or storage, which is a time-consuming process; and artefactual damage
occurs when whole blood is frozen without a cryopreservative. To
address this, a novel approach has been described that significantly
simplifies biomonitoring in vivo: small volumes of whole blood are
sufficient (250 µl from a finger prick), which facilitates simple collec-
tion and storage without artefacts, together with use in the comet assay
without prior isolation of peripheral blood mononuclear cells [333].
Recently, a novel comet assay tank and rack design was described,
which exploits holding the slides in a vertical orientation, rather than
horizontal [334]. This innovation results in significant improvements in
sample throughput (~90% decrease in slide handling time), together
with a much smaller footprint, and enhanced cooling. In contrast to
blood, urine is non-invasive, although it is also possible to measure
biomarkers of oxidative stress in other extracellular matrices [335].
Mass spectrometric approaches remain the gold standard for urinary 8-
oxodG analysis, but modifications to a commercially available ELISA
for 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) have improved its
accuracy [336,337]. Most recently, the Cooke laboratory has estab-
lished an approach that allows genome-wide assessments of DNA.
There are many reports of increased excretion of the guanine
nucleoside into urine or elevated tissue levels in many diseases, and
this has led many researchers to conclude that nucleic acid oxidation is
important in many diseases. Oxidative stress-induced damage to nucleic
acids (including DNA, RNA and the corresponding nucleotide pools) has
been implicated in the pathogenesis of numerous diseases, including
cancer, cardiovascular disease and neurodegenerative disease [338].
However, there is a difference between occurrence and importance, and
also there is the problem of whether the lesion causes the disease or is a
consequence of the disease. The classic criteria for causation are given
by the nine Bradford-Hill criteria [339]: strength, consistency, specifi-
city, temporality, biological gradient, plausibility, coherence, experi-
ment, and analogy. For DNA oxidation there are few publications on the
strength (urinary excretion of the oxidized deoxyguaninosine nucleo-
side (8oxodG)). Consistency is limited and there are only a few existing
cohort studies, yet they have shown an association with lung cancer in
non-smokers [340] and with breast cancer [341]. These effects are
small and probably not important on an individual basis, although they
might be important from a public health point of view. There are no
important data to evaluate criteria 2,3,4,5. Criterion 6 (plausibility) is
provided by the demonstration of GC: TA transversion mutations, even
though the quantitative effect is not established. Criterion 7 is partly
fulfilled by epidemiological and experimental evidence, and for criter-
ion 8 (experiment) there are data from DNA repair knock-out animals
that support the idea that the oxidative modifications are linked to
cancer development, or to premature aging [342].
RNA oxidation has only recently attracted attention. The evidence is
limited to hemochromatosis [343] and diabetes [344,345]. The data
support criterion 1 in that the effects are considerable, but the rest of
the criteria are only supported by hypotheses [346].
Beside the Bradford Hill criteria, there are some additional aspects
that need to be considered in the context of clinical utility. If a high
level of a biomarker is associated with a disease, are there means to
reduce the levels and will this either prevent the disease or improve
survival of patients with the disease? There are no data on this.
Presently, the quest is to identify non-pharmacological or pharmacolo-
gical means that are non-toxic and that can reduce markers of DNA or
RNA oxidation. Hitherto, the only example is blood-letting for the
treatment of hemochromatosis that reduces the biomarker for RNA
oxidation and also is well established to reduce the morbidity from high
body iron [343]. Still, particularly regarding type 2 diabetes, the clear
association between morbidity/mortality and the levels of RNA oxida-
tion is very promising with a potential to identify or develop novel
treatments for type 2 diabetes.
4.5. Conclusion
This comprehensive review has provided a summary of some of the
protein-, lipid-, and nucleic acid-based biomarkers of oxidative stress,
some of the latest developments in the assay methods by which they
may be measured, and some of the applications of these methods in
clinical studies. As described above, in general, gas/liquid chromato-
graphy-mass spectrometry often provides the platform of choice for the
determination of all these types of biomolecules, due to the specificity
and sensitivity of this platform. However, this type of platform does not
necessarily provide a method that is suitable for large-scale clinical
studies because of the relatively high cost of mass spectrometry
equipment and, frequently, the relatively high time demands for sample
preparation. Even mass spectrometry approaches are not without the
dangers of artefacts. It should also be borne in mind that good
analytical sensitivity and specificity for a particular biomarker does
not necessarily translate into good clinical diagnostic sensitivity and
specificity when testing the utility of the biomarker in the diagnosis of a
specific human disease.
Immunochemical methods such as ELISAs might provide alterna-
tive, high-throughput approaches for the analysis of oxidative stress
biomarkers (as described above for a range of protein oxidation
products, including 3-nitrotyrosine within the albumin polypeptide
backbone). However, great caution should be exercised in relation to
the specificity of the antibodies used in ELISAs, and it is evident from
Table 4.1 that many commercially available antibodies directed against
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protein oxidation products have received limited validation.
One of the challenges in this area is for the “redox biology
community” to work together to validate a group of harmonized assays,
which will constitute reference standards for oxidative stress biomar-
kers in clinical studies. An important series of investigations (the
National Institute of Environmental Health Biomarkers of Oxidative
Stress Study), addressed the question of which assays provide valid
read-outs of oxidative stress induced in animal models. The mass
spectrometry-based measurement of F2-isoprostanes was identified as
a “gold standard” biomarker of free radical damage caused by carbon
tetrachloride in rats [347]. A viewpoint regarding the current status of
oxidative stress biomarkers as clinically useful tools was provided by a
recent review [6]. Visualization of biomarkers measured in various
diseases by cluster analysis (Fig. 4.2) shows that the majority of studies
have used ROS-induced modifications as markers of oxidative stress
[6]. There is also ongoing discussion on whether traditional assays for
ROS and RNS detection are still useful in certain setups or should be
replaced by more advanced techniques [348–350].
The current review has included some indications as to how
oxidative stress biomarkers assays may be applied to medical research
studies, but the demonstrated clinical value of oxidative stress measures
in diagnosis or monitoring in patients has so far been disappointing. In
this respect, the challenge is to validate oxidative stress assays in terms
of clinical utility – i.e. clinical diagnostic sensitivity and clinical
diagnostic specificity. The development of oxidative stress biomarkers
needs the substantial further attention of researchers, particularly in
relation to the identification of validated biomarkers for the study of: (i)
the pharmacodynamics of novel redox-based therapeutics in animal
models of disease, (ii) the clinical diagnosis and/or monitoring of
human diseases in which oxidative stress is involved, and (iii) clinical
trials of novel redox-based therapeutics. As long as the above three
areas remain inadequately addressed, we will continue to struggle to
translate our increasing understanding of redox biology into advances
in human disease therapies based on redox medicine. The studies
described above, in relation to nitrated albumin as a biomarker in
perinatal asphyxia and neonatal hypoglycemia, begin to take us in the
right direction. But the important challenge of identifying reference
methods for oxidative stress assays still has some way to go.
5. Optimizing ROS detection using EPR or fluorescence: in vivo
applications to mammalian cells, tissues and plant biology
Yves M. Frappart (E-mail: yves.frapart@parisdescartes.fr).
5.1. Introduction
When oxygen first appeared on Earth, living systems had to adapt to
this particular oxidant molecule. This resulted in various reactive
oxygen species (ROS: mainly superoxide anion, hydrogen peroxide,
but also 1O2, hydroxyl radical) that must be regulated by all aerobic
organisms. Due to the regulatory role of ROS and crosstalk between
these molecules, their level and localization are therefore critical
parameters for biology and medicine. In order for the measurements
to be most useful, it often is essential to measure the amount of ROS at
particular sites and under appropriate conditions. Specific, sensitive
and localized measurements of ROS require special methodologies. As
ROS are correlated to oxygen levels, in vivo conditions should be
applied to study their biological effects, which is not always possible.
Oxygen concentration is therefore a key element in every experiment.
There is no gold standard modality to determine, quantify or localize
the various ROS species. Scientists who evaluate ROS have to use
different modalities, with different qualities and limitations depending
on the experimental conditions. Over the last decade, approximately
75% of all reports on ROS have been determined with fluorescence
imaging, especially in vitro [355]; almost all the other references have
used electron paramagnetic resonance (EPR or electron spin resonance
[ESR]) with or without spin trapping for their detection or imaging
[356]. Nevertheless other modalities are emerging such as nuclear
magnetic resonance imaging (MRI) [357], echography [358] or posi-
tron emission tomography [359]. New methodologies such as immuno-
spin trapping [360] are also emerging all the time so that it is not
possible to give an exhaustive list. Fig. 5.1 shows enzymatic sources of
RONS, the reactive species being formed, the potential footprints they
leave and imaging techniques that may be applied to measure them
Fig. 4.2. Cluster analysis of ROS biomarkers in disease. Different diseases were clustered according to described ROS biomarkers in Refs. [351–353] and studies described in this review.
Some disease conditions cluster as might be expected, such as ischemia/reperfusion and heart failure, and amyotrophic lateral sclerosis and multiple sclerosis. A comprehensive analysis
of ROS markers and pattern analysis in diseases might uncover common disease mechanisms or new measures of disease progression or treatment outcome. Cluster analysis was
performed using Genesis software (https://genome.tugraz.at/genesisclient/genesisclient_description.shtml) as described in Mengozzi et al. [354]. Adpated from [6]. With permission of
Mary Ann Liebert, Inc. Copyright 2015.
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[361].
Despite its limitation, EPR is still the most suitable technique to
detect ROS. EPR can be used in different methodologies such as EPR
coupled to spin-trapping. It is the most specific method, as stated by K.
Abbas and F. Peyrot.
5.2. Spin trapping coupled to EPR is an under used specific method to
measure oxidative stress in biological systems
Electron paramagnetic resonance (EPR) is the gold standard to
detect paramagnetic species. However, when the aim is the detection of
short-lived radicals involved in oxidative stress, such as O2•- in living
systems, direct detection is not possible due to the low sensitivity of the
technique. To overcome this limitation, the spin trapping method was
introduced in the 1970s. It relies on the specific single-step addition
reaction of the radical of interest on an EPR-silent molecule, named the
spin trap, which yields a persistent radical, called the spin adduct, the
EPR spectrum of which is characteristic of the trapped radical. The most
commonly used spin traps for O2•- in aqueous medium are derivatives of
the cyclic nitrone 5,5-dimethyl-1-pyrrolidine N-oxide (DMPO, e.g.
DEPMPO) (Fig. 5.2). Since its first application to biological systems in
1979, important contributions have been made to improve spin trap
structures based on mechanistic analysis of the spin trapping reaction
and of the spin adduct decomposition pathways [362,363], but also to
improve the methodology by characterizing its limitations, artefacts,
and sources of misinterpretations [364–368]. Intracellular detection
and quantification are not straightforward, and in vivo detection of O2•-
is impossible with spin traps coupled to EPR. However extracellular
detection of O2•- produced by cells can now be achieved with excellent
specificity and satisfactory sensitivity with CD-DIPPMPO, an extracel-
lular spin trap [369]. Spin trapping of NO is based on its high affinity
towards ferrous iron and trapping as stable nitrosyl-iron complexes is
achieved by either adding iron-diethyldithiocarbamate (Fe(II)(DETC)2)
to tissues or isolated cells [63,370], or by measurement of endogen-
ously formed nitrosyl-iron complexes such as Hb-NO [371,372].
Nitrosyl-iron complexes produce typical triplet EPR signals (Fig. 5.2).
Though a few spin traps are commercially available, their cost is
prohibitive considering that their purity is usually not sufficient for
biological studies. Since the quality of the supplies has not improved
over the years, there is a need for a greater collaboration between
biologists, synthetic chemists, experts in EPR spectroscopy and spin
trapping from platforms dedicated to EPR studies of biological systems
at national and European levels so that recent advances can be made
accessible to all, in order to address questions relative to oxidative
stress in biological systems. A few years ago, as Ron Mason was trying
to find new accurate ways to use spin trapping in order to determine
superoxide levels in living systems, he introduced immuno spin-
trapping, which he presented in a recent review [360]. Immuno spin-
trapping uses spin-trap antibodies to ensure the detection of the long
lived biological species with various methodologies (UV, mass spectro-
metry, MRI). Spectroscopists can now specifically detect superoxide in
vitro; they have therefore moved on to try to overcome the problem in
vivo by studying the redox status. Redox status is related to the balance
of many biological species (oxidants and reductants or antioxidants).
Despite its hazy definition, the redox status can be used as a tool by
biologists in many cases. This kind of measurement is based on the
aminoxyl (nitroxide), hydroxyamine redox equilibrium. It is suitable for
in vivo imaging [374] and often uses soluble molecular probes. When
aminoxyl linked to proteins is used, the redox status and conforma-
tional changes can be addressed, as presented by A. Pavićević and M.
Zatloukalová: the “Assessment of redox status and conformational
changes of proteins using EPR spin labeling”, which gives biologists
two important sets of information for their studies. Under different
physiological and patho-physiological conditions, proteins undergo
various conformational changes, which can be studied with a variety
of experimental techniques. One of these techniques is EPR, also known
as electron spin resonance spectroscopy (ESR), coupled with the use of
paramagnetic compounds called spin labels (SLs). SLs, which are
commonly employed for such measurements, are derivatives of cyclic
aminoxyl (often addressed as nitroxide) radicals, a class of compounds
containing an>N-O∙ moiety sterically shielded by methyl groups (or
other types of groups) attached to the neighboring carbon atoms. In
solutions, these molecules are allowed to rotate freely (short rotational
correlation time, τc), and thus the resulting EPR spectrum is composed
of three sharp isotropic lines (for 14N nitroxides). However, when
molecular motions are restricted (long τc) the overall spectral shapes
change, i.e. a broadening of the lines occurs due to the anisotropy of
hyperfine splitting constants and g-values. If an appropriate SL is
attached to a protein, the anisotropic spectra of the immobilized>N-
O∙ moiety provide valuable information about: 1) the hydrophobic/
hydrophilic nature of the binding site in the protein; 2) the influence of
the local environment induced by various reagents, temperature and pH
change, etc.; 3) the binding capacity of the protein; 4) the distances
between the active sites of the protein; 5) the folding and unfolding of
the protein, which is an especially interesting topic when membrane
proteins are studied; 6) the secondary structure of the protein; 7) the
dynamics of the protein backbone; and 8) protein-protein and lipid-
protein interactions [375,376]. Numerous SLs have been synthesized
for this purpose, a few of which are commercially available. Some of the
SLs bind non-covalently to the proteins, while others are intended to
covalently bind to specific amino acid residues, such as sulfhydryl
groups (-SH). The technique involving the application of the latter is
known as site-directed spin labeling (SDSL), and is frequently used in
synergy with site-directed mutagenesis. Even though the application of
SDSL can be beneficial, the use of conventional site-specific spin labels
(SSLs) suffers from a number of drawbacks, so the label has to be chosen
prudently, and experiments must be planned thoroughly. For instance,
the methanethiosulfonate spin label (MTSSL) binds solely to the
sulfhydryl group of free cysteine residues. However, it also tends to
form dimers, resulting in dipole-dipole interactions, and consequently
in the formation of extra spectral features [377]. On the other hand,
Fig. 5.1. Spectrum of different ROS imaging techniques. In the upper part, different
sources of ROS are shown: Mitochondria (mito), lipoxygenases (LPO), monoamine
oxidase (MAO), nicotinamide adenine dinucleotide phosphate oxidase (NOX4 and NOX
1/2/5), xanthine oxidase (XO), functional nitric oxide synthases (NOS) and dysfunctional
/ uncoupled eNOS (u-eNOS). These result in different types of ROS [including superoxide
radical (O2•─), hydrogen peroxide (H2O2), hypochlorous acid (HOCl, not shown in the
scheme), peroxynitrite anion (ONOO─), nitric oxide (•NO)] and ROS-induced modifica-
tions of GSH, NADPH, proteins, or glucose uptake, which, in turn, are detected by
different imaging technologies. Adpated from [361]. With permission of Mary Ann
Liebert, Inc. Copyright 2016.
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maleimido- (MSLs) and 2-iodoacetamido- spin labels (IASLs) need to be
incubated with the protein at certain pH values, otherwise they bind
not only to –SH, but also to the amino groups.
The protein spin labeling EPR technique has not been used
exclusively to study protein conformations and interactions, but has
also been applied as a diagnostic tool for various malignancies and
benign tumors [378], sepsis [378], diabetes [379], atherosclerosis
[379], and cirrhosis [380]. The commonly used methods to detect the
aforementioned pathologies include the labeling of blood plasma/
serum with 16-doxyl stearic acid (16-DS). 16-DS was chosen due to
its high affinity for human serum albumin (HSA). Peptides and
metabolites synthesized in the affected organ become attached to
HSA, thereby changing its binding capacity and conformation. Such
modification is expressed as varied contributions of the unbound,
strongly and weakly bound 16-DS to the albumin from the sera of
patients, as opposed to healthy individuals. These contributions are
calculated using simulation software to decompose EPR spectra, and
data are further processed, mainly by neural network software or
discriminant analyses. On the other hand, in vitro studies demonstrate
that ROS may damage HSA and affect its transport function [381].
Though this methodology offers satisfying accuracy, sensitivity and
specificity, and though the procedure seems relatively simple, there are
several technical issues that make this diagnostic tool anything but
easy. In a recent work by A. Pavićević et al., the analysis of the binding
of two spin-labeled fatty acids (SLFAs) to commercial HSA was reported
[382]. The obtained data indicate that ethanol, which is extensively
used in diagnostic spin labeling protocols, affects the binding of SLFAs
to HSA. In order to avoid using ethanol, test tubes should initially be
labeled with a small volume of SLFAs dissolved in an organic solvent
and left to evaporate. Afterwards, a certain amount of serum should be
added and incubated under constant vortexing. The weakness of such
an experimental setup is that SLFAs bind to a lower extent to HSA, due
to their low water solubility. There are also other difficulties with using
16-DS. One of them is its binding to seven possible sites of HSA;
consequently, information about conformational changes cannot be
obtained from the specific site. The other issue is that the doxyl group is
positioned nearly at the end of the hydrocarbon chain, opposite the
carboxylic group. Therefore, anchoring the 16-DS molecule to HSA
causes the doxyl moiety to protrude through the albumin's surface
[382,383]. Accordingly, 16-DS appears to be an unreliable reporter to
Fig. 5.2. (A) Determination of mtROS triggered NADPH oxidase activation in isolated human neutrophils by electron paramagnetic resonance measurement. Freshly isolated human
neutrophils (22x106 PMN/mL) were incubated in PBS with 300 µM Ca2+/Mg2+ and 10 mM DEPMPO for 15 min at 37 °C. Activators and inhibitors of phagocytic NOX were added as
shown in the figure. The spectrum for phorbol ester (PDBu)-stimulated PMN is displayed at decreased intensity (1/10). All reactions below the red spectrum contained 20 µM
myxothiazol. Incubations were with NOX inhibitor (VAS2870), intracellular calcium chelator (BAPTA-AM), cSrc kinase inhibitor (PP2) and PKC inhibitor (chelerythrine). All spectra were
recorded at room temperature in 50 µl glass capillaries (Hirschmann Laborgeräte GmbH, Eberstadt, Germany). EPR conditions: B0 =3300 G, sweep =150 G, sweep time =60 s,
modulation =3000 mG, MW power =10 mW, gain =9x102 using a Miniscope MS200 from Magnettech (Berlin, Germany). Representative spectra of mixed DEPMPO-OOH• and
DEPMPO-OH• adduct for 2 independent experiments. Spectra were recorded as described previously [373]. With permission of Mary Ann Liebert, Inc. Copyright 2014. (B) Whole blood
Hb-NO levels were determined by electron paramagnetic resonance spectroscopy as a read-out of iNOS activity in endotoxemic (lipopolysaccharide-treated) rats. The EPR measurements
were carried out at 77 K using an X-band table-top spectrometer MS400 (Magnettech, Berlin, Germany). The instrument settings were as follows: 10 mW microwave power, 7000 mG
amplitude modulation, 100 kHz modulation frequency, 3300 G center field, 300 G sweep width, 60 s sweep time and 3 scans. With permission of Springer-Verlag Berlin Heidelberg.
Copyright 2015. (C) Aortic •NO formation was measured in untreated control and angiotensin-II infused hypertensive mice by EPR spin trapping using Fe(DETC)2. Each spectrum was
measured from one murine aorta. The representative spectra below the bar graph are the mean of all measurements. EPR conditions: B0 =3276 G, sweep =115 G, sweep time =60 s,
modulation =7000 mG, MW power =10 mW, gain =9x102 using a Miniscope MS400 from Magnettech (Berlin, Germany). The A23187-stimulated •NO signal was absent when the aorta
were denuded, L-NAME (200 µM) was added, or when aorta from eNOS-/- mice were used (not shown). With permission of Mary Ann Liebert, Inc. Copyright 2014.
(a) Adapted from [63]. (b) Adapted from [371]. (c) Adapted from [63].
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detect local changes in albumin hydrophobic pockets.
Considering all the indicated difficulties, the course of our research
was oriented towards estimating the diagnostic potential of other SLs,
initially through in vitro studies on purified HSA, and eventually on
blood serum samples. The emphasis was on SSLs and SLFAs with a
doxyl group attached to the hydrocarbon chain closer to the carboxylic
moiety. The preliminary data indicated that the 3-maleimido proxyl (3-
MSL) is able to report changes in the cysteine-34 (Cys-34) environment,
induced by the binding of fatty acids, warfarin, ibuprofen and
benzodiazepines, whose interactions with HSA have been studied
exhaustively.
The use of SSLs can also reflect the antioxidant capacity and redox
state of HSA (from its free –SH group), since this probe does not bind to
the oxidized forms of –SH. The joint electrochemical and EPR study of
cytochrome c derivatives indicates that the use of SLs specific for
cysteine residues has great potential to estimate the redox state of other
proteins bearing free –SH groups as well.
It is very difficult in such innovative methods to reach satisfying
accuracy. One way can be to combine multiple methodologies such as
“electrochemistry and EPR”. EPR can be completed by electrochemistry
to get accurate oxygen concentration information by EPR [384]. Better
than adding these methods, one can couple them; this is the proposition
of J. Vacek and M. Mojovic that encourages efforts to “couple
Electrochemistry and EPR”.
5.3. Electrochemistry and EPR to investigate antioxidant and prooxidant
systems
Redox-active and reactive chemical forms directly contribute to
homeostasis, the maintenance of a stable internal environment. There is
therefore an emphasis on the direct detection and imaging of these
chemical entities, among which we classify free radicals, or substances
collectively known as RONS as well as an extensive group of anti-
oxidants. Therefore, combining electrochemical methods and EPR
spectroscopy represents a highly efficient solution, and both methods
can be complementary (thus off-line) or may be applied in situ (i.e. on-
line). Electrochemical methods may be used to monitor redox pro-
cesses; cyclic voltammetry is preferred, or advanced pulse voltammetric
techniques, which have a higher sensitivity due to the elimination of
capacitive currents [385].
Usually carbon electrodes and anodic voltammetry are used to
predict the electron-donor capacity and general reactivity of the
examined molecules. The oxidation products can then be identified,
which can be further investigated electrochemically, or even isolated
and characterized after electrolysis. When interpreting the electroche-
mical data (voltammograms), we assume that an effective antiradical or
antioxidant agent is oxidized at potentials approaching zero, where the
electron-donor capacity, and hence its effectiveness, decreases with the
increase of anodic potential. Given that many antioxidants are subject
to multicomponent (pH-dependent) redox transformations, we always
evaluate the potential of the first oxidation peak. Analyses are
conveniently performed in an aqueous medium at pH 7.4 in the
presence or absence of molecular oxygen, to eliminate artificial effects
associated with the spontaneous oxidation of the examined samples. If
the redox process is associated with the formation of a radical
intermediate, it is practically impossible to detect by electrochemical
approaches. For this purpose, EPR spectroscopy, also known as electron
spin resonance (ESR) spectroscopy is used [386]. With EPR, we can
monitor the absorption of microwave radiation by chemical forms with
one or more free electrons, e.g. free radicals, in a strong magnetic field.
They can be analyzed using the EPR directly in solution or cell
homogenates, in a tissue or even during the anodic reaction on the
electrode surface. If the lifetime of the radical forms is too short, the
spin-trapping technique is used.
Mojovic et al. present their research on the oxidation of phenolic
antioxidants as an example of an effective combination of electroche-
mical and EPR methods. Although this type of exogenous antioxidant is
often perceived sceptically in terms of its biological effect in vivo, a
number of these substances are highly effective experimental antiox-
idants, and in some cases, even chemoprotective agents are fully usable
in prophylactic treatments and complementary medicine [387]. One of
the most important examples is that of flavonolignans, which are used
as hepatoprotectants and antidotes for selected mushroom poisoning.
The main example is silybin and its 2,3-dehydroderivative, whose
mechanisms of redox transformations and antioxidant effects have
been studied [388]. Both of these substances, and also their structural
congeners, are characterized by a pleiotropic mode of action, which is
partly based on their ability to modulate signaling pathways, or
receptor systems in cells (see Section 10.4.2), and also by a combination
of their antioxidant vs. prooxidant effects. The antioxidant effect is
associated with a relatively high electron-donor capacity, especially for
flavonolignan 2,3-dehydroderivatives, and also their metal-chelating
capacity. Conversely, pro-oxidant effects are associated with the
transition of flavonolignans to reactive aryloxy radical forms or with
the formation of highly reactive flavonolignan-metal complexes, which
may secondarily generate free radicals through a Fenton-like reaction
[389]. Square-wave voltammetry on carbon electrodes [388] was used
to investigate the mechanism of redox behavior and analyze the
electron-donor capabilities of these substances. EPR spectroscopy was
further applied for the direct analysis of aryloxy radicals of flavono-
lignans that were generated in a strongly alkaline environment accord-
ing to the methodology developed initially for the purpose of research-
ing flavonol and flavone derivatives [390]. However, aryloxy radicals
can also be generated during the electrochemical oxidation of flavono-
lignans. Their short lifetime, however, makes their identification or
further analysis impossible. For this purpose, an in situ spectroelec-
trochemical technique was developed, where the oxidation of the
flavonolignan occurs in the presence of the spin-trap probe 5-tert-
butoxycarbonyl-5-methyl-1-pyrroline-N-oxide (BMPO). The radicals
produced during the electrooxidation therefore associate with BMPO
and give rise to a stable radical adduct, which can be subsequently
quantified by EPR [391]. In addition to the above, we see EPR as an
effective tool to analyze metal flavonoid complexes. EPR techniques
were applied to the characterization of the highly reactive oxovana-
dium(IV)/silybin complex, which induces the formation of RONS in the
cellular environment [392].
The main prerequisite to combining electrochemical methods and
EPR spectroscopy in the study of antioxidant and prooxidant molecules
(or molecules which combine both effects) is based on the fact that EPR
enables the visualization of free radicals in situ, which are not
detectable by electroanalytical approaches. By contrast, EPR exhibits
zero interference with the parent forms of the studied species, nor with
the final products formed during their redox transformations. Off-line
applications of EPR and electroanalysis have recently started to find
applications in research of more complex cellular systems and in vivo
monitoring and imaging [393]. In the above, in situ approaches (e.g.
[391]) were previously only applied in molecular studies with isolated
chemical species, whereas future applications clearly point towards the
on-line connection of EPR spectroscopy with electroanalysis under
more complex (preferably in vivo) conditions. There is clearly potential
in the application of implantable microelectrode systems, in the
optimization of new technical solutions for spectroelectrochemical
instrumentation and in the development of new hybrid techniques
based on electrochemical microscopy in combination with EPR imaging
approaches.
Applications of electroanalysis in conjunction with EPR spectro-
scopy are demonstrated here with low-molecular redox-active sub-
stances, monomeric flavonolignans, exhibiting an antioxidant effect
while under other specific conditions, exhibiting a prooxidant effect.
The applicability of the above techniques in research on biopolymers,
specifically proteins, is demonstrated in Section 5.2.
As discussed before, fluorescence is the most used methodology,
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especially for microscopy. As an example, one can use genetically
encoded probes, as proposed by Vsevolod Belousov to detect hydrogen
peroxide.
5.4. H2O2 detection using genetically encoded probes and nanoparticles
Out of the many techniques to study redox reactions, imaging using
fluorescent genetically encoded biosensors offers the widest set of
advantages. First, most importantly, it allows the monitoring of redox
events in real time in situ and in vivo. Second, the protein nature of the
sensors allows subcellular targeting similar to conventional fluorescent
proteins. Recently several technological improvements in the area of
redox imaging were achieved.
Since the development of the first genetically encoded redox
biosensors, they have all been based on fluorescent proteins with green
emission [394]. The development of the first red fluorescent probes for
H2O2, HyPerRed, made multiparameter imaging possible by using co-
expression of this sensor with green-emitting probes for H2O2, GSH/
GSSG and pH. Using HyPerRed, ER stress- induced H2O2 transients in
the mitochondrial matrix were detected for the first time within living
cells [395]. Interestingly, the increase in H2O2 was not associated with
any detectable increase in the mitochondrial matrix GSSG content.
Moreover, no H2O2 increase was observed in the inter-membrane space
or the cytoplasm of the same cells.
Another important direction in the improvement of genetically
encoded redox sensors is the expansion of the concentration limits of
detection. For example, for H2O2 signaling studies, it would be
important to have a sensor that reflects changes in near-basal concen-
trations of H2O2. Although it is not yet clear what the basal concentra-
tions of H2O2 are, the first successful attempt to make the H2O2 probes
more sensitive has been made recently [396]. The sensor consists of the
redox-sensitive fluorescent protein roGFP2 fused to yeast peroxiredoxin
Tsa2. This peroxidase has a 100 fold higher reaction rate than OxyR and
Orp1 - the domains used in previous H2O2 sensors, HyPer [397] and
Orp1-roGFP2 [398]. The Tsa2 part of the sensor is, however, made non-
sensitive to H2O2. Instead, it brings roGFP2 in close proximity to
endogenous Tsa1 incorporating into Tsa1 decamers. Therefore roGFP2
within the probes form redox relays with endogenous Tsa1 rather than
with fused Tsa2 inactivated by point mutagenesis. The resulting probe
is half-oxidized under basal conditions and sensitive to both increases
and decreases in H2O2. Still some effort has to be made to make
roGFP2-Tsp2 functional in cells other than yeast and to improve the
reduction speed of the sensor.
One of the basic properties of redox signaling is a high spatio-
temporal control over location, and the amounts of the oxidants
produced [399]. However, the exact sizes of H2O2 microdomains are
not easy to estimate because of the optical limits of fluorescent
microscopy. Super-resolution microscopy becomes a more and more
popular instrument to study fine structures in cells, however it has
never been used before to study dynamic processes, such as second
messenger dynamics and enzymatic activities. Recently, the H2O2
sensor HyPer2 was successfully used in sub-diffraction microscopy.
The exceptional photo stability of the sensor made its use in Stimulated
Emission Depletion (STED) microscopy possible. Fused to cytoskeleton
structures, HyPer2 was able to resolve the structures with superior
resolution and report H2O2 dynamics in growth factor- stimulated cells.
Uneven dynamics of the sensor oxidation between two filaments
separated by a distance of 100–200 nm suggests a less than ~100 nm
diffusion radius of H2O2 in the cytoplasm of fibroblasts.
On the other hand, developments have been made in the chemical
probes used for detection [400], such as near-infrared sensitive probes
[401], biphoton probes or nanoparticles (NPs). According to A. Suha
Yalçın, NPs are becoming widely used tools in the field of sensing and
imaging. Success in developing different luminescence probes has
enabled the monitoring of ROS production both in cells and whole
animals [402–404]. Among these are peroxalate-based NPs formulated
from peroxalate esters and fluorescent dyes that are used to image H2O2
in vivo with high specificity and sensitivity. Peroxalate NPs were
capable of imaging H2O2 in the peritoneal cavity of mice during a
lipopolysaccharide-induced inflammatory response [402]. The method
was further improved by reducing the size of the NPs and modifying
their content to detect H2O2 at physiological concentrations. Chemilu-
minescent NPs have also been exploited for the in vivo targeting and
imaging of tumors and were successfully used to image H2O2 as a tumor
signal molecule [405]. Probes that improve the stability of peroxalates
in aqueous systems are sensitive to low concentrations of H2O2 within
the physiological range. Chen et al. [406] have recently developed a
novel upconversion luminescence nanoprobe to detect ROS in aqueous
solutions, as well as diagnose rheumatoid arthritis and to bioimage ROS
in living cells.
5.5. High throughput assays for superoxide and hydrogen peroxide for
rigorous and specific activity of NADPH oxidases
J. Zielonka and B. Kalyanaraman propose that the combination of
fluorescence and EPR spin trapping may yield better results. RONS
encompass a range of species displaying oxidizing, nitrating, nitrosating
and/or halogenating properties. To better understand the pathophysio-
logical mechanisms of ROS/RNS it is crucial to detect and identify the
specific species responsible for a given biological effect and to
selectively inhibit the source of its formation. NADPH oxidases are a
family of enzymes, the only known function of which is transferring
electrons from NADPH to molecular oxygen, and the concomitant
generation of O2•– and H2O2. NADPH oxidases have been identified as
a promising therapeutic target for diseases bearing an oxidative stress
component. Despite the wide effort to develop inhibitors of the NOX
isoforms, only a limited number of such inhibitors are available. This is
due to serious limitations of the assays used to develop NOX inhibitors.
Typically, sensitive, but non-selective and artefact-prone assays have
been applied for the detection of NOX-derived oxidants, leading to a
high rate of false positive hits in high throughput screenings. For
example, it has been demonstrated that the L-012 probe to detect
superoxide requires one-electron oxidation and may generate super-
oxide by itself [407]. Also, in many assays horseradish peroxidase
(HRP) is used as a catalyst of the oxidation of the probe by NOX-derived
H2O2. The lack of probe selectivity for a specific oxidant and the
susceptibility of the HTS assays to peroxidase substrates and inhibitors
led to the controversy over the NOX-inhibitory potency of the positive
hits selected, including apocynin, VAS2870 and 2-acetylphenothiazine
[408].
Recently, Zielonka et al. have developed new assays to monitor the
activity of the NADPH oxidases [409] and used them to screen a small
library of bioactive compounds for potential NOX2 inhibitors [410].
These assays take advantage of the probes, which react directly with
O2•– or H2O2 and form easily detectable, fluorescent products. The
authors designed and synthesized a cell-impermeable analog of hydro-
ethidine, called hydropropidine (HPr+) to detect NOX2-derived O2•–
[411]. Upon its reaction with superoxide, HPr+ undergoes oxidation to
red fluorescent 2-hydroxypropidium whose fluorescence quantum yield
can be increased further in the presence of DNA. In order to detect H2O2
the authors applied coumarin boronic acid (CBA), which upon oxida-
tion forms the blue fluorescent 7-hydroxycoumarin (umbelliferone).
Both assays can be carried out in a 384-well plate format, with rapid
measurements using a fluorescence plate reader. For the secondary
assays, they applied two probes: hydroethidine (HE) for O2•– and
Amplex Red with HRP for H2O2. HE-based assay was coupled to rapid
UHPLC-based detection of 2-hydroxyethidium as a specific product of
the reaction of HE with O2•–. The Amplex Red-based assay was used in
combination with the fluorescence plate reader. Both secondary
(orthogonal) assays can be carried out in a 384-well plate format. All
four assays can be used for high throughput monitoring of NOX activity,
with the HE assay requiring rapid, microwell plate-compatible UHPLC
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instruments. Rapid UHPLC analyses also enable simultaneous monitor-
ing of O2•– and H2O2 formation, using a mixture of HE and CBA probes
[409,410]. The positive hits identified with these assays can be tested in
confirmatory assays, including the measurement of the rates of oxygen
consumption by NADPH oxidase in a medium throughput manner using
a Seahorse XF96 extracellular flux analyzer and in lower throughput
EPR spin trapping of superoxide using DEPPMPO or DIPPMPO cyclic
nitrone spin traps.
The newly developed assays provide a framework for reliable
measurement of the activity of NADPH oxidases and other cellular
sources of O2•– and H2O2. Rapid and rigorous detection and quantita-
tion of O2•– and H2O2 will lead to better understanding of the chemical
biology of O2•–/H2O2-producing enzymes (e.g. NOX isoforms) and will
also help discover specific inhibitors of NOX isoforms.
Most of the time, ROS detection is applied to biomedical science,
but very important results can be obtained in plant science, which helps
to understand posttranslational modifications, as proposed by B. De
Smet, F. Van Breusegem and J. Huang. The oxidation of crucial
cysteines to sulfenic acid (SOH), has emerged as a biologically relevant
post-translational modification (PTM) with particular importance in
redox-mediated signal transduction [412]. Thus, identifying the sulfe-
nome under oxidative stress would allow us to identify key redox-
sensors and –transducers [413,414].
5.6. Chemical and genetic tools for plant sulfenomics
The oxidation of crucial cysteines to sulfenic acid (SOH), has
emerged as a biologically relevant post-translational modification
(PTM) with particular importance in redox-mediated signal transduc-
tion [412]. Thus, identifying the sulfenome under oxidative stress
would allow us to identify key redox-sensors and -transducers
[413,414].
Sulfenomic studies have only recently been applied to plants
[414–416]. As sulfenic acid is often unstable, its identification was
mainly examined on a protein-by-protein-basis. At present, both
chemical and genetic approaches are used in plants. The majority of
the chemical probes are dimedone derivatives (5,5-dimethyl-1,3-cyclo-
hexanedione), that selectively react with sulfenic acid [417]. The bio-
DCP1 probe, which was used in Medicago truncatula, is a dimedone
analog carrying a biotin affinity tag used for purification [416]. As
biotin has many drawbacks, new azido- and alkyne-functionalized
dimedone-analogs were developed that allow the addition of biotin
post-extraction on the dimedone-tag using click chemistry [415,418].
Their small size and membrane permeability allow the in vivo tagging
of sulfenylated proteins. In Arabidopsis cells, the DYn-2 probe was used
to identify the sulfenome under oxidative stress [415].
The yeast AP-1 (YAP1)-based probe offers a genetic way for the in
vivo identification of plant sulfenomes [54,55]. This was first applied in
Medicago truncatula to identify the sulfenome upon Medicago truncatu-
la–Sinorhizobium meliloti symbiosis [416]. Recently, a YAP1C-GS probe
has been developed and expressed in Arabidopsis cells to reveal the
sulfenome under oxidative stress [414].
Using a genetic approach has the advantage that, once the material
is transformed, experiments are cost-efficient, allowing multiple repeats
and treatments. Additionally, the probe can be targeted to specific
tissues or even organelles. On the other hand, chemical probes generate
a larger coverage of the sulfenome in a single experiment, as they
penetrate whole cells; they do not require transformation and generate
stable covalent bonds between the sulfenylated protein and the probes.
Another attractive difference is the mode of trapping the sulfenic acid.
Whereas the YAP1C genetic probe traps sulfenic acid in its protein
context, defined by protein-protein interaction, the chemical probes
trap sulfenic acid independently of the protein environment. Another
characteristic to consider is that the incubation of the chemical probe
can influence the oxidation within a cell, which should not be a
problem for the permanently expressed genetic probe, although its
expression can act as a scavenger of the oxidized proteins and hence,
alter the cell/plant redox state.
As both genetic and chemical probes have specific advantages, the
combination of their data obtained with both probes covers the largest
part of the plant sulfenome. Current tools are based on protein-
identification, rather than on site-identification. Therefore, future
research should focus on mapping specific sulfenylation sites.
Quantifying the protein sulfenylation, or even the specific cysteine-
sulfenylation in response to several elicitors would further improve the
sulfenomic approaches and assess the role of cysteine-oxidation upon
redox signaling.
5.7. Conclusions
As outlined above, imaging ROS is still very challenging, and the
choice of the method will largely depend on the experimental condi-
tions. For the selective in vitro specific detection of superoxide on cells,
for example, EPR coupled to spin-trapping is the gold standard method.
Abbas et al. have recently developed the detection on living cells under
conditions close to in vivo conditions. Less selective, but allowing in
vivo EPR imaging and protein folding and mobility, EPR can be coupled
to spin labeling to allow redox status determination. Coupling to
electrochemistry allows the accurate determination of either the oxygen
levels, or the anti-oxidant's ability. Genetically encoded biosensors
make it possible to determine hydrogen peroxide and open the way to
in vivo luminescence bio imaging. Strong efforts are made in chemistry
to allow the selective and easy detection of ROS with fluorescent
probes, such as nanoparticles. NPs are versatile, and can be used to
detect superoxide anion and hydrogen peroxide. EPR and fluorescence
can be coupled, as recently proposed by Zielonka et al.; this yields very
accurate detection of NADPH oxidase activity, a key enzyme in
oxidative stress. Combining different methods can help understand
oxidative stress in a post-transcriptional pathway, as proposed by De
Smet, Van Breusegem and Huang in plant biology.
There is still no gold standard for ROS detection and imaging. Many
methods are under development, and more collaboration between
biologists, methodologists of the modality (e.g. fluorescence, EPR)
and chemists is needed to make progress and avoid misinterpretations
of experiments leading to false conclusions.
6. Reactive oxygen and nitrogen species in cardiovascular
pathologies
Rainer Schulz (E-mail: rainer.schulz@physiologie.med.uni-gies-
sen.de), Andreas Daiber (E-Mail: daiber@uni-mainz.de) and Fabio Di
Lisa (E-mail: fabio.dilisa@gmail.com).
6.1. Introduction
In the cardiovascular system, reactive oxygen and nitrogen species
(RONS) play an ambivalent role in that small amounts of RONS mediate
protective effects (anti-atherosclerotic [Schröder], pro-angiogenesis
[Matsui, Bachschmid], endogenous cardioprotection [Andreadou]),
while large quantities of RONS cause cell injury eventually leading to
loss of viability. RONS-induced cell derangements occur at the level of
any organ, including heart [Görbe, Giricz, Ferdinandy] and brain
[Casas, Schmidt], especially in the presence of co-morbidities (e.g.
diabetes [Schröder; Görbe, Giricz, Ferdinandy]). Furthermore, recent
work highlights the contribution of alterations of the intracellular Zn2+
pool [Tuncay, Turan] in RONS-induced cell injury. Importantly, the
source of RONS due to its cellular (parenchyma [Casas, Schmidt] vs.
vasculature [Schröder]) and subcellular localization might contribute
to the beneficial [Schröder] or deleterious [Casas, Schmidt] action of
RONS. Among the many sources of RONS, a relevant role is played by
NADPH oxidases (NOX), uncoupled nitric oxide synthases (NOS) [Li,
Förstermann], and various processes in mitochondria. For instance, the
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ischemic heart accumulates succinate that upon reperfusion is oxidized
causing a burst in ROS formation due to reverse electron transport
[Mulvey, Krieg]. Strategies to reduce excessive RONS include admin-
istration of antioxidant enzymes (more recently incorporated in endo-
somes and targeted by antibodies to specific cell types [Muzykantov])
or pharmacological up-regulation of the endogenous antioxidant de-
fense [Lazou]. In addition, an antioxidative effect has been reported for
compounds already used in daily practice. This is the case with
glucagon-like peptide-1 or DPP4-inhibitors [Steven, Daiber] that abro-
gate stress-induced blood cell derived RONS. However, antioxidant
strategies must be used with caution since they might interfere with
endogenous organ protection [Andreadou]. The chapter
“Cardiovascular Pathologies” discusses many of the above aspects and
is structured according to the importance of RONS in the blood vessels,
the heart and the brain (Fig. 6.1).
6.2. Oxidative stress and redox processes in atherogenesis and angiogenesis
As pointed out by Katrin Schröder, atherosclerosis is a vascular
disease characterized by plaque and neo-intima formation, as well as
local inflammation of the vessel wall. The latter is, in part, a
consequence of endothelial dysfunction. Monocytes are attracted and
adhere at sites of endothelial activation, invade the vessel wall and
support a vicious cycle of inflammation and cellular recruitment by
processes involving the formation of reactive oxygen and nitrogen
species (RONS). Especially the superoxide anion (O2•¯) is potentially
detrimental for vascular function and promotes atherosclerosis [419].
O2•¯ not only limits •NO-bioavailability, but also gives rise to ONOO¯,
which mainly acts as a potent toxic agent. The main source of RONS in
the vascular system is the family of NADPH oxidases, whose only
known function is the formation of O2•¯ and H2O2. The first NADPH
oxidase identified was NOX2, which is the primary NADPH oxidase in
macrophages and leukocytes. Its native function is host defense by the
massive formation of O2•¯, H2O2 and resulting RONS, in a process
termed oxidative burst. Beside the detrimental consequence of massive
RONS formation, these species also play an essential role in signal
transduction. Recently additional NADPH oxidases have been identified
and it is now clear that the number of RONS produced, the site of their
formation as well as the type of RONS influences the subsequent
signaling. Within the NOX family, NOX4 is an exception as it mainly
produces intracellular H2O2 in a constitutive manner at very low
concentrations. NOX4-derived H2O2 does not influence •NO bioavail-
ability, rather it can directly react with proteins in signaling pathways.
In fact, NOX4 appears to exert a protective role in the vascular system
and prevents vascular inflammation [420]. This protection is, among
other mechanisms, mediated by the maintenance of NRF2 expression,
which eventually leads to the expression of heme oxygenase-1 (HO-1).
Through this pathway, NOX4 favors CO production, which contributes
to endothelial quiescence and prevents leukocyte adhesion. The pro-
tective role of NOX4 is supported by genetic approaches. Nox4 deletion
has been reported to promote atherosclerosis in both ApoE-/- mice and
in a model of locally defined atherosclerosis through flow restriction
(partial carotid artery ligation with high fat diet) [421]. Similar
evidence has been obtained in an LDL receptor knockout mouse
[422]. On the other hand, endothelial specific overexpression of Nox4
protected ApoE-/- mice against high fat diet induced atherosclerosis
[423]. Notably, Nox4 expression is reduced in diabetic patients who
develop atherosclerotic plaques when compared to diabetic individuals
without atherosclerosis [424]. In conclusion, various forms of stress
induce an increased expression of Nox4 that elicits protective mechan-
isms at least in the vascular system. Importantly, there is evidence that
the beneficial role of NOX4 in vascular injury occurs not only in mice,
but it may also apply to clinical settings.
Matsui and Bachschmid propose that angiogenesis is redox regu-
lated by the formation of protein glutathione adducts. Oxidative post-
translational modification may alter protein functions and mediate
cellular signaling. Protein thiols form reversible oxidative modifications
including S-sulfenylation (-SOH) and S-nitrosylation (-SNO) [425],
which may react with glutathione (GSH), an abundant intracellular
thiol, to form more stable GSH-protein adducts (S-glutathionylation)
[426]. Protein GSH-adducts can regulate enzyme activity, localization,
protein interactions and stability. Various proteins are known to be
modified by GSH adducts [427]. GSH adducts can be removed by
glutaredoxin-1 (Glrx), a cytosolic thioltransferase that in this way
completes the redox signaling cycle. The in vivo role of Glrx and its
protein targets in pathophysiology has been explored recently
[428–430]. Oxidants are increasingly recognized as factors that pro-
mote angiogenesis, and mouse studies revealed that decreasing oxi-
dants may impair ischemic revascularization after hind limb ischemia
[164]. Conversely, increasing oxidants by NOX4 or decreasing the
antioxidant response by means of Nrf2 deletion may improve ischemic
limb revascularization. These data put forward the concept that
oxidants play a protective role in ischemic revascularization, in
accordance with multiple reports on ROS conferring beneficial redox
Fig. 6.1. Processes contributing to the increase in ROS levels in various tissues. Mitochondrial pathways are highlighted as prominent sources of ROS, especially in the heart. Besides their
involvement in tissue injury, ROS have been described also as mediators of cardiac protection against ischemia/reperfusion damage.
J. Egea et al. Redox Biology 13 (2017) 94–162
120
signaling in other settings. Glrx is not merely an antioxidant, but
obviously also exhibits anti-angiogenic properties. Increased Glrx
expression inhibits the angiogenic activity of cultured endothelial cells
[431]. Consistent with this finding, Glrx overexpression in vivo also
attenuates revascularization after hind limb ischemia [430]. Glrx is
known to activate the NF-κB pathway [432]. NF-κB hyper-activation in
endothelial cells likely stimulates non-canonical Wnt5a signaling,
which induces expression and release of the soluble vascular endothe-
lial growth factor (VEGF) receptor 1 (sFlt-1) into plasma [430]. sFlt-1 is
a VEGF decoy receptor, blocking VEGF binding to the proangiogenic
VEGF receptor 2. Impaired ischemic revascularization in diabetic mice
is associated with elevated levels of sFlt-1 in the ischemic muscle.
Because Glrx expression is also NF-κB dependent, proinflammatory
conditions such as atherosclerosis [433] and diabetes [432] may
increase Glrx leading to impaired or dysregulated angiogenesis. Ablat-
ing endogenous Glrx further accelerates ischemic limb revasculariza-
tion. Hypoxia-inducible factor (HIF-1α), a major angiogenic transcrip-
tion factor, is stabilized by GSH adducts [428]. In normoxia HIF-1α is
hydroxylated and binds to ubiquitin ligase pVHL, which targets HIF-1α
to proteasomal degradation. GSH adducts, induced by oxidants or Glrx
inhibition, stabilize and activate HIF-1α. As previously reported, nitric
oxide-induced S-nitrosylation of HIF-1α [434] may also be converted
into more stable GSH adducts in the presence of GSH. Watanabe et al.
confirmed a HIF-1α GSH adduct of Cys520 (mouse Cys533) by mass
spectrometry and demonstrated increased expression of HIF-1α and
VEGF-A in ischemic muscle of Glrx KO mice [428]. Increased GSH
protein adducts in ischemic limbs are not a hallmark of oxidative stress,
but rather contribute to beneficial responses to ischemia through HIF-
1α activation. This may be a mechanism by which oxidants promote
ischemic revascularization. In summary, Glrx deletion may facilitate
revascularization of ischemic muscles not only by means of HIF-1α
stabilization, but also by an increase in GSH adducts of other proteins
involved in angiogenesis. Therefore, inhibiting Glrx can be a therapeu-
tic strategy to restore circulation in ischemic limbs.
6.3. RONS formation in ischemic preconditioning, cardiac cycle, ischemia/
reperfusion and cardiomyopathy
According to Andreadou, low levels of RONS may be associated
with beneficial cardioprotection by interventions known as ischemic
pre- and post-conditioning (PC, PostC). Cardiac injury associated with
post-ischemic reperfusion is contributed mostly by an increased level of
reactive oxygen and nitrogen species (RONS), but also by the reduced
availability of “beneficial” reactive species such as nitric oxide and
intracellular Ca2+ overload. These deleterious factors synergize in
favoring a prolonged opening of the mitochondrial permeability
transition pore (mPTP) that is generally considered as a determining
factor in ensuing cell death. However, despite the well-established
association between RONS elevation and reperfusion injury of the
heart, so far antioxidant treatments have hardly provided any ther-
apeutic benefit in clinical studies of cardiac disease [435,436]. On the
other hand, reperfusion injury is greatly reduced by PC and PostC
[435,437]. Although the cardioprotective mechanisms triggered by
conditioning protocols are still a matter of debate [438], a general
consensus exists that RONS play a crucial role. Indeed, while an
excessive formation of RONS contributes to irreversible injury, small
amounts of RONS contribute to protection, possibly through a redox-
dependent activation of protective cytosolic kinases [439]. In this
respect RONS share the same paradox with the conditioning phenom-
ena per se, in that a short ischemia/reperfusion episode protects the
same as a mild RONS elevation, whereas a prolonged duration of
ischemia followed by reperfusion induces injury that largely depends
on lethal levels of intracellular RONS [439]. The role of antioxidant
compounds in cardioprotection induced by conditioning strategies is an
emerging issue, which needs elucidation in order to provide useful
information for the translation of the conditioning phenomena in
clinical practice [438]. We should mention that PC is mediated in part
by a mild formation of RONS, possibly in response to the opening of
mitochondrial KATP channels, and also PostC may lead directly or
indirectly to a decrease in RONS [440]. Since the role of antioxidant
Fig. 6.2. The data show marked increases of [Zn2+]i under either ROS (A) or RNS (B) increases. Bars represent means (± ) and *P<0.05 w.r.t. initial value. Inset: Representative
electron micrograph images under ZnPT (1-μM) exposure. Magnification: x12,930; bar: 1000 nm; N: nucleus, M: mitochondria, z: Z-line, L: lysosome, arrow: T-tubule, arrow head: sarco/
endoplasmic reticulum (SER).
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compounds in these conditioning phenomena might differ to some
extent, it is important to distinguish their role in pre-and/or postcondi-
tioning separately. Several in vivo studies have thus far shown
divergent results concerning the role of widely used antioxidants in
the prevention and/or abrogation of the beneficial effects of PC in
reducing myocardial infarct size. Skyschally et al. [441] demonstrated
that the administration of ascorbic acid in pigs abolished the beneficial
effect of PC on infarct size possibly due to ROS scavenging [442].
Accordingly, we also showed that in rabbits the antioxidant action of
the acute administration of vitamin C, reflected by a decrease in blood
and tissue levels of lipid peroxidation products, abolished PC-induced
protection [441]. It is worth pointing out that the use of antioxidants is
increasing. This is related especially to the commercialization of
numerous nutritional supplements or plant extracts containing antiox-
idant compounds, such as polyphenols and flavonoids that are mar-
keted for the prevention of cardiovascular diseases [443]. Based upon
the dependence of endogenous protective mechanisms on ROS genera-
tion, it is essential to know the role of all the antioxidant compounds in
different physiological and pathological conditions of the cardiovascu-
lar system. The complete understanding of redox mechanisms control-
ling RONS levels in cardiovascular pathophysiology is likely to allow
the design of new clinical trials for the use of antioxidants in cardiac
diseases.
According to Tuncay and Turan, Zn2+ release during the cardiac
cycle results in increased intracellular free Zn2+([Zn2+]i) levels, and
this release is increased in the setting of oxidative stress [444,445].
However, it is not known whether or not there is a direct relationship
between the increased production of RONS and [Zn2+]i changes in
cardiomyocytes. Thus, by using confocal microscopy and the specific
fluorescence dye FluoZin-3 AM (3 µM), [Zn2+]i changes were mon-
itored in a H9c2 cardiomyoblast cell-line exposed to RONS. Acute
increases in hydrogen peroxide (H2O2, 100 μM) induced marked
increases in [Zn2+]i, which could be reversed by a thiol reducing agent
like dithiothreitol (DTT, 500 μM) (Fig. 6.2A). The NO donor NaNO2
(100 µM) induced similar marked increases in [Zn2+]i, which was not
observed in the presence of a selective/potent soluble guanylyl cyclase
inhibitor like ODQ and was normalized with a heavy-metal Zn2+
chelator like TPEN (Fig. 6.2B).
Electron microscopic analysis also demonstrated that increased
[Zn2+]i can induce marked alterations in the ultrastructure of rat
cardiomyocytes such as clustering of mitochondria, disruption and
damage of myofibrils, enlargement in T-tubules and distortion in the T-
tubules (TT) and sarcoplasmic reticulum (SR) intersection (Fig. 6.2,
inset). Acute increases in RONS can induce marked elevation of [Zn2+]i
in cardiomyocytes, which may underlie cardiac dysfunction under
oxidative stress. In conclusion, in cardiomyocytes, elevated [Zn2+]i
correlates with increased RONS levels.
Mulvey and Krieg highlight the important role of mitochondrial
metabolism and RONS formation in myocardial ischemia. RONS have
long been known to be key mediators of ischemia/reperfusion (IR)
injury, driving not only acute damage but also initiating the patholo-
gical cascade that develops over the subsequent weeks and months.
This RONS production has generally been assumed to be a non-specific
effect of oxygen interacting with a dysfunctional mitochondrial respira-
tory chain upon its reintroduction to ischemic tissue at reperfusion, a
process, which is complex and imprecise. However, recent work from
our laboratory shows that contrary to this hypothesis there is in fact a
distinct metabolic mechanism responsible [136]. Using an untargeted
metabolomic approach, a metabolic hallmark of ischemia was identi-
fied from a range of ischemic tissues, which notably included the
selective accumulation of succinate. Despite previous descriptions of
this in the literature [446], neither the mechanism behind this nor its
implications had been characterized. The succinate accumulated during
ischemia was found not to originate from normal cardiac metabolism,
but rather through aspartate-mediated pathways and reverse action of
succinate dehydrogenase (SDH), driven by accumulated ischemic
NADH passing electrons through complex I and onto the coenzyme Q
(CoQ) pool, which favors the reduction of fumarate by SDH to drive
succinate accumulation. Following reperfusion there was then a rapid
metabolism of is chemically accumulated succinate, with baseline levels
re-established within 5 min [136,447]. RONS generation from electrons
stored in the succinate pool is then thought to occur primarily through
the reverse action of complex I in a phenomenon known as reverse
electron transport (RET) that has been well characterized in vitro but
whose importance in vivo has only been recently understood [448].
Importantly, this model provided several testable predictions with
regard to the effect of manipulating succinate levels in ischemic tissues
and therefore the downstream extent of RONS production and also
infarct size as a clinically relevant indicator of IR injury. Decreasing
mitochondrial succinate levels during ischemia using either an infusion
of the competitive SDH inhibitor dimethyl malonate [136] or sodium
malonate [449] resulted in a decrease in RONS production and reduced
infarct size in an in vivo mouse model of myocardial IR injury. These
could both be brought back to control levels by an infusion of dimethyl
succinate. In addition to modulation of mitochondrial metabolism,
recent evidence suggests it is also possible to modulate the quantity of
RONS produced at reperfusion from the electrons stored in the ischemic
succinate pool through inhibition of the active/deactive transition of
Complex I. During ischemia, Complex I enters the deactive state but is
rapidly reactivated at reperfusion, enabling it to support RONS
production by RET [450]. A growing body of evidence suggests a
central role for the Cys39 residue found within the ND3 subunit of
Complex I, and indeed it has recently been demonstrated using the
mitochondria-targeted S-nitrosothiol MitoSNO that S-nitrosation of this
residue can inhibit the active/deactive transition and so allow dissipa-
tion of the mitochondrial ischemic succinate pool via alternative
pathways to minimize the production of RONS by Complex I [451].
Based on considerations by Görbe, Giricz and Ferdinandy, mito-
chondrial RONS play an important role in metabolic cardiomyopathies.
A growing body of evidence indicates that mitochondrial oxidative
stress has a major role in the development of cardiomyopathies in
metabolic diseases [452–454]. Cardiac function relies heavily on intact
mitochondrial function including mitochondrial biogenesis, fusion,
fission, and autophagy-mitophagy. Disturbances in these processes
have been linked to increased mitochondrial oxidative stress and the
development of metabolic cardiomyopathies. Several oxidative and
nitrative stress-related cellular processes have been shown to be
deranged in metabolic disorders. In a rat model of hypercholesterole-
mia enhanced cellular peroxynitrite formation due to an upregulation
of NOX4 has been described and discussed as a potential mechanism of
cardiovascular complications [455,456] – of note, this finding high-
lights that NOX4 can play different roles in different organs or disease
settings depending on whether it confers beneficial redox signaling or
contributes to excessive RONS formation. In the same model, mito-
chondrial expression of connexin43, which may reduce mitochondrial
reactive oxygen species production, was decreased [457]. Evidence
obtained in models of metabolic syndrome suggests that mitochondrial
oxidative stress is linked to cardiac dysfunction. Indeed, in high-fat diet
(HFD)-induced mouse models of metabolic syndrome the elevation in
myocardial mitochondrial RONS production was associated with re-
duced diastolic circumferential strain rate assessed by tagged cardiac
magnetic resonance imaging [458]. In addition, in mice, diastolic
dysfunction induced by a high-fat high-sucrose (HFHS) diet was
accompanied by a 3-fold greater rate of mitochondrial H2O2 production
along with a decrease in both oxygen consumption and ATP synthesis.
In this latter model transgenic expression of mitochondria-targeted
catalase alleviated oxidative stress and improved diastolic function
[459] indicating that mitochondrial ROS formation is causally linked to
contractile impairment. This relationship is further supported by
pharmacological approaches suggesting that decreasing mitochondrial
RONS levels might have a great therapeutic potential – keeping in mind
that RONS can also have beneficial effects as discussed for precondi-
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tioning phenomena above [438], and therefore the use of antioxidants
is always a two-edged sword that needs to be used with great caution.
Diabetic mice treated with a mitochondria-targeted antioxidant, Mito-
TEMPO, showed preserved heart rates and improved survival after
myocardial infarction [460] along with a decrease in mitochondrial
RONS generation, apoptosis and myocardial hypertrophy [461]. The
latter observations were also obtained ex vivo in hyperglycemic cultured
cardiomyocytes [461]. Drug candidates other than direct antioxidants
have also shown efficacy in the treatment of metabolic cardiomyopa-
thies. Mitochondrial RONS cause opening of the mPTP channels in
which cyclophilin D has a major role. A novel inhibitor of cyclophilin D,
NIM811, reduced infarct size in diabetic rats [462]. Mitochondrial
aldehyde dehydrogenase-2 (ALDH-2), an enzyme responsible for the
removal of cardiotoxic aldehydes, is activated by physiological levels of
mitochondrial RONS. ALDH-2 overexpression is reported to reduce
diabetic cardiomyocyte hypertrophy and contractile dysfunction, while
activation of ALDH-2 by Alda-1 has been shown to alleviate high
glucose-induced apoptosis and the reduction in mitochondrial mem-
brane potential in H9C2 cells [463]. Although the above reports
connect increased mitochondrial RONS production to metabolic cardi-
omyopathies, a few studies showed a lack of correlation between
mitochondrial RONS formation and diabetic cardiomyopathy
[464,465]. These findings suggest that mitochondrial oxidative stress
might not be present in all models and at all stages of metabolic diseases
and that it might not be the common underlying mechanism of
metabolic cardiomyopathies, again, warranting caution with the use
of antioxidants although the targeted modulation of mitochondrial
RONS production and its downstream targets might represent applic-
able future therapeutic strategies.
6.4. RONS formation in cerebral ischemia and stroke
As pointed out by Casas and Schmidt, NADPH oxidase and nitric
oxide synthase derived RONS represent potential targets for stroke
therapy. Stroke is the leading cause of neurological impairment in
industrialized countries, making it the second leading cause of death
worldwide and the primary cause of disability. Despite this high
medical and social need, no neuroprotective agent is available for
clinical therapy and only a single drug reached the market, the anti-
thrombolytic drug rt-PA for ischemic stroke. However, due to its
multiple contraindications almost 85% of all stroke patients are
excluded from receiving this treatment. RONS have been considered
as key players in post-stroke neurodegeneration [466]. Targeting
pathologically relevant sources of RONS, such as NOX and NOS, may
thus provide promising innovative therapeutic approaches. NADPH
oxidases, which include the already mentioned NOX4, constitute the
only known enzyme family with the sole function to produce O2•¯ and
H2O2. The NOX family consists of seven isoforms: NOX1-5 and the dual
oxidases (DUOX 1–2). Due to accessory proteins, each isoform has a
distinct quaternary structure, activity regulation, tissue expression and
product. Therefore, not all isoforms may contribute equally to ischemic
injury [32]. Based on a systematic review and meta-analysis, NOX1
seems to play no role in stroke, neither in infarct size reduction nor in
neurological outcome. Similarly, the evidence for NOX2 is extremely
contradictory and more or less disproven by a pre-clinical randomized
controlled trial with the aim to validate NOX2 as a stroke target. This
study turned out negative highlighting a persistent publication bias
towards positive findings and the lack of statistical power in many
studies [467]. Conversely, brain ischemia is one of the best-validated
disease indications for NOX4. Under hypoxic conditions, NOX4 is
upregulated leading to oxidative damage, cytotoxicity and neuronal
death. Therefore, NOX4 inhibition has been recently considered as a
promising target for this pathology. Preclinical results show that NOX
inhibition by VAS2870 significantly reduces infarct size and post-stroke
RONS formation, suggesting indeed a major contribution of this NOX.
Further pre-clinical experiments are being currently conducted using
specific NOX4 inhibitors and different animal models of stroke [468].
Similarly, nitric oxide is also considered a member of the RONS family,
generated by different NOS isoforms. Studies in mice showed that
deletion of neuronal NOS (isoform 1) leads to a significant reduction of
post-stroke brain damage, suggesting therapeutic targeting of NOS-1. In
fact, it has been recently reported that NOS inhibition (L-NAME)
significantly reduces tissue damage and infarct size post-stroke using
both in vitro and in vivo ischemia models [469]. However, this was not
the case for NOS1-PSD-95 interaction inhibitors, possibly by also
interfering with other, protective pathways. Pharmacological targeting
of NOX and NOS dependent oxidative stress clearly has neuroprotective
effects and reduces infarct volume and RONS production after stroke
leading to improved neuronal function and survival. Current and future
experiments are aimed at validating these findings in phase II and III
clinical trials in other rodent and large animal species for further
clinical development as first-in-class neuroprotective treatment of
stroke.
6.5. Therapeutic targeting of eNOS uncoupling and cardiovascular
oxidative stress and inflammation
Based on considerations by Li and Förstermann, pharmacological
prevention of eNOS uncoupling is another antioxidant therapeutic
strategy that may not interfere with the protective role of redox
signaling in the cardiovascular system [9]. Oxidative stress plays a
crucial role in the pathogenesis of cardiovascular disease. Among the
major producers of RONS, the uncoupled endothelial nitric oxide
synthase (eNOS) makes a significant contribution to RONS generation
in cardiovascular tissues [470,471]. Under physiological conditions,
eNOS produces •NO. Endothelium-derived •NO has anti-hypertensive,
anti-thrombotic and anti-atherosclerotic properties by relaxing blood
vessels, inhibiting platelet aggregation/adhesion, preventing leukocyte
adhesion/migration, and inhibiting smooth muscle cell proliferation
[472]. Under pathological conditions associated with oxidative stress
and inflammation, eNOS can be converted from a •NO-producing
enzyme to a superoxide-generating molecule, a process termed eNOS
uncoupling. All cardiovascular risk factors, such as diabetes, hyperten-
sion, hypercholesterolemia and smoking, may induce eNOS uncoupling
[472]. A number of mechanisms may contribute to eNOS uncoupling
[9,473], with deficiency of the eNOS cofactor tetrahydrobiopterin
(BH4), deficiency of the eNOS substrate L-arginine, and eNOS S-
glutathionylation being the most important ones. Peroxynitrite and
superoxide can oxidize BH4 to dihydrobiopterin (BH2), leading to BH4
deficiency. A lack of BH4 can also be caused by a reduction of BH4 de
novo synthesis (e.g. due to down-regulation of the BH4-synthesizing
enzyme GTP cyclohydrolase I) or by a decrease of BH4 regeneration
from BH2 (e.g. down-regulation of the recycling enzyme dihydrofolate
reductase). A recent study demonstrates that BH4-dependent and S-
glutathionylation-induced eNOS uncoupling are mechanistically inde-
pendent but functionally linked [474]. L-Arginine deficiency can be
caused by inflammation-induced up-regulation of arginases, enzymes
that compete with eNOS for the same substrate. By producing super-
oxide, uncoupled eNOS augments the pre-existing oxidative stress and
further enhances eNOS uncoupling, creating a vicious circle. Interest-
ingly, some established cardiovascular drugs (and some other com-
pounds) show the potential to prevent eNOS uncoupling. The recou-
pling of eNOS may represent pleiotropic effects of these drugs and
contribute to their therapeutic benefit. Angiotensin-converting enzyme
(ACE) inhibitors, angiotensin II type-1 (AT1) receptor antagonists,
statins, the organic nitrate pentaerythritol tetranitrate (PETN), eNOS
transcription enhancers and the red wine polyphenol resveratrol have
been shown to reverse eNOS uncoupling in disease models by elevating
tissue BH4 levels [475,476]. PETN [477] and the AT1 receptor blocker
telmisartan [478] additionally prevent eNOS S-glutathionylation.
Furthermore, arginase inhibition also represents a promising strategy
to recouple eNOS [479,480].
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As suggested by Muzykantov, the previously described detrimental
but also beneficial effects of RONS warrant careful targeting without
interfering with the beneficial signaling pathways by using site- and
species-specific approaches [9]. Liposomes and other nanocarriers
improve the pharmacokinetics of antioxidants including N-acetyl
cysteine (NAC) and antioxidant enzymes (AOE, i.e. catalase and SOD)
and thus help alleviate vascular oxidative stress predominantly via
detoxification of extracellular RONS [481]. In order to achieve targeted
endothelial interventions, these agents can be conjugated with anti-
bodies to endothelial determinants including cell adhesion molecules
ICAM [482] and PECAM [483]. In preclinical studies, diverse formula-
tions of such AOE conjugates (Ab/AOE) show binding to endothelium
after i.v. injection [482]. Targeting of these formulations qualitatively
improves protection of endothelial cells from extracellular RONS [484]
and RONS produced inside these cells [485]. As a result, Ab/AOE
injected into animals attenuated ischemia-reperfusion injury in lungs of
diverse species [486,487], normalized vasoreactivity in angiotensin II-
challenged mice [487], inhibited endothelial pro-inflammatory activa-
tion caused by cytokines and potentiated the anti-inflammatory effect
of NO donors [485]. Further, an indirect inhibitor of NADPH-oxidase
loaded in Ab/liposomes accumulated in endothelial cells, inhibited
RONS production and provided more potent protection vs. non-targeted
counterparts against oxidative stress in mice [488]. Ab/liposomes
loaded with EUK-134, a superoxide dismutase/catalase mimetic, bound
to endothelial cells and alleviated endotoxin-induced lung inflamma-
tion in mice [489]. Likewise, PECAM-targeted nanocarriers loaded with
tocopherol and EUK-134 alleviated endothelial inflammatory activa-
tion. Encapsulation in polymeric nanocarriers protects AOE from
proteases [490]. Modulation of geometry and affinity features of
targeted AOE formulations enables their delivery into endothelial
endosomes, quenching RONS produced in these vesicles and intercepts
pro-inflammatory endothelial signaling and abnormal activation [485].
Endothelial targeting of antioxidants enables anti-inflammatory me-
chanisms based on interception of endothelial RONS [9]. This drug
delivery strategy may find utility in the management of acute vascular
oxidative stress and inflammation (Fig. 6.3).
As explained by Lazou, accumulating evidence supports a key role
for peroxisome proliferator activated receptors (PPARs) in regulating
the redox state in the cardiovascular system through transcriptional or
post-translational effects and thereby controls the redox balance in
cardiac diseases [491]. PPARs are ligand activated transcription factors
that belong to the superfamily of nuclear hormone receptors, with well-
documented roles in the transcriptional regulation of cardiac lipid
metabolism and energy homeostasis. Their non-metabolic, anti-oxidant,
anti-ischemic and anti-inflammatory properties have emerged over the
past years and are being actively investigated in relation to cardiac
dysfunction. All three PPAR isoforms (α, β/δ, γ) have been implicated
in the modulation of oxidative stress, although different mechanisms
may be employed by each of them. PPARα and PPARγ function in a
similar way towards the modulation of oxidative stress, mostly through
the transcriptional regulation of target antioxidant enzymes. PPARα
activation via clofibrate diminishes RONS production and lipid perox-
idation in rat hearts subjected to acute myocardial ischemia through the
upregulation of transcription and activity of antioxidant enzymes such
as Cu/Zn-SOD (SOD1), Mn-SOD (SOD2), and catalase in the heart tissue
as well as the suppression of AT-1 induced NADPH activity [492]. The
PPARα agonist, WY14643, ameliorated oxidative stress in a rat model
of IR [493], which is reflected by HO-1 down-regulation post IR in
WY14643-treated myocardium. PPARγ agonists like troglitazone, rosi-
glitazone and pioglitazone induce glutathione peroxidase (GPx 3) in
human skeletal muscle cells and thioredoxin in neonatal rat cardiac
myocytes [491]. RONS generation was also suppressed in cultured
cardiac myocytes treated with a PPARβ/δ agonist due to upregulation
of catalase [494]. PPARβ/δ also inhibits RONS generation in vascular
muscle cells through inhibition of NADPH oxidases [495]. The effect of
PPARβ/δ activation on antioxidant defense may also be attributed to
improved mitochondrial biogenesis through regulation of target genes
such as PGC-1 and mitofusin 2 [496]. Upregulation and activation of
PPARs have been also implicated in the endogenous mechanisms of
cardioprotection implying that PPAR activation prior to IR could confer
Fig. 6.3. Overview on therapeutic options for the improvement of vascular dysfunction. Targeted antioxidant interventions to alleviate pro-inflammatory activation and oxidative stress
in endothelial cells. Endothelial ROS from activated NOX2 enzyme in endosomes are formed in response to cytokine binding to the receptors and ignite signaling cascade of transcription
factor NFκB. Targeted delivery of antioxidants, antioxidant enzymes (AOE) and inhibitors of ROS production can be achieved using antibodies and other ligands of endothelial surface
determinants including cell adhesion molecules PECAM and ICAM. Surface-bound targeted AOE intercept extracellular ROS, whereas targeted formulations using the same ligands
configured in a way permitting internalization into the ROS-signaling endosomes allows interception of pro-inflammatory activation manifested among other characteristics by exposure
of inducible cell adhesion molecules – E-selectin, VCAM-1, and ICAM-1 - that can be detected using imaging probes conjugated to the ligands of these molecules. With permission of the
publisher. Copyright © 1999–2017 John Wiley & Sons, Inc. All Rights Reserved.
Adapted from [9].
J. Egea et al. Redox Biology 13 (2017) 94–162
124
preconditioning-like protection to the myocardium. Activation of the
PPARα isoform results in significant anti-infarct protection, comparable
with the effect of classical ischemic preconditioning that appears to
involve survival cascades (ERK1/2 and PI3K/Akt), upregulation of
eNOS and the opening of mitochondrial KATP channels [497,498].
There are several remaining issues that need to be addressed regarding
the biological role of PPARs as regulators of the cardiac redox state,
especially regarding the translation of in vitro findings in the in vivo
setting. However, the pleiotropic activity of these receptors makes them
interesting therapeutic targets for the development of antioxidant
strategies that aim to control the intracellular redox balance in various
cardiac pathologies, especially linked to dyslipidemia, atherosclerosis,
and diabetes, that are frequently associated with cardiovascular
disorders.
Steven and Daiber emphasize the importance of the pleiotropic
antioxidant, anti-aggregatory and anti-inflammatory potential of estab-
lished drugs as exemplified by DPP-4 inhibitors and GLP-1 analogs
[19]. Glucagon-like peptide-1 (GLP-1) is an incretin hormone and
released from L-cells in the intestine after food uptake [499,500]. Its
receptor belongs to the family of G-protein-coupled receptors and
binding of GLP-1 induces insulin release from beta cells of the pancreas.
GLP-1 is involved in glycemic control and due to rapid degradation by
the exopeptidase dipeptidyl peptidase-4 (DPP-4) its half-life is below
two minutes [501,502]. Accordingly, inhibition of DPP-4 and supple-
mentation of GLP-1 represent new therapeutic targets for the manage-
ment of diabetes. Besides this first line indication, there are several
reports on beneficial effects of DPP-4 inhibition on cardiovascular
disease associated with atherosclerosis [503,504], but also with psor-
iasis [505], hepatic steatosis [506] and stroke [507]. All of these
diseases have in common, that inflammation and oxidative stress
contribute to their pathophysiology. It was previously shown that
DPP-4 inhibition suppresses the proinflammatory phenotype of isolated
myelomonocytic cells and proinflammatory cascades in endotoxemic
rats [508]. Investigation of the effects of DPP-4 inhibition and GLP-1
supplementation on endotoxemia and septic shock revealed improved
survival of septic mice (lipopolysaccharide i.p. injection), even when
the therapy with the DPP-4 inhibitor linagliptin or the GLP-1 analog
liraglutide was started six hours after induction of endotoxemia [371].
The improvement of mortality is based on the control of the initial
inflammatory response, which characterizes LPS-induced endotoxemia.
The oxidative burst of inflammatory, myelomonocytic cells, oxidative
stress measured by dihydroethidium fluorescence, expression of typical
inflammatory genes, as well as vascular infiltration of CD11b+ cells
was decreased in endotoxemic animals treated with linagliptin and
liraglutide. As a consequence, hemodynamic control was recovered by
linagliptin and liraglutide treatment preventing the development of
lethal hypotension in the endotoxemic animals, all of which was based
on activation of the AMP-dependent protein kinase (AMPK) [371]. Our
data suggest that DPP-4 inhibitors and GLP-1 analogs have inhibitory
effects on myelomonocytic cells, which in the case of DPP-4 inhibition
do not entirely rely on the GLP-1 receptor [372]. Inflammation and
hemostasis are subject to a complex interplay in the setting of sepsis.
Thrombocytopenia and disseminated intravascular coagulation (DIC),
characteristic features leading to end organ damage and death in septic
shock, were significantly improved by both drugs [372]. Similar results
were obtained in an animal model of experimental thrombosis [509].
Further support of this concept was based on the observation that GLP-1
analogs inhibit platelet activation and aggregation directly via the GLP-
1 receptor, which is expressed on murine and human thrombocytes, and
by cAMP/adenylyl cyclase signaling [372,509]. In conclusion, sepsis is
still a main cause of death all over the world. DPP-4 inhibition and GLP-
1 supplementation reduced the mortality in endotoxemic animals by
antioxidant, anti-inflammatory and antiaggregatory effects (Fig. 6.4).
The potential use of these drugs in patients with sepsis or other
inflammatory diseases needs further exploration.
6.6. Conclusion
Evidence derived by experimental approaches exploiting powerful
tools of molecular and cell biology is rapidly advancing our under-
standing of redox reactions involved in RONS formation. These
molecules, which were once investigated only for their possible
involvement in numerous diseases, are now attracting wide interest
for their role as intracellular signals, especially those in response to
metabolic or mechanical changes. Therefore, besides the well-estab-
lished notions that high intracellular levels of RONS impair function
and viability of practically any cell type, a large body of evidence
indicates that ROS are involved in countless physiological processes and
trigger powerful mechanisms of protection against cell injury.
In this review section we summarized established concepts and
recent advances supporting the dual role of RONS in cardiovascular
pathophysiology. These novel findings might support the therapeutic
potential of antioxidant interventions and explain the failure of clinical
trials using this approach. Indeed, the issues that remain to be
elucidated outnumber those that have been clarified.
7. ROS and the aging process
Jose Vina (E-mail: Jose. Vina@uv.es) and Gloria Olaso-Gonzalez (E-
mail: gloria.olaso@uv.es).
7.1. Introduction
The free radical theory of aging postulated by Harman in 1956 has
provided a theoretical framework for research oriented toward under-
standing the mechanisms of aging. This theory states that “aging and
Fig. 6.4. Proposed mechanisms of lipopolysaccharide (LPS)-induced vascular dysfunction
and improvement by linagliptin therapy. LPS treatment activates white blood cells (WBC,
envisaged by increased oxidative burst), increases serum levels of xanthine oxidase (XO),
increases DPP-4 serum activity and activates vascular cells (detected by expression of
endothelial adhesion molecules and inducible cyclooxygenase [COX-2]). This leads to the
infiltration of WBC to the vascular wall (detected by aortic FACS analysis for
myelomonocytic cells, inducible nitric oxide synthase [NOS2], NOX2 and myeloperox-
idase [MPO] expression) and oxidative damage of the vasculature (NOX1 expression, ROS
formation, 3-nitrotyrosine levels and lipidperoxidation by malondialdehyde [MDA]).
Finally, the tissue damage results in smooth muscle constriction and endothelial
dysfunction. With permission by Oxford University Press. Copyright © 2012.
Adopted from [508].
J. Egea et al. Redox Biology 13 (2017) 94–162
125
the degenerative diseases associated with it are attributed basically to
the deleterious side attacks of free radicals (ROS) on cell constituents
and on the connective tissue” [510]. Mitochondria have a major role in
ROS production [511]. On the other hand, NADPH oxidases (NOXs) are
important enzyme systems involved in inducible ROS formation, since
they catalyze the partial reduction of O2 to form ROS. It has been shown
that the enhanced expression and/or activity of NOX family members,
in particular NOX4, plays an important role in age-associated diseases
such as cardiovascular disease, fibrosis, cancer and neurodegenerative
diseases like Alzheimer's disease [512,513]. In this situation of mis-
balance, proteasome-mediated degradation of oxidized proteins is a
critical player for protein homeostasis maintenance. Proteasome dys-
function takes place during aging [514]. Proteasome up-regulation in
terms of assembly, quantity and function has been achieved through
genetic manipulation in animal models. This activation was shown to
be successful to decelerate aging progression by enhancing resistance to
oxidative stress. However, genetic manipulation is not applicable in
humans, so new studies should focus on the identification of nutritional,
pharmacological or physiological interventions with proteasome acti-
vating properties.
Oxidative stress has been linked with age-associated diseases, but
also with a geriatric syndrome characterized by diminished functional
reserve and increased vulnerability to low power stressors, i.e. frailty
(Fig. 7.1). An association between systemic oxidative stress biomarkers
(malondialdehyde, isoprostanes, protein carbonylation and lipoprotein
phospholipase A2) and frailty has been reported in the geriatric
population [515,516]. Nevertheless, recent data have shown that lower
expression of genes related to antioxidant responses to oxidative stress
in older people is associated with a higher risk of being frail
independently of age and sex (see El Assar et al. contribution, Section
7.6).
In recent years, epidemiological as well as laboratory data have
shown that antioxidant supplementation is at least useless if not
detrimental in aging [517]. Indeed, antioxidant supplementation did
not lower the incidence of many age-associated diseases but, in some
cases, increased the risk of death [518].
This has cast doubts on the classical “free radical theory of aging”.
We thus proposed “the cell signaling disruption theory of aging”. This
theory postulates that “ROS” cause aging inasmuch as they alter—-
sometimes irreversibly—the signaling network of the cell. If the cell can
cope with the stress caused by relatively mild action of ROS, then
adaptation takes place and damage does not occur. If, however, the cell
is overwhelmed by the action of radicals, subcellular damage and aging
will take place”. Indeed, radicals serve as signals and interaction
between them is tightly balanced. In this sense, we cannot support
the idea of proposing antioxidant supplementation for the general
population. It is much better to increase endogenous defenses by
nutritional or physiological manipulation than administering antiox-
idant compounds, such as vitamin C or E. In any case, these considera-
tions do not detract from the free radical theory of aging, which has
been extremely useful and has fostered research by providing a general
theoretical framework on which many of us have based decades-long
experimental research.
7.2. NADPH oxidases in aging and age-associated diseases
Pidder Jansen-Dürr and Rafal Koziel summarize that superoxide
anions and other ROS can exert beneficial effects under normal
conditions through adaptive cellular signaling responses. On the other
hand, ROS are able to induce direct damage to biologically sensitive
targets like lipids, proteins and nucleic acids, and their overproduction
is involved in both chronic diseases and age-related diseases. To date, a
variety of different theories of biological aging have been discussed
[519,520]; however, many of them describe ‘oxidative stress’ as the
Fig. 7.1. Scheme summarizing the main concepts of the free radical theory in aging and development of aging associated diseases and syndromes.
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common cause of aging.
The ‘free radical theory of aging’ predicts the major role of
mitochondria-derived ROS in aging [510], however, recent data
indicate a key role of other ROS sources in this process. A significant
number of enzymatic or chemical processes are capable of producing
ROS in vivo; however, the NOXs are the primary enzyme systems
involved in inducible ROS formation [65,521,522]. The NOX family of
membrane-associated enzymes consists of seven isoforms, Nox1-5 and
Duox1-2, and catalyzes the reduction of O2 to form ROS [512,521]. The
role and mechanism of the activation of NOXs is isoform type,
intracellular localization as well as tissue type specific, and NOX
mediated oxidative stress is strongly associated with a variety of human
age-related diseases [523](see also below). A growing number of
studies indicate that NOX4 is localized to mitochondria in many cell
types and promotes aging. We have previously suggested a new
pathway by which sustained NOX4 activity decreases mitochondrial
function and induces premature senescence in human umbilical vein
endothelial cells (HUVEC). NOX4 induced premature senescence by
decreasing the concentration and activity of mitochondrial respiratory
chain complex I [524,525]. Accordingly, NOX4 knockdown reduced
mitochondrial H2O2 production and markers of oxidative DNA damage,
increased the cellular proliferation rate and prolonged the replicative
lifespan by more than 2-fold [524,525]. It remains to be shown if
increased NOX4 activity contributes to aging of the vasculature in
mammals.
The effector role of NOX4, a constitutively active NOX isoform, to
drive cellular senescence is conserved for oncogene-induced senes-
cence, a tumor suppressor pathway that restricts the growth of pre-
neoplastic cells in mice and humans. Weyemi et al. found that NOX4 is
a critical mediator in the oncogenic H-RasV12-induced DNA-damage
response and subsequent senescence [526]. H-RasV12 overexpression
correlated with increased NOX4 expression, higher ROS levels, DNA
damage, histone H2A.X phosphorylation and p21Cip1 accumulation.
Similar conclusions were reached by Kodama et al. who showed that
NOX1- and NOX4-generated ROS play an important role in Ras-induced
premature senescence, which may involve the DNA damage response
and p38MAPK signaling pathways in primary human lung TIG-3 cells.
Both NOXs were upregulated by the Ras oncogene. Ablation of Nox1
and Nox4 by small interfering RNAs (siRNAs) blocked the RasV12
senescent phenotype including β-galactosidase activity, growth arrest
and accumulation of tumor suppressor proteins such as p53 and
p16Ink4a. The involvement of Nox1 in Ras-induced senescence was
also confirmed with embryonic fibroblasts derived from Nox1 knockout
mice [527]. Another study suggested an important role of NOX4 in
oncogene-independent senescence of hepatocellular carcinoma cells
[528].
Of interest is compelling evidence that enhanced expression and/or
activity of NOX family members, in particular NOX4, plays an
important role in age-associated diseases, including cardiovascular
disease, fibrosis and cancer. In the vasculature, NOXs are a major
source of ROS and are key players in mediating redox signaling under
both physiological and pathological conditions. Cardiovascular disease
(CVD) is the leading cause of death, and aging is a major risk factor for
CVD development. A substantial number of studies describe the role of
NOX4 in the age-related pathology of the cardiovascular system. It was
shown that NOX4 has an impact on vasoconstriction, atherosclerosis
development, vascular cells hypertrophy, apoptosis and differentiation.
One of the major age-related arterial phenotypes thought to be
responsible for the development of CVD in older adults is endothelial
dysfunction. It was speculated that mitochondrial oxidative stress rises
when antioxidants are unable to counteract the ROS produced by
NOX4, triggering the aging process of the heart [529]. Wang et al.
[530] examined the involvement of NOX in age-associated cardiac
remodeling in a rodent model of aging and found that age-dependent
increases in blood pressure, cardiomyocyte hypertrophy, coronary
artery remodeling and cardiac fibrosis were associated with increased
myocardial NOX2 activity. Another study indicates that NOX4 and
mitochondrial oxidative stress, but not NOX1 or NOX2, are mediators of
CVD in aging mice under hyperlipidemic conditions [531]. Whereas
initial results obtained with Nox4 KO mice did not reveal striking
phenotypical differences relative to wild type mice, there is now solid
evidence that the absence of NOX4 alters a number of physiological
heart parameters (see also above), and increases susceptibility to tissue
damage in a mouse model for stroke [532].
A crucial role of NOX4-derived ROS in age-related diseases was also
implicated in the initiation, establishment, and development of tissue
fibrosis (reviewed in [533]). In particular, strong experimental evi-
dence suggests that pulmonary fibrosis (also referred to as idiopathic
pulmonary fibrosis, IPF, for the lack of a well-defined etiology) is
caused by excessive NOX4 activity and can be at least partially reverted
by targeting the NOX4-NRF2 redox imbalance [534]. On the other
hand, work by the Armanios group has established that genetic
deficiencies in telomere maintenance systems cause IPF late in life
[535], which therefore has been referred to as a “short telomere
disease” [536], and the percentage of genetic lesions affecting telomere
maintenance in IPF patients is steadily increasing. From these data, it
appears conceivable that telomere shortening and activation of NOX
enzymes, in particular NOX4, are mechanistically linked; however such
links have so far remained elusive. A potential role of NOX2 has been
found in age-related neurodegenerative diseases like Alzheimer's dis-
ease [513] and Parkinson's disease [537].
The incidence of most cancers increases dramatically with age,
indicating that, with a few exceptions, cancer is primarily an age-
associated disease. Concerning the role of NOX family members, a dual
role in carcinogenesis has been postulated. On the one hand, the
function of NOX to mediate oncogene-induced senescence, leading to
tumor suppression (see above), indicates that NOX activity restricts
tumor growth in some instances. On the other hand, production of ROS
by NOX enzymes is essential for signaling pathways driving cell
proliferation and survival, indicating that enhanced NOX activity in
epithelial cells favors tumorigenesis. This dual role of NOX-derived ROS
is best illustrated in prostate cancer, clearly one of the most relevant
age-associated malignancies. Analysis of radical prostatectomy tissue
samples and benign and malignant prostate epithelial cell lines
identified NOX5 as an abundantly expressed NOX isoform and sug-
gested that NOX5-derived ROS and subsequent depletion of PKCζ and
JNK inactivation play a critical role in modulating intracellular signal-
ing cascades driving the proliferation and survival of PCa cells [538].
On the other hand, increased expression of Nox4 in prostate stromal
cells (fibroblasts) during their age-associated trans-differentiation to
myofibroblasts leads to benign prostate hyperproliferation [539], a
condition referred to as “reactive stroma” [540] that is known to favor
the emergence of (epithelial) tumor cells in the prostate.
In conclusion, the existing evidence suggests that NOX family
members are important drivers of age-associated pathology, and
regulating NOX activity/expression and using mitochondrial antioxi-
dants are potential approaches to reducing aging-associated diseases.
7.3. Protein aggregates as redox signaling mediators in aging
The aging process and a number of age-associated diseases are
accompanied by the accumulation of high-molecular protein aggre-
gates, as reported by Tilman Grune. In the aging process these protein
aggregates are often referred to as lipofuscin, ceroid or age associated
fluorophores. This material is largely composed of proteins, often
amounting to 60–80%. Some of these proteins are oxidized or modified
by various reactive metabolites, e.g. carbohydrates forming advanced
glycation end products. Various lipids form another major part of such
aggregated material. Interestingly, several authors report also the
inclusion of various metals in such protein aggregates.
This raised the question, whether included metals are able to trigger
metal-catalyzed redox reactions. It could be demonstrated that iron in
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protein aggregates is able to catalyze the Fenton-reaction and is only
partially chelatable by iron-chelators [541]. Moreover, in the same
study it could be demonstrated that in senescent cells protein aggre-
gates contribute to an age-associated shift in the redox-state [541].
Further studies revealed that such protein aggregates do have an
active surface. It is likely that due to the reactive surface of the
aggregate, e.g. due to reactive hydroperoxides or aldehydes, and due to
the hydrophobic patches – a result of the unfolding of the included
proteins - protein aggregates can bind cellular proteins. This inter-
actome might either be random or at least partially specific due to the
binding of protein-protein-interacting structures. The latter includes
certainly the binding of chaperones [542] or proteases designed to
degrade unfolded proteins, as in the proteasome [543].
The 20S proteasome is known to be the major intracellular protease
responsible for the degradation of damaged and oxidized proteins
[543]. On the other hand, it is also the central catalytic part of the
ubiquitin-proteasomal-system and, therefore, involved in the degrada-
tion of most cytosolic proteins [543]. The proteasome recognizes
unfolded protein structures. In the case of protein aggregates this leads
to an inhibition of the proteasome upon binding. This was shown in in
vitro senescence models [544] or in neurons of Alzheimer's disease
patients [545]. Proteasomal inhibition, in turn, leads to a proteasomal
mal-performance, leading to disturbances of the regulated turnover of
transcription factors, as shown in the case of AP-1 [546], HSF1 and
NRF2 [547]. Furthermore, it should be noted that proteasomal inhibi-
tion leads also to a vicious cycle in which a reduced level of degradation
of newly formed oxidized proteins leads to enhanced protein aggregate
formation.
In conclusion, it should be noted that accumulating protein
aggregates have multiple pathophysiological effects and cannot be seen
as inert waste materials. However, more studies are needed to acquire a
more complete scheme of the action of protein aggregates and their
contribution to cellular senescence.
7.4. Proteasome activation as an anti-aging and anti-aggregation strategy
From the least to the most complex organisms, aging is a natural
inevitable process accompanied by several molecular and biochemical
failures. As explained by Niki Chondrogianni and Nikoletta
Papaevgeniou, damaged and/or wrongly produced macromolecules
tend to accumulate and aggregate, resulting in proteostasis impairment
that then triggers a cataract of system deficits. Proteasome-mediated
degradation is a critical player for protein homeostasis maintenance;
proteasomes are large enzymatic complexes that regulate the cellular
protein load equilibrium by degrading the unnecessary peptides and
proteins. Proteasomal dysfunction is associated with the progression of
aging and protein aggregation further aggravates the problem [514].
Consequently, proteasome activation appears to be a promising anti-
aging and anti-aggregation approach.
Proteasome up-regulation in terms of assembly, quantity and
function has been achieved through genetic manipulation of various
catalytic or regulatory subunits or through treatment with specific
activating compounds. This activation has been shown to lead to
decelerated aging progression and to enhanced longevity. More speci-
fically, overexpression of β1 and β5 catalytic subunits endowed WI38
human fibroblasts with increased resistance to oxidative stress and
elongated cellular lifespan [514]. Overexpression of the pbs-5 subunit
(nematode ortholog of β5) in C. elegans resulted in increased protea-
some content and function that led to enhanced resistance to oxidative
stress and extended lifespan in a daf-16-, skn-1- and hsf-1-dependent
manner [548]. In accordance, rpn-6.1 overexpression in C. elegans
triggered elevated proteasome activities leading to enhanced longevity
under conditions of mild heat stress [549]. The positive effect of
proteasome activation on longevity was also shown in the fruit fly
where overexpression of the RPN11 19S subunit resulted in enhanced
proteasome activities and extended lifespan [550]. With regard to
compounds, treatment with a pentacyclic triterpenoid, namely 18α-
glycyrrhetinic acid, resulted in increased proteasome content and
activity both in cellular (human fibroblasts) and organismal (C. elegans)
models [551,552]. This compound was shown to promote proteasome
activation in an NRF2-dependent manner in fibroblasts [551] and a
SKN-1-dependent manner in nematodes [552], with elongated lifespan
and increased stress resistance as the end result. Finally, rejuvenating
and anti-aging properties were attributed to quercetin-mediated pro-
teasome activation in human fibroblasts [553].
Proteasome activation has also been shown to confer protection
against the devastating consequences of protein aggregation.
Enhancement of proteasome function through pbs-5 overexpression in
nematodes endowed animals with increased survival against expanded
polyglutamine and Aβ peptide proteotoxicity [548]. Similarly, rpn6.1
overexpression conferred proteotoxic stress resistance in a nematode
polyglutamine disease model [549], while RPN11 overexpression
suppressed the expanded polyglutamine- induced progressive neurode-
generation in fruit flies [550]. Proteasome activation through 18α-
glycyrrhetinic acid treatment led to reduced Aβ peptide deposits both in
murine neuronal cells and in an Alzheimer's disease nematode model
thus resulting in decelerated progression of the disease's phenotype
[552]. Likewise, the polyphenol quercetin was found to induce protea-
some activity resulting in inhibition of paralysis in a transgenic C.
elegans strain serving as an animal model for Alzheimer's disease [554].
In conclusion, proteasome activation emerges as a promising
strategy in the battle against aging and proteotoxicity. Given that
genetic manipulation is not applicable in humans, future studies should
focus on the identification of compounds with proteasome activating
properties as well as in the elucidation of the involved signals and
biochemical pathways.
7.5. Free radical theory of aging – dead or alive?
The “free radical theory of aging” was introduced in the early 1950s
through the work of Harman [510] and comprises investigations of the
role of reactive oxygen species (ROS) formation and mitochondrial
function in the aging process and, more recently, the implications of
ROS-triggered epigenetic processes and DNA damage for the etiology of
aging [555]. Lately, as discussed by Andreas Daiber and Yuliya Mikhed,
the field of epigenetics has received considerable attention in the
context of aging theories. It has been shown that cellular senescence
leads to massive DNA demethylation, causing a state of DNA hypo-
methylation, particularly in the CpG islands [556] and multiple
epigenetic processes are regulated in a redox-dependent manner
[238]. Although the lessons learned from animal models of genetic
deletion or overexpression of important antioxidant enzymes such as
superoxide dismutases, glutathione peroxidases and catalase were
rather disappointing, since no clear correlation between life span and
the abundance of these antioxidant defense enzymes could be observed,
at least some of them (e.g. Sod1-/-) or double gene ablation combina-
tions showed reduced life expectancy, which would be in line with the
“free radical theory of aging” [557,558]. Moreover, the importance of
mitochondrial superoxide formation for survival (longevity) is high-
lighted by the fact that homozygous SOD2 deletion leads to perinatal or
neonatal lethality [559] and by the observation that mice deficient in
the p66Shc-/- gene, a source of mitochondrial ROS formation, display a
30% longer life span [560]. According to more recent data, oxidative
stress in general and mitochondrial ROS formation in particular may
play an even more important role for the quality of life, healthy aging,
or the so-called “healthspan” than for the lifespan per se [561,562].
Healthy aging may be an even more important need and challenge in
our aging Western societies, also from an economical point of view
considering the tremendous costs associated with our public health
systems. The cardiovascular system seems to be an excellent example of
this concept. From a mechanistic basis the increasing superoxide
formation (coming from gradually increased mitochondrial leakage of
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electrons and NADPH oxidase-derived production due to low grade
inflammation) with progressing age will lead to antagonization of nitric
oxide, a major vasodilator and antiatherothrombotic signaling molecule
of the cardiovascular system [555]. Oxidative depletion of nitric oxide
bioavailability by superoxide and the reaction product peroxynitrite
will lead to impaired cGMP formation, inhibition of prostacyclin
synthase by tyrosine nitration and activation of the renin-angiotensin-
aldosterone system as well as endothelin-1 signaling, which will lead to
a complete switch from a vasculoprotective to a proatherothrombotic
phenotype [9]. In support of this concept, genetic deletion of mitochon-
drial antioxidant enzymes (Aldh2-/- and Sod2+/-) led to an increase in
mitochondrial ROS formation, 8-oxoguanine-dependent mitochondrial
DNA strand breaks and, most importantly, an impairment of endothe-
lium-dependent and –independent relaxation (vascular function)
(Fig. 7.2A-B) [563]. Likewise, genetic deletion of GPx-1 led to an age-
dependent impairment of endothelium-dependent and –independent
relaxation, increase in oxidative stress markers and eNOS uncoupling as
well as aggravation of inflammatory phenotype of the vasculature
(summarized in Fig. 7.2C) [62]. Although these animals showed no
obvious decrease in lifespan, it may be assumed that the proathero-
thrombotic and inflammatory phenotype will ultimately lead to in-
creased prevalence of cardiovascular complications as a consequence of
the higher burden of oxidative stress, thereby decreasing the health-
span.
Fig. 7.2. Correlations between mitochondrial oxidative stress (mtROS), mitochondrial DNA (mtDNA) damage and vascular (endothelial) function (ACh-induced maximal relaxation). (A)
mtROS formation was plotted for all age-groups and mouse strains versus the corresponding maximal efficacy in response to acetylcholine (ACh). (B) mtROS was plotted for all age-groups
and mouse strains versus the corresponding mtDNA damage. ROS were measured using L-012 (100 µM) enhanced chemiluminescence in isolated cardiac mitochondria upon stimulation
with succinate (5 mM). r is the correlation coefficient. (C) Hypothetic scheme of aging-induced vascular dysfunction and the role of mitochondria in this process. Aging-induced
mitochondrial dysfunction triggers mitochondrial reactive oxygen species (mtROS) formation from respiratory complexes I, II, and III (Q = ubiquinone). Break-down of mtROS is
catalyzed by glutathione peroxidase (GPx, for H2O2) or manganese superoxide dismutase (MnSOD), the latter is in turn inhibited by mitochondrial peroxynitrite (ONOO-) formation.
mtROS increase the levels of toxic aldehydes and inhibit the mitochondrial aldehyde dehydrogenase (ALDH-2), the detoxifying enzyme of those aldehydes. Increase in mtROS and toxic
aldehydes also leads to mtDNA strand breaks which leads to augmented dysfunction in respiratory chain complexes and further increase in mtROS since mtDNA encodes mainly for those
respiratory complexes. mtROS also activates mitochondrial permeability transition pore (mPTP), which upon opening releases mtROS to the cytosol leading to protein kinase C (PKC)-
dependent NADPH oxidase activation, eNOS uncoupling and finally to endothelial dysfunction [61]. Cytosolic reactive oxygen and nitrogen species (ROS/RNS) in turn were demonstrated
to activate KATP channels, which causes alterations in mitochondrial membrane potential (C) and further augments mtROS levels [564]. Effects of rotenone (Rot), cyclosporine A (CsA),
diazoxide (Diaz) and glibenclamide (Glib) have been recently demonstrated in related models of vascular dysfunction and oxidative stress, nitroglycerin-induced nitrate tolerance and
angiotensin-II triggered hypertension [61,564]. With permission of the European Society of Cardiology. All rights reserved. © The Author and Oxford University Press 2008.
Adopted from [563].
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In conclusion, there is solid evidence for the “free radical theory of
aging” in experimental studies but translation to the clinical situation
requires large scale clinical trials, as currently undertaken by the
CHANCES consortium (10,622 individuals) reporting on a clear asso-
ciation between oxidative stress markers and all-cause mortality [565]
and the MARK-AGE consortium (3337 individuals) the data of which
are currently being prepared for final dissemination [566].
7.6. ROS and frailty. Understanding the mechanisms of disability in older
people
According to Mariam El Assar and Leocadio Rodríguez-Mañas,
frailty is a geriatric syndrome characterized by diminished functional
reserve and increased vulnerability to low power stressors. Frailty
precedes disability, and, in addition, epidemiological cohorts have
demonstrated that the frailty phenotype predicts several outcomes such
as falls, hospitalization and mortality [567]. Although the biological
determinants of frailty are not well defined, oxidative stress and
inflammation have been closely related to aging and seem to be
potential drivers of frailty pathogenesis. Inflammation and oxidative
stress are closely related processes with crosslinks between their
respective signaling pathways. In line with this, observational studies
have shown that frailty is associated with different systemic inflamma-
tory biomarkers, including C-reactive protein, and interleukin-6 [568].
Elevated levels of pro-inflammatory cytokines have been shown to be
associated with increased risk of morbidity and mortality in frail older
subjects. Furthermore, an association between systemic oxidative stress
biomarkers (malondialdehyde, isoprostanes, protein carbonylation and
lipoprotein phospholipase A2) and frailty has been reported in a
geriatric population [515].
The prevalence of chronic diseases such as diabetes, cardiovascular
diseases and pulmonary diseases increases with aging. These chronic
conditions compromise muscle function, cardiovascular performance
and pulmonary function leading to increased vulnerability of the
organism when exposed to low intensity stressors. This scenario
represents the phenotypic manifestation of frailty. Consistently, all
these chronic diseases are associated with a higher risk of frailty in aged
populations. The contribution of oxidative stress and reactive oxygen
species (ROS) to the decline of different functional systems associated
to aging and to age-related chronic diseases has been established [569].
For example, the defective nitric oxide signaling in aged muscle
vasculature has been attributed to increased inactivation of this
molecule by ROS leading to decreased muscle perfusion. On the other
hand, the lung is continuously exposed to oxidative stress while the
activity of antioxidant enzymes such as superoxide dismutase and
glutathione peroxidase decreases with aging. In addition, the induction
of heme oxygenase, which is involved in cellular protection against
oxidative stress, is defective in lungs of aged mice, further supporting
the involvement of oxidative stress in age-related pulmonary dysfunc-
tion.
Since frail older adults have minimal injury resilience and a notably
decreased response to stress, the different pathways regulating cellular
response to stress (oxidative stress, hypoxia and inflammation among
others) stand out as possible players in the development of a frailty
phenotype. In this sense, aging, sedentary lifestyle and chronic diseases
could cause down-regulation of signaling pathways responsible for the
cellular response to oxidative stress, such as NRF2. This results in
impaired response to stress and increased oxidative stress leading to a
situation of vulnerability to stressors such as frailty. In fact, very recent
data obtained by our group have demonstrated that lower expression of
genes related to response to oxidative stress in older people is
associated with a higher risk of being frail independently of age and
sex (El Assar and Rodríguez-Mañas group).
Further investigations are definitely needed to fill the gap of
knowledge of this evolving field and provide possible targets for
intervention to promote health and independence in the elderly.
8. ROS and inflammation in health and disease
Manuela Garcia Lopez (E-mail: manuela.garcia@uam.es) and Javier
Egea (E-mail: javier.egea@inv.uam.es).
8.1. Introduction
Over the past decade, the study of the biological activity and
significance of ROS have gained particular interest from both a
physiological and pathological perspective. Since ROS are highly
unstable and reactive molecules, they interfere with many cellular
processes. ROS react with lipids, nucleic acids and proteins, disrupting
their cellular functions. Oxidative stress occurs when the damaging
effects of ROS exceed the ability of biological systems to neutralize the
oxidizing agents and to repair cellular damage. Physiologically, anti-
oxidant defenses are efficient enough to neutralize the damaging effect
of oxidizing molecules. In these conditions, the presence of ROS is
important for many physiological cellular processes and they partici-
pate as signaling molecules in a wide range of cellular functions. Hence,
ROS modulate intracellular transduction pathways and transcriptional
factors involved in cell proliferation, differentiation, and maturation
[570–572].
Chronic Granulomatous Disease (CGD) is a rare inherited innate
immunodeficiency caused by defective NADPH oxidase activity in
phagocytes and is recognized as a disease model to understand the
pathophysiological consequences of ROS deficiency [22]. CGD patients
suffer from life-threatening infections, but an apparent paradox be-
tween the absence of ROS production and hyperinflammation is often
observed in this disease [32,33]. The key producers of ROS in many
cells are the NOX enzymes, of which there are seven members with
different tissue distributions and regulatory mechanisms. ROS produced
by the isoform NOX2 is essential to organize the response in host
defense against pathogens [573].
In the brain, ROS production regulates neuronal development from
neuronal precursors [574]. Redox signaling is also required to trigger
neuronal differentiation and axon formation [575]. Nitric oxide (•NO),
a diffusible intercellular messenger produced by neuronal nitric oxide
synthase (nNOS) exerts a dual regulatory role in neurovascular coupling
and neuroenergetics by regulating mitochondrial oxygen consumption
[576]. Therefore, ROS act as messengers in the transduction pathways
important for synaptic plasticity in the CNS.
The brain is particularly vulnerable to oxidative stress because it
consumes a large amount of oxygen, has abundant lipid content, and
has little antioxidant activity compared to other organs. The major
antioxidants in the brain are ascorbate, glutathione (GSH), and vitamin
E in the plasma membrane. GSH production is increased in response to
oxidative stress in astrocytes, cells that act as the main supplier of GSH
to neurons for antioxidant protection [577]. ROS accumulation in the
brain has been associated with the onset of neurodegenerative and
psychiatric diseases, whose main consequence is to reduce several
neuronal cellular functions. ROS accumulation in neurons and the
resulting oxidative stress are responsible for the loss of cognitive and
motor functions in several brain diseases.
Oxidative stress and chronic low grade inflammation are interde-
pendent processes that have been implicated in aging and many
pathological conditions like cardiovascular disease, neurodegenerative
diseases or cancer. Inflammatory cells can release ROS at the site of
inflammation increasing oxidative stress, while ROS can initiate
intracellular signaling cascades that increase proinflammatory gene
expression [47,578].
Chronic inflammation as a consequence of immune failure is often
associated with cancer (known as inflammation-induced tumorigen-
esis). Hence, in different types of cancers, multiple pathways contribute
to chronic cytokine release. Hyperinflammation combined with loss of
adhesion and the release of angiogenic factors leads to cellular
proliferation.
J. Egea et al. Redox Biology 13 (2017) 94–162
130
Here we will put forward some examples of how ROS and
inflammation can regulate physiological or pathological conditions in
different systems.
8.2. Dual actions of NOX2-derived ROS
As pointed out by Jamel El-Benna and Pham My-Chan Dang, the
production of ROS by NOX2 is essential to mount a rapid response to
bacterial and fungal invasion; however, excessive or inappropriate ROS
production can induce severe tissue injury that participates in the
pathophysiology of acute and chronic inflammatory diseases
[579,580]. For several years, NOX2-derived ROS have been considered
as pro-inflammatory agents, but recent reports challenged this dogma
and suggested that they can also be anti-inflammatory [581].
Under physiological conditions, the objective of ROS production by
phagocytes is to kill and eliminate pathogens trapped inside the
phagosome [579]. When this goal is successfully achieved, ROS
production is terminated and the inflammation is resolved. Thus, the
physiological role of transient ROS production is anti-inflammatory as it
helps to eliminate inflammation resulting from the infection. In
addition to the “direct-ROS-killing effect” during phagocytosis, NOX2-
derived ROS can have “paracrine-redox signaling effects” that can
modulate the immune response. Indeed, NOX2-derived ROS can
dampen T-cell-dependent inflammation through alteration of T-cell
membrane oxidation status [582] and of Th17/Treg cell development
[583]. The anti-inflammatory role of NOX2-derived ROS is well
illustrated in chronic granulomatous disease (CGD) patients who have
a genetic defect in one of the NOX2 genes (see Section 8.3). Thus,
chronic NOX2 deficiency may cause “ROS-independent” inflammation
where ROS are not the causative factor. This “ROS-independent”
inflammation is also observed in autoimmune diseases as shown in
animal models [581,582,584]. In the presence of high levels of pro-
inflammatory mediators (cytokines, TLR agonists, lipid mediators…),
NOX2 can be hyper-activated, leading to excessive and prolonged ROS
production [583]. This high ROS production is undoubtedly deleter-
ious, as evidenced by the multiple antioxidant strategies that have been
developed by the organism to protect against ROS [585]. ROS,
particularly the diffusible hydrogen peroxide, can oxidize cellular
macromolecules (proteins, lipids, DNA), which leads to tissue injury
or to the alteration of cellular functions such as imbalance of
intracellular signaling pathways, cytokine production, protease activa-
tion and release [585], all of which participate in the “ROS-dependent
inflammation.” Indeed, inhibition of NOX2 and the use of certain anti-
oxidants protect from inflammation in animal models [586].
8.3. Chronic Granulomatous Disease (CGD): implication of NOX2
According to Marie José Stasia, Joe Dan Dunn and Thierry Soldati,
CGD is a rare inherited disorder in which phagocytic cells are unable to
kill pathogens during an infection. The molecular basis of this disease is
the absence of ROS production by the NADPH oxidase complex of
phagocytes which is composed of NOX2 and p22phox, also named the
membrane flavocytochrome b558, and the cytosolic factors p47phox,
p67phox and p40phox. It is a genetically heterogeneous disease with all
ethnic groups equally affected. The molecular basis of CGD is char-
acterized by two types of transmission and four main genetic forms. As
mentioned earlier, the major genetic form is X-linked CGD caused by
mutations in the CYBB gene encoding NOX2. X-CGD accounts for about
70% of the total cases reported to date [587]. The other types of CGD
are autosomal recessive forms (AR), characterized by mutations in
CYBA, NCF1 and NCF2 encoding p22phox, p47phox and p67phox
respectively [588]. Clear information on the severity of CGD according
to the genetic forms is difficult to establish. However Kuhns et al.
demonstrated a relationship between the presence of residual ROS
production and the survival of CGD patients [589]. In addition,
mutations affecting the membrane flavocytochrome b558 composed
of p22phox and NOX2 seem to be associated with the most severe
clinical features of CGD [590]. Indeed, cytochrome b558 is the redox
core of the enzyme in which the electron transfer occurs to reduce the
molecular oxygen into superoxide.
The soil-dwelling, social amoeba, Dictyostelium discoideum (there-
after Dictyostelium) is an ideal model organism to determine immunity
functions of ROS and the consequences of ROS deficiency, i.e., CGD.
Dictyostelium amoebae prey on bacteria using phagocytic machinery
and intracellular killing mechanisms that are conserved in the immune
phagocytes of metazoa, e.g., mammalian macrophages and neutrophils,
and are utilized as a model phagocyte to study cell-autonomous
immunity [591,592]. Among the conserved machinery are three
NOX2 homologs of the NADPH oxidase catalytic subunit (NOX A, B
and C), a p22phox homolog, a single, putative NOX-activating protein
(NcfA, a homolog of p67phox), a secreted myeloperoxidase-like enzyme
(PoxA), and enzymes for metabolizing ROS such as superoxide dis-
mutases and catalases [593,594]. Dictyostelium also has homologs of
STATs, TRAFs, and guanylate-binding proteins, which are regulated by
ROS in macrophages [594], and employs autophagy as a defense
mechanism against cytosolic bacteria [595], which is activated down-
stream of ROS in macrophages.
Dictyostelium undergoes a developmental cycle during which
100,000 amoebae aggregate to form a multicellular slug that ultimately
differentiates into a spore-containing fruiting body. ROS scavengers
inhibit the initial aggregation of amoebae, and both NOX-deficient
mutants and catalase deficient mutants exhibit defects in fruiting body
formation [593,596,597]. The multicellular slug contains specialized
sentinel cells (s-cells) that serve as its patrolling innate immune system
[598]. Like neutrophils, S-cells extrude DNA-based extracellular traps
(ETs) via a NOX-dependent mechanism: S-cells from NOX-deficient
mutants lose the ability to secrete ETs and to clear bacteria from the
slug and subsequent fruiting body [599]. Consequently Dictyostelium,
on the cusp of multi-cellularity, can be used to model CGD and the
influence of NOXs and ETs on the evolution of specialized immune cells
and to study the role of ROS in a host-pathogen interaction [600].
CGD patients suffer from recurrent and life threatening infections
during early childhood. Phagocytic cells from CGD patients adhere to
blood vessels, reach infectious sites by chemotaxis and phagocytose the
involved pathogens, but are unable to kill them because of the absence
of ROS production by the defective NOX complex. Thus, accumulation
of live pathogens in phagocytes, combined with the continuous release
of proinflammatory cytokines by these cells, leads to the formation of
granulomas in infected tissues. In addition, granuloma formation in
hollow organs like the kidneys or the gastrointestinal tract is respon-
sible for obstruction syndromes. Infections can be localized in tissues in
direct contact with the environment like the skin, the otorhinolaryngol-
ogy sphere or, more severely, the lungs. The disease has a more
dramatic effect when infections and granulomas are in deep organs
such as the brain or the liver. Aspergillosis in the lungs is the first cause
of death of CGD patients. One seemingly paradoxical observation that
needs to be addressed is: how does the absence of ROS lead to
hyperinflammation in CGD? Several hypotheses have been proposed.
The oldest one is that efferocytosis by macrophages is reduced in CGD
[601]. The overall consequence will be unbalanced neutrophil necrosis,
an increase of proteases and toxic oxygen-derived components and
release of proinflammatory cytokines, which all contribute to local
inflammation. In addition, the absence of ROS production can be
responsible for defective activation of genes that regulate NFκB
signaling, which is involved in the restriction of the development of
inflammatory disorders [602]. Recently, it was shown that ROS
deficiency in CGD causes autophagy dysfunction in phagocytes, which
contributes to increased production of proinflammatory IL-1β. Indeed,
two CGD patients treated with an IL-1 receptor blocker showed rapid
and sustained improvement in colitis [603]. Furthermore, defective
ATM activation due to the absence of ROS production in a CGD patient
was linked to an exacerbation of proinflammatory cytokine release and
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apoptosis, which might explain the hyperinflammation in this disease
[604].
As components of the phagocytic NOX complex are expressed in
cells and tissues other than phagocytes, inactivating mutations in these
proteins can have pathophysiological consequences unrelated to im-
munodeficiency syndromes. ROS production by NOX enzymes controls
vascular function via modulation of NO bioactivity. Indeed NOX2
deficiency in CGD patients was related to enhanced arterial dilatation
[605]. Violi et al. demonstrated that in vivo platelet activation might be
directly associated with NOX2 activity. Thus decreased platelet marker
activation correlated with the absence of NOX2 expression found in
CGD patients. As NOX2-deficient mice demonstrated impaired memory
and synaptic deficit, a role of NOX2 in these processes was proposed
[606]. However, clinical studies in children with CGD were rather
ambiguous [607,608].
8.4. Neuromodulatory actions of nitric oxide
As summarized by J. Laranjinha and R.M. Barbosa, the brain is
bioenergetically exigent and, to optimize neuronal function and
survival it is equipped with fine mechanisms for a precise spatial and
temporal control of cerebral blood flow (CBF) that provides energy
substrates according to cellular activity. This process is achieved
through neurovascular coupling, an orchestrated intercellular commu-
nication among all components of the neurovascular unit (neurons,
astrocytes, perycites and microvessels) that results in a rapid and
restricted increase in CBF [609]. Yet neuronal energetics is non-linearly
coupled to an activity-dependent increase of CBF, i.e. neuronal activity-
induced increases in CBF are not accompanied by proportionate
increases in oxygen consumption by neuronal mitochondria [610].
Therefore, an activity-dependent CBF increase and oxygen utilization
by active neural cells are inextricably linked and establish a functional
metabolic axis in the brain termed the “neurovascular-neuroenergetic
coupling axis.” This axis incorporates interdependent processes that
need to be coordinated in the normal brain. An impaired functionality
of the neurovascular-neuroenergetic coupling axis poses a threat to the
healthy brain and can prove particularly detrimental for Alzheimer´s
disease and the aged brain.
•NO, a diffusible intercellular messenger synthesized by the neuron-
associated synthase isoform (nNOS), coordinates an integrated regula-
tion of this axis by mediating the neurovascular coupling process and by
regulating oxygen utilization by mitochondria. Two lines of reasoning
support this hypothesis. The first is based on the in vivo dynamic and
simultaneous recordings [611] of •NO, oxygen and CBF. It has been
shown that upon glutamatergic stimulation of rodent hippocampus, •NO
synthesized by nNOS associated with the glutamate NMDA receptor
diffuses into neighboring vessels and induces an increase of CBF, which
couples to neuronal activity by activating soluble guanylate cyclase in
smooth muscle cells [612]. The transitory increases of •NO and CBF
from a basal level are temporarily and spatially coupled with oxygen
delivered from the vessels, encompassing a sequence of events consist-
ing of glutamatergic neuronal stimulation, •NO transients, CBF in-
creases and oxygen transients. According to the second line of reason-
ing, the best characterized interaction of •NO with the mitochondria is
the inhibition of cytochrome c oxidase by nanomolar concentrations of
•NO in competition with oxygen [613]. At physiological oxygen
concentrations, NMDA-evoked •NO production inhibits hippocampal
oxygen consumption at submicromolar concentrations and induces a
small difference in the concentration dynamics of •NO, reflecting that
different states of neuronal activation may lead to different outcomes in
terms of metabolic rate [614,615].
8.5. Thiol redox homeostasis in astrocytes
According to Gethin J. McBean, several decades of research have led
to the conclusion that astrocytes, the so-called ‘metabolic support’ cells
of the brain, act as the central supplier of glutathione (γ-glutamyl-
cysteinyl-glycine, GSH) for antioxidant protection of neurons. De novo
synthesis of GSH in astrocytes fulfills the antioxidant capacity of those
cells and also provides precursors for GSH synthesis in neurons [616].
Cysteine is the rate-limiting substrate for GSH synthesis and is supplied
either by transport from the extracellular medium in the form of cystine
into astrocytes using the xc- exchanger, or directly into neurons as
cysteine via the EAAT3 subtype of the high-affinity glutamate trans-
Fig. 8.1. Cysteine supply pathways in astrocytes. Cysteine is either taken up in its oxidized form, cystine, from the extracellular medium via the xc- cystine-glutamate exchanger, or
generated from methionine via the transsulfuration pathway. Cysteine is the immediate precursor for GSH, which is synthesized by the first two enzymes of the γ-glutamyl cycle, as well as
taurine and hydrogen sulpfide. CBS, cystathionine-β-synthase; CDO, cysteine dioxygenase; CSA, cysteine sulfinic acid; CSE, cystathionine-γ-lyase; GCS, glutamate cysteine ligase; GS,
glutathione synthase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.
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porter. As the extracellular redox potential dictates a 5:1 ratio of cystine
to cysteine, the bulk of uptake takes place into astrocytes. In addition to
the xc- cystine-glutamate exchanger, cysteine can also be supplied by
transsulfuration (TS) from methionine via homocysteine, as shown in
Fig. 8.1. In normal astrocytes, the TS pathway supplies up to one third
of the cysteine required for GSH, with the majority coming from the
extracellular space [577,617].
It is well documented that GSH production in astrocytes is increased
in response to oxidative stress. Similarly, upregulation of both the xc-
exchanger and the TS pathway (via increased expression of the rate-
limiting enzyme, cystathionine-γ-lyase (also known as cystathionase;
CSE)) occurs following oxidative stress [617,618]. Interestingly, ex-
perimentally-induced oxidative stress in primary rat cortical astrocytes
shows that the relative contribution of the TS pathway to cysteine for
GSH increases to 60%, meaning that, under these conditions, the
majority of cysteine for GSH comes from this pathway, rather than
the xc- exchanger [577]. Pharmacological blockade of the xc- cystine-
glutamate exchanger in vitro also acts as a signal to upregulate CSE,
leading to enhanced synthesis of GSH [577]. It is not clear at present
whether the signal to increase flux through the TS pathway occurs in
response to a fall in GSH within astrocytes, or to increased oxidative
stress, or both. It has been proposed that upregulation of cystine intake
under oxidative stress conditions is decoupled from GSH synthesis and,
instead, regulates an intracellular-extracellular cysteine-cystine redox
cycle [619]. This proposal fits with our results showing that GSH
synthesis under oxidative stress conditions increases reliance on the TS
pathway. However, further work is required to fully evaluate the
interrelationship between these sources of cysteine for GSH, and other
important neuroprotective products, for example, taurine and hydrogen
sulfide.
Understanding the origin of cysteine for GSH is important for
evaluation of the antioxidant capacity of cells in neurodegenerative
disease. There are several examples in the literature of up-regulation of
the xc-cystine-glutamate exchanger during neurodegenerative disease
[620,621]. Indeed, at first glance, it would appear that the capacity to
increase GSH synthesis during neurodegenerative disease-related oxi-
dative stress would be beneficial. However, the downside is that
increased capacity of the xc-cystine-glutamate exchanger is inevitably
coupled to the release of glutamate. If this cannot be matched by high-
affinity uptake, then the likelihood of glutamate-mediated neurotoxi-
city threatens neuronal well-being. This situation is well illustrated in
the case of glioma/astrocytoma. Here, tumor cells up-regulate the
xc-cystine-glutamate exchanger, but down-regulate the high-affinity
glutamate transporters [622]. This imbalance generates the capacity
for destruction of neurons and increases the likelihood of epileptiform
activity. However, strategies to block the xc- exchanger in glioma
therapy have been unsuccessful. It is now recognized that drugs that
target both the xc- exchanger and the TS pathway have greater potential
as effective therapeutics [623]. Research is ongoing to fully understand
the beneficial potential of the TS pathway in astrocytes, particularly in
the context of astrocyte activation and the immune response.
8.6. Regulation of the oxidative and inflammatory response by microglial
α7 cholinergic receptors
As reported by Manuela G Lopez and Javier Egea, dysfunction of the
cholinergic system and mitochondria together with increased oxidative
stress and neuroinflammation has been reported during aging and
diseases related to age like Alzheimer´s and Parkinson´s disease
[624,625]. The α7 acetylcholine nicotinic receptor subtype (α7nAChR)
is expressed in neuronal and non-neuronal cells. Wang et al. [626]
identified that α7 nAChRs in blood monocytes control inflammation
under vagal stimulation and proposed the “cholinergic anti-inflamma-
tory pathway,” which regulates inflammation in the periphery. In the
central nervous system, microglia regulate the innate immune response
and also express α7 nAChRs; therefore, the role of these receptors in
microglial function is being studied.
Primary glial cultures exposed to the α7 nicotinic agonist
PNU282987 increased their mitochondrial mass and mitochondrial
oxygen consumption without generating oxidative stress. These
changes were not seen when the transcriptional factor NRF2 was
absent, when the HO-1 enzyme was inhibited and when PGC-1α was
silenced. In isolated microglia of adult animals treated with the
α7nAChR agonist, a significant increase in mitochondrial mass was
also detected. Interestingly, LysMcre-Hmox1Δ/Δ animals, which lack
HO-1 in microglial cells, and PGC-1α-/- animals, which do not express
PGC-1α protein, showed lower microglial mitochondrial levels, and
treatment with PNU282987 did not change the mitochondrial levels.
These results indicate the important function of the α7nAChR/NRF2/
HO1 and PGC-1α axis to increase mitochondrial biogenesis and thereby
improve the bioenergetic status in microglia [627].
The α7 microglial nicotinic receptor also plays a strategic role in
controlling neuroinflammation to afford neuroprotection under brain
ischemia conditions as shown in in vitro and in vivo models.
Organotypic hippocampal cultures (OHC) exposed to oxygen and
glucose deprivation (OGD) elicited cell death. However, the selective
α7nAChR agonist PNU282987 incubated post-OGD, reduced cell death,
ROS production and TNF-α release. The protective effect of PNU282987
was lost in microglia-depleted OHCs as well as in OHCs from Nrf2
deficient mice. Administration of the α7nAChR agonist 1 h after
induction of photothrombotic stroke in vivo reduced infarct size and
improved motor skills in Hmox1lox/lox mice that express normal levels of
HO-1, but not in LysMCreHmox1Δ/Δ in which HO-1 expression is
inhibited in myeloid cells, including the microglia [628]. These results
show that α7 microglial nicotinic receptors play a key role in control-
ling neuroinflammation and affording neuroprotection under brain
ischemia.
Therefore, microglial activation of the α7 nAChR/NRF2/HO-1 axis
seems to play an important role in improving microglial bioenergetics
and reducing oxidative stress and neuroinflammation [629].
8.7. Regulatory mechanisms of ROS in the motor neuron
According to Anastasia Shakirzyanova and Rashid Giniatullin ROS
can also regulate neurotransmission at the neuromuscular junction.
Curiously, the actions of ROS are remarkably different in the synapses
of newborns, adults and old rats [630]. Thus, it has been reported that
the inhibitory effect of the diffusible mild oxidant H2O2 is much
stronger in old rats. In newborns tested during the whole first postnatal
week, H2O2 did not affect spontaneous transmitter release from nerve
endings and even potentiated the end-plate potentials. The resistance of
neonates to H2O2 inhibition was associated with higher catalase and
glutathione peroxidase activities in skeletal muscle. In contrast, the
activities of these enzymes were downregulated in old rats. These
results indicate that the vulnerability of transmitter release to oxidative
damage strongly correlates with aging and might be used as an early
indicator of senescence [630]. Consistent with this, it was shown that
the concentration of the redox active amino acid homocysteine
increases with aging and in many neurodegenerative diseases signifi-
cantly aggravates ROS-induced depression of transmitter release from
motor nerve terminals. This provides a potential mechanism of
peripheral impairment in motor neuron diseases associated with
hyperhomocysteinemia [631]. Related to this, is has been reported
that the co-transmitter ATP, which operates via a ROS-dependent
mechanism, activates presynaptic P2Y12 receptors coupled to NOX to
generate endogenous ROS and that this signaling complex likely resides
in lipid rafts [632].
The association between ROS and motor neuron disease is exem-
plified in the case of amyotrophic lateral sclerosis (ALS), a neurode-
generative disease characterized by a progressive loss of motor neurons
and degradation of the neuromuscular junctions. In ALS, the decline in
synaptic function initiates from the presynaptic terminals. Experimental
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data have shown that in the neuromuscular junction, a classical model
of synaptic transmission, ROS have an inhibitory action on the
presynaptic releasing machinery, and it was proposed that the pre-
synaptic sensor of ROS was the SNARE protein Snap25 [633].
8.8. Inflammation and ROS in cancer
As explained by Kemal Sami Korkmaz and Bilge Debelec–Butuner,
chronic inflammation subsequent to immune failure or insults such as
microbial infections is often associated with cancer. The well-known
examples come from Helicobacter pylori and human papillomavirus
infections in stomach and cervix cancers respectively, where multiple
pathways synergistically contribute to the activation of cytokine
release, that combined with the loss of adhesion and the release of
angiogenic factors, may eventually contribute to cellular proliferation,
differentiation and tumor progression [634]. Thus, the immune defense
mechanisms that play important roles in guarding the organism against
environmental insults, might induce malignant growth in these tissues.
This event is termed inflammation-induced tumorigenesis.
Toll like receptor (TLR) function is critical for regulation of innate
and adaptive immune responses in normal cells and usually necessitates
distinguishing the defective functionality of the malignant cells that
might influence the sensory ability of the immune defense. Since
activation of the pro-survival factors such as NF-κB, ERK and JNK
kinases as well as increased levels of IL-6 and IL-12 correlate with
highly expressed TLR4 levels in malignant cells [635], these findings
indicate the important role of TLRs in chronic inflammation and cancer
development.
Interestingly, TLR4 has been associated with metastasis in various
types of cancer including the prostate. Highly metastatic human
prostate cancer cell lines, PC-3 and DU145, express higher levels of
TLR4 [636] compared to RWPE and LNCaP prostate cell lines
[634,637,638]. When these cells are treated in vitro with LPS, TNFα
is induced, reaching nM concentrations, and proliferation and migra-
tion of prostate cancer cells is observed [637,638]. Consistently, the
depletion of TLR4 expression inhibits the invasion of these cells and
also improves the survival of tumor-bearing animals [636,639], which
suggests that the higher TLR4 level or its activation significantly
augments tumor cell proliferation upon cytokine exposure. Thus,
TLR4 expressed in normal and low-grade tumors could be a contribut-
ing factor to chronic inflammation that promotes carcinogenesis.
Nevertheless, the well-known prostate specific and androgen recep-
tor (AR) regulated tumor suppressor NKX3.1 encodes a homeobox
protein and facilitates the antioxidant response through transcription-
ally upregulating the glutathione peroxidases and peroxiredoxins
[640], which leads to subsequent deregulation of the intracellular
ROS levels and activation of the DNA damage response.
In addition, the growth rate is metabolically regulated via stress-
sensing Sirtuin 1 (SIRT1), an NAD-dependent deacetylase. Under
oxidative conditions, such as inflammation, SIRT1 deacetylates a
number of transcription factors, including p53, NBS1 and AR, which
contribute to the control of the cell cycle, DNA damage response and
steroid hormone action in prostate cells respectively. Therefore, SIRT1
has also been linked to tumor cell survival, particularly in prostate
cancer, by the deacetylation of AR. Thus, the inflammation induced via
TLR4-related cellular mechanisms contributes to the deregulation of the
antioxidant response and DNA damage recognition in prostate, where
the increased genetic heterogeneity is suppressed via AR, and its
deacetylation by activated SIRT1 counteracts the deregulation of cell
growth leading to stress tolerance in tumor progression.
8.9. Summary and conclusions
In this section we have seen some examples of how ROS formation
has regulatory mechanisms that can be implicated in health and
disease. ROS formed from NOX, mitochondria, or NO-producing
enzymes are not necessarily toxic, but rather compose a network
signaling system, known as redox regulation.
In the case of NOX2, we have seen that under physiological
conditions ROS production derived from NOX2 may have an anti-
inflammatory role when produced in a limited time and space, while a
defect in NOX2 can lead to “ROS-independent inflammation.” However,
when they are overproduced, they become pro-inflammatory as they
induce oxidative stress and changes in cell homeostasis during a “ROS-
dependent inflammation.” While the use of NOX2-deficient mice has
advanced our knowledge on the role of NOX2, it is probably not the best
approach to determine whether the absence of NOX2 is protective
against inflammation, as the deletion of NOX2 inherently leads to a
dysregulation of the immune response. A clear example of a human
disease related to defects in NOX2 or associated subunits is chronic
granulomatous disease [641]; as a consequence of NOX2 deficiency,
neutrophil killing is defective due to the extremely low respiratory
burst in these cells during phagocytosis [642,643].
ROS generated by NOX enzymes can control vascular function via
modulation of NO bioactivity [644]. In the brain, NO can exert a
modulatory role both in the neurovascular coupling and in the
functionality of energy formation by the mitochondrial respiratory
chain. Therefore, neuronal-derived NO can be considered a master
regulator of the neurovascular-neuroenergetic coupling axis. Further-
more, dysfunction of the NO-dependent neurovascular and neuroener-
getic coupling has been related to the cognitive decline associated with
brain aging and Alzheimer´s disease [576].
Besides the regulatory mechanism of neuronal NO, glial cells also
play an active role in maintaining the redox balance in the brain. In line
with this, astrocytes act as the central supplier of GSH for antioxidant
protection of neurons. Cysteine is required to produce GSH in order to
control the antioxidant capacity of cells in neurodegenerative disease;
therefore, it is now recognized that drugs that target both the xc-
exchanger and the TS pathway have greater potential as effective
therapeutics [623]. On the other hand, in microglial cells, cholinergic
stimulation of the α7 nicotinic receptor subtype is being recognized as a
target to control neuroinflammation and oxidative stress by inducing
hemoxygenase-1 to provide neuroprotection [628].
Homocysteine (HCY) is a pro-inflammatory sulfur-containing redox
active endogenous amino acid, whose concentration increases in
neurodegenerative disorders including ALS. At the neuromuscular
junction, the effect of HCY on oxidative stress-induced impairment of
transmitter release was shown to be age-dependent [631]; older rats
were more sensitive to the inhibitory effect of H2O2 than newborns,
most probably because the latter have higher levels of antioxidant
enzymes. Furthermore, activation of P2Y12 receptors by ATP, which is
co-released with ACh at the neuromuscular junction, can induce ROS
production by activating NADPH oxidase [632] and thereby control
neurotransmission.
Finally, inflammation and oxidative stress can participate in cancer.
Activation of pro-inflammatory cascades via TLR4 has been related to
highly metastatic tumors [636]. On the other hand, ROS production via
NOX2 can regulate inflammation [645]. In line with these observations,
it has been reported that NOX activity and expression is associated with
tumorigenesis of lung cancer, and that inhibition of NOX function or
mRNA expression can significantly block lung cancer formation and
invasion [646].
In conclusion, ROS play a Janus-faced role: they can provide
physiological actions or contribute to pathogenesis. We have seen in
this review that the regulatory actions of ROS are complex and can
differ from one cell system to another. Therefore, understanding the
fine regulatory mechanisms of ROS in specific cells and tissues will
contribute to the identification of precise targets and thus to the
development of more efficient therapeutic strategies.
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9. The emerging roles of redox networks in tumor cell
proliferation, hearing loss, neuropsychiatric disorders and
cardiovascular pharmacology
Isabel Fabregat (E-mail: ifabregat@idibell.cat) and Santiago Lamas
(E-mail: slamas@cbm.csic.es).
9.1. Introduction
Our COST Action has invested a significant amount of work and
interaction on major biomedical and clinical problems in which ROS
have an established role or where significant evidence has been
mounted for their participation in the initiation, perpetuation or
resolution of the most pressing health challenges in the developed
world in the next decade. The focus of this section are the ideas,
expertise and studies of the members of the EU-ROS COST Action.
We have grouped the contributions in this sub-section into four
major categories: cancer, metabolic diseases, neuropathology and
cardiovascular diseases. A summary of these is depicted in Fig. 9.1.
A fundamental problem in cancer biology has to do with the
migration of tumor cells to extraneous tissue environments where they
may constitute the core of metastatic niches. The role of oxidative stress
germane to this phenomenon is far from clear and remains controver-
sial. For example, it has been found that melanoma metastasis may
progress by suppressing redox-related effector molecules such as APE1/
REF-1 [647] and making melanoma cells less responsive to oxidative-
induced DNA damage. In contrast, it has been also reported that
oxidative stress may inhibit distant melanoma metastasis in vivo
[648]. In a similar vein, the targeting of fundamental endogenous
antioxidant systems, such as GSH and thioredoxins, has been proposed
as a potential advantageous therapy for cancer and HIV [649]. A more
detailed analysis on the molecular mechanisms related to redox
responses in the context of cancer cell migration is provided below.
Of interest, the cellular and molecular sources responsible for ROS
generation have been the object of intense study in pathophysiological
settings such as liver fibrosis and carcinogenesis. Here too, the jury is
still out regarding the beneficial or detrimental role of NOXs, especially
in reference to the apparently opposite effects of NOX1 and NOX4 in
liver tumorigenesis, as discussed in the following paragraphs.
The Action has benefited from the work of groups interested in the
redox regulation of neurological and psychiatric diseases with a specific
emphasis on two relatively unexplored areas: the inner ear and
schizophrenia. Of all the NOX isoforms, NOX3 is clearly the most
elusive, less studied and even less well understood, primarily due to its
restricted topological expression in the inner ear. One of the labora-
tories involved in this COST action has shed light on the function of
NOX3 in balance regulation and hearing function by developing
sophisticated mouse models that lend themselves to investigation of
this issue. The problem of hearing loss, either genetically based or
acquired after environmental exposure to noise or aging, has experi-
enced a recent twist where redox regulation has taken center stage.
Indeed, a very captivating report has described that pejvakin, a protein
related to peroxisomal function and proliferation, lies at the basis of an
inherited sensorineural form of deafness and its lack or malfunction
induced by oxidative stress makes the inner ear extremely vulnerable to
noise-induced damage [650]. NOX3 is expressed in the cochlea even
though mice devoid of it do not show an apparent hearing loss-related
phenotype. Whether peroxisomal generation of ROS is connected to
NOX3 function is a possibility that remains to be investigated. Another
set of diseases where the role of redox regulation is intriguing is in the
realm of neuropsychiatry. While a significant amount of evidence
regarding the role of oxidative stress has accumulated in neurodegen-
erative diseases (please see the corresponding section), much less is
known in the context of psychoses. In the particular case of schizo-
phrenia, aside from profound alterations in the levels of several
neurotransmitters, a disturbed redox homeostasis has been evidenced
with a major focus on glutathione regulation. These intriguing findings
are discussed below highlighting the major advances and pitfalls in the
knowledge of this exciting research avenue.
There is currently little doubt about the relevant role played by
oxidative stress in the metabolic syndrome and in particular in type 2
diabetes. Both insulin production, as well as insulin signaling, are redox
sensitive processes, highly determined by the levels of O2•- and •NO, and
their interplay. Thus, impairment of physiological signaling by ROS/
RNS is implicated in the etiopathology of diabetes [651]. Some groups
in our COST Action are interested in exploring how the fine tuning of
the O2•-/•NO ratio is regulated and how it affects insulin synthesis and
degradation. Furthermore, oxidative stress contributes to pancreatic β
Fig. 9.1. Summarizing scheme on the contribution of ROS signaling to different physiological and pathophysiological conditions. This section covers an ample spectrum of disorders with
the theme of redox signaling and nitroxidative stress as the common modulator of disturbances related to tumor cell migration, fibrogenesis, hearing loss, neuropsychiatric disorders,
metabolic syndrome, drug metabolism, renal hemodynamics and lung hypoxia. In the slide the participation of relevant enzymatic pathways (NOXs, SODs, ALDH-2) are indicated. BMI:
body mass index. The rest of the abbreviations are defined in the text.
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cell loss, which impairs insulin secretion [652]. Therefore, therapeutic
strategies to prevent β cell dysfunction require better knowledge about
how to protect them against direct or indirect effects of free radicals
and lipid peroxidation. Also relevant is the fact that both insulin
sensitivity and metabolic homeostasis depend on the capacity of
adipose tissue to take up and utilize excess glucose and fatty acids.
This buffering capacity depends on physiological levels of •NO, whose
function may be altered by excessive formation of O2•- [653]. Interest-
ingly, recent evidences indicate that redox signaling and oxidative
stress may contribute to adipose tissue remodeling and this is a relevant
area of research. These new aspects about the relevance of ROS and
RNS in the context of metabolic syndromes and diabetes are expanded
below highlighting the major challenges addressed by research mem-
bers within the EU-ROS COST Action.
Cardiovascular physiology and pathophysiology have also been a
major object of this COST Action and this is reflected in the present
section of this overview. In this section we also include contributions of
the COST members related to vascular aspects with a specific focus. One
of these is the still unresolved and important problem of toxicity and
tolerance derived from the clinical use of organic nitrates. In the last
few years new light has been shed upon the molecular mechanisms
related to the side effects of nitroglycerin and other nitrates evidencing
a major role for mitochondrial dysfunction and disruption of redox
homeostasis. A detailed update of the problem is provided in the section
that follows. A disturbed vascular redox balance underlies the patho-
physiology of important morbid conditions in other organs such as the
lung and kidney. In the lung, chronic hypoxic pulmonary hypertension
leads to vasoconstriction and vascular remodeling, two phenomena that
self-perpetuate the vicious cycle. In the kidney, studies in animals using
superoxide dismutase (SOD) mimetics point to an important role of
redox dysfunction in the increased vascular resistance associated with
chronic kidney disease and open the possibility of therapeutic inter-
vention. Both sets of concepts and data are appropriately discussed
below.
9.2. Cancer
The following subsections were composed by Esther Bertrán, Isabel
Fabregat, Ana Fernandes, and Nuno Saraiva.
9.2.1. Redox regulation of tumor cell migration
Several cellular and extracellular events are involved in ROS
production and can directly or indirectly impact on mechanisms
involved in different types of cell migration thus contributing to the
invasiveness and poor prognosis of several cancers. These mechanisms
include invadopodia formation, MMP activation/expression, focal
adhesion dynamics, cell-cell contact, cytoskeleton remodeling, and
gene expression regulation (Fig. 9.2) [654–656]. In turn, many
mechanisms involved in cell migration, such as integrin signaling or
Ca2+ homeostasis affect ROS production, creating intricate and still
poorly understood regulatory mechanisms [656,657]. ROS can act as
second-messengers by oxidizing cysteine residues that impose func-
tional changes on cell migration-relevant kinases, phosphatases and
transcription factors [658]. The uneven physical and temporal distribu-
tion/activity of the elements involved in ROS production (Fig. 9.2) can
lead to heterogeneous ROS accumulation within a migrating cell and
during the migration process. Several sources may contribute to the
generation of ROS (see figure). Their topological distribution influences
the localization and oxidative status of many regulatory elements, thus
allowing a redox-dependent spatial and temporal regulation of cell
migration/adhesion mechanisms. Mitochondrial ROS are associated
with the initial ECM contact while a cytosolic ROS increase is involved
Fig. 9.2. ROS and cell migration. (A) There are several sources of reactive species (RS) whose subcellular distribution dictates the fate and direction of cell migration. In this cartoon they
are indicated by Arabic numbers. (B) Key mechanisms involved in the redox-regulation of cell migration. The main effectors participating in cell-cell contact adhesion, gene expression
activation, matrix degradation, cytoskeletal remodeling and focal adhesion are indicated.
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in cytoskeleton remodeling and NOX-derived ROS are involved in
invadopodia formation [186]. Additionally, the existence of an elevated
reductive potential as well as strong redox buffers is essential to limit
ROS diffusion and maintain a polarized distribution of oxidant inter-
mediates [657]. The final outcome in cell proliferation, migration and
adhesion depends on the activation of a series of effectors regulating
gene expression, matrix degradation, cytoskeletal remodeling and cell-
cell contact adhesion (see figure).
The complexity of mechanisms by which ROS mediate cancer cell
migration is still far from being understood. A general pattern of the
impact of ROS and antioxidants on tumor metastatic potential is
difficult to depict given the inherent differences among cancer types.
For example, MnSOD expression may be highly dependent on the
primary tissue [659]. Even considering tumors from the same organ of
origin, the stage and grade of disease progression may influence
intracellular ROS and antioxidant enzyme levels. Most of the previous
studies on the influence of ROS in cell migration were performed in cell
culture models. However, the activity of antioxidant enzymes varies
with the culture conditions and declines after a high number of cell
passages. Another aspect that limits the usefulness of cell culture
models is their inability to recreate the tumor microenvironment,
which includes cancer cells, cancer stem cells and stromal components,
such as extracellular matrix, fibroblasts, immune cells, adipocytes, and
vascular cells. The analysis of specific subsets of tumor cells is both
essential and challenging, since tumors contain different cell types,
necrotic material and stroma. Differences between conventional cell
culture models and the metastatic microenvironment contribute to the
discrepancies observed in the literature, reinforcing the need for more
physiologically relevant approaches.
The implementation and standardization of in vivo techniques to
measure the levels of specific ROS and their sub-cellular distribution is
essential to dissect and confirm several mechanisms by which ROS
impact cancer cell migration.
9.2.2. Role of NADPH oxidases in fibrogenesis and cancer
The oxidative stress that takes place during chronic liver diseases is
due to increased ROS production, as well as to decreased activity of
antioxidant systems. It is not only a consequence of chronic liver injury,
but also a significant contributor to excessive tissue remodeling and
fibrogenesis. The main source of ROS implicated in liver fibrosis is the
NOX family of proteins [523,660]. NOX proteins are also likely to act as
a persistent, endogenous source of ROS during Hepatitis C virus (HCV)-
induced pathogenesis [661]. These enzymes are expressed in diverse
cells and tissues, and their products are essential in several physiolo-
gical settings [662]. NOX1, NOX2 and NOX4 have been proposed to
play essential roles in liver fibrogenesis. Transforming growth factor-
beta (TGF-β)-induced activation of hepatic stellate cells (HSC) to
myofibroblasts (MFB) is mediated by NOX4-derived ROS [184]. More-
over, NOX1, activated either by TGF-β or other stimuli, promotes
myofibroblast proliferation by PTEN inactivation to positively regulate
an AKT/FOXO4/p27 signaling pathway [663]. Furthermore, NOX1
activity might further contribute to the inflammatory process that
promotes COX-2 expression and prostaglandin synthesis in hepatocytes
[664]. Promotion of hepatocyte apoptosis is another crucial event
during fibrogenesis since it triggers Kupffer cell and HSC activation by
secreting cytokines, chemokines and microparticles. NOX4 is necessary
to mediate apoptosis induced by TGF-β [177,184]. However, the pro-
apoptotic effect of the cytokine can be attenuated when NOX1 is active
[179]. NOX2 is expressed in both endogenous liver cells and bone
marrow-derived cells, possibly acting in the process of phagocytosis of
dead hepatocytes [665]. The role of NOX in hepatocarcinogenesis is
more complex and is still a matter of study in different laboratories.
NOX4 may play essential roles mediating TGF-β tumor suppressor
functions, in particular its effects on cell death [177,528]. In this sense,
recent results indicate that silencing NOX4 in liver tumor cells increases
their proliferative and tumorigenic properties [185]. In contrast, NOX1
might control autocrine cell growth of liver tumor cells through
regulation of the EGFR pathway [179,666]. In fact, recent studies
indicate that NOX1 and NOX4 proteins have opposite prognostic effects
in HCC. High NOX1 and low NOX4 expression were independent
predictors of both shorter recurrence-free survival and shorter overall
survival [667]. In view of the essential roles played by NOX4 in liver
fibrosis, recent preclinical studies with a NOX4/1 inhibitor
(GKT137831) have demonstrated its efficiency as a potent inhibitor
of fibrosis and hepatocyte apoptosis [668], thus paving the way for
future translational studies.
9.3. Neurological and psychiatric disorders
The following subsections were composed by Vincent Jaquet, Karl-
Heinz Krause, Francis Rousset, and Tamara Seredenin.
9.3.1. Redox imbalance in the pathogenesis of schizophrenia
The etiology of schizophrenia is unknown, but it is generally
thought that a combination of genetic and environmental factors
modulates the disease. A popular theory of schizophrenia involves an
imbalance between inhibitory and excitatory neurotransmission. This is
evidenced at the neuropathological level by a decrease in number of
parvalbumin-positive GABAergic interneurons (PV neurons) and altera-
tions of N-methyl-D-aspartate (NMDA) receptor subunits [669]. The
molecular mechanisms involved at onset, during psychotic episodes and
chronicity of schizophrenia are unknown, but numerous studies in both
humans and rodents point towards a contribution of neuroinflamma-
tion, increased reactive oxygen species (ROS) generation and dysfunc-
tion of redox signaling [670,671].
Most studies using post-mortem analysis of brains of schizophrenic
patients indicate (i) increased markers of oxidative modifications of
biomolecules, including lipids (4HNE), nucleic acids (8-hydroxydeox-
yguanosine) and proteins (carbonylation); (ii) decreased levels of
glutathione and enzymes involved in glutathione metabolism, (iii)
microgliosis and astrogliosis and increase of microglia activation
markers. Rodent models of social isolation and administration of
NMDA receptor antagonists recapitulate several neuropathological
features (loss of PV neurons and pro-oxidative phenotypes). Several
studies have proposed a key role of specific redox systems in the
pathogenesis of diseases of the central nervous system (CNS). Low
glutathione (GSH) levels are a hallmark of schizophrenia [672]. GSH is
a major regulator of intracellular redox homeostasis. Schizophrenic
patients show low levels of GSH in blood and in prefrontal cortex, and
mice deficient in the Glutamate-Cysteine Ligase gene, the rate-limiting
enzyme for GSH synthesis, display behavioral and neurochemical
abnormalities commonly associated with schizophrenia [673]. Clinical
trials using the general antioxidant agent N-acetylcysteine (which can
act as a GSH precursor) show promise for treating some features of
schizophrenia. Behrens et al. observed an increase in NOX2 activity in
neurons following repeated administration of subanesthetic doses of the
NMDA receptor antagonist ketamine [674]. Importantly, ketamine
administration led to the loss of PV neurons, which could be pharma-
cologically reversed by administration of the antioxidant apocynin. The
efficacy of apocynin was further confirmed in another study using a
transgenic model of NMDA receptor hypofunction (Ppp1r2-Cre/fGluN1
knockout mice), which endured social isolation. However, the increase
of neuronal oxidation was not changed in NOX2-deficient mice,
suggesting that NOX2 is not the main source of ROS in this model
[675]. Interestingly PGC-1α – a key regulator of mitochondrial biogen-
esis and antioxidant response – is enriched in GABAergic interneurons
[676]. In this social isolation model, PGC-1α downregulation correlates
with increased oxidation in PV interneurons, suggesting a role for
mitochondrial ROS [675]. Other studies failed to detect NOX2 in
mature neurons, but showed that NOX2 is mainly expressed in
microglia and adult neural stem cells in the CNS [677,678]. Microglia
are the CNS cell type that expresses the highest levels of proteins
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regulating redox dynamics suggesting a prominent role in the CNS
redox balance [679]. Further studies assessing microglial perturbations
in psychiatric diseases may highlight how redox genes are involved in
modulating neuronal activity by pruning synapses and regulating
neurogenesis. Altogether, there are strong arguments for redox imbal-
ance in schizophrenia; however, the sources of ROS, redox kinetics,
contribution of specific redox pathways and the cell types implicated
require further studies.
9.3.2. Role of NOX3 in inner ear pathologies
Research over the last decades has identified a major role for ROS in
hearing disorders, including overexposure to noise, ototoxic drugs (e.g.
cisplatin) and age-related hearing loss [680]. While the sources of ROS
are complex and only partially understood (e.g. mitochondria), there is
increasing evidence that activation of NOX enzymes, in particular
NOX3, plays a key role in hearing loss. High level and specific
expression in the inner ear identifies NOX3 as a prime drug target to
combat hearing loss [681]. NOX3 is a multi-subunit NADPH oxidase,
functionally and structurally closely related to NOX1 and NOX2. NOX3
is active as a multiprotein complex including the membrane-bound
NOX3 and p22phox and the cytosolic subunits NOXO1 and NOXA1.
NOX3 is crucial for the formation of otoconia, small proteinaceous
carbonate crystals involved in balance [682]. Mice carrying a loss of
function mutation within the NOX3 complex – including the common
NOX1 to NOX4 subunit p22phox, or the cytosolic subunit NOXO1 – have
a vestibular phenotype similar to NOX3 mutant mice (referred to as
head-tilt mice). However, the role of NOXA1 is less clear and has mostly
been addressed in vitro. So far, the physiological relevance of NOX3
expression in the cochlea remains unclear as no hearing phenotype was
described for NOX3 loss of function mutant animals. The role of NOX3
in cisplatin induced hearing loss is actually the best documented. An
agonist effect of the antineoplastic drug cisplatin on the NADPH oxidase
activity of NOX3 was observed in vitro, suggesting a potential role of
NOX3 in cochlear damage [683]. Moreover, an increased NOX3 mRNA
level has been described in the cochlea of cisplatin treated rats while
siRNA against NOX3 were able to prevent cisplatin-mediated hearing
loss in this model [684]. Together, it is now accepted that NOX3 is a
major source of ROS in the cochlea. However, the role of NOX3 may not
be limited to cisplatin-induced ototoxicity. Indeed, oxidative stress is
also a major component in other hearing pathologies such as presby-
cusis, Meniere's disease or noise-induced hearing loss. For these
conditions, further experimental confirmation and a deeper confirma-
tion and understanding of the role of NOX3 in hearing loss based on loss
of function mutant mice is required. Three mouse models of hearing
loss have been successfully developed in one of the laboratories of this
COST action – namely noise overexposure, cisplatin and age-related
hearing loss models and investigation of the role of NOX3 is currently
ongoing through both NOX3 and p22phox mutant mice. In parallel,
specific approaches allowing inhibition of pathological NOX3 activity
should be developed. At this point, it is difficult to predict whether
classical pharmacological approaches, i.e. small molecule NOX3 in-
hibitors, or rather molecular biology-based therapies, i.e. siRNA-
mediated knock-down, will be the ultimate tools for NOX3-targeted
therapies.
9.4. Metabolic diseases and diabetes
The following subsections were composed by David Bernlohr, Bato
Korac, Irina Milisav, Tatjana Ruskovska, Shlomo Sasson, and Ana
Stancic.
9.4.1. Importance of setting superoxide/nitric oxide ratio in diabetes. Role
of L-arginine
A hallmark of the diabetic state is the increased level of O2•- in many
tissues as a result of hyperglycemia and hyperlipidemia. The high level
of O2•-, along with the reduced endogenous synthesis of NO, is
responsible for the low bioavailability of NO in diabetic conditions.
The product of O2•-/NO interaction, peroxynitrite (ONOO-) and more
potent oxidants, deriving from ONOO-, play a significant role in the
metabolic complications that accompany diabetes including obesity
and insulin resistance. To increase NO bioavailability and/or to
simultaneously reduce the O2•- level in order to improve prediabetic
and diabetic states, supplementation with L-arginine, the substrate for
NO synthases, as well as mimics of superoxide dismutase (SOD) have
been proposed as a potential therapeutic strategy. Several beneficial
effects of L-arginine have been observed in diabetes. In the pancreas L-
arginine induces β-cell regeneration [685] and positively regulates
insulin synthesis and secretion [686]. The favorable effects of L-arginine
in obesity and insulin resistance are well-established and could be
ascribed to the role of L-arginine in improving fat metabolism, by
increasing lipolysis and β-oxidation [687] as well as thermogenesis-
related energy expenditure [653,688,689] and insulin sensitivity [687].
It seems likely that all these effects of L-arginine may be related to
improved NO bioavailability. An innovative mechanism-based ap-
proach for controlling NO and O2•- levels includes the use of redox-
modulating compounds such as selective functional mimics of SOD.
SOD mimics were initially designed to scavenge excessive O2•-, but
additional data suggest that a decreased formation of peroxynitrite and
nitr(os)ative stress and restoration of NO signaling underlie the
therapeutic benefits of these agents [690–692]. These compounds show
positive effects on insulin sensitivity and metabolic complications in
diabetes, in part through the recovery of mitochondrial function
[690,692,693]. Altogether, using specific potent redox-active agents
to adjust the O2•-/NO ratio seems to have potential in the treatment of
degradation by
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Fig. 9.3. Structure of the insulin degrading enzyme complex with amyloid-β, sites of redox regulation and major functions as a peptidase. The structure was displayed by the Visual
Molecular Dynamics program [698] from the structure PDB ID: 2G47 [699]. Yellow: the sulfur atoms of cysteines; orange: Glu111; red/gold: ATP, light green: amyloid-β fragment. We
acknowledge the help of Jure Stojan to prepare the crystal structure image.
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this widespread metabolic disorder. The fact that traditional antiox-
idants failed to show significant benefits in diabetes emphasizes the
importance of the aforementioned approaches.
9.4.2. Regulation of insulin degradation by redox-related pathways
S-Nitrosylation (the covalent addition of NO-related species to
cysteine residues of target proteins resulting in the formation of
nitrosothiols-SNOs) has recently emerged as a relevant mechanism that
activates or inhibits protein function, and alters protein conformation,
protein aggregation, protein localization and protein-protein interac-
tions [694]. S-nitrosylation can affect other post-translational modifica-
tions of cysteine thiol groups (like palmitoylation, which is important
for protein-membrane associations), bond formations and cellular
signal transduction pathways [695,696] Only specific cysteine residues
are S-nitrosylated, as this depends on the proximity to reactive species,
local hydrophobicity and is counterbalanced by denitrosylation en-
zymes, like the thioredoxin system and protein disulfide isomerases.
Insulin degrading enzyme (IDE) is a zinc metalloprotease that
degrades insulin, small peptides and amyloidogenic peptides, like
amyloid β peptides, α-synuclein, amylin, and atrial natriuretic peptide
(Fig. 9.3) [696]. IDE deficit increases the abundance and signaling of
the pancreatic hormones insulin, amylin and glucagon. Increased
insulin improves glucose tolerance, increased amylin levels slow
postprandial gastric emptying. IDE deficit increases levels of amylin,
α-synuclein, and Aβ monomers. These molecules impair the secretory
function and survival of pancreatic β cells and neurons through the
formation of toxic oligomers. Whereas IDE is expressed in all tissues,
the regulation of its levels is an intricate and still unclear process. Cell
stress, glucagon and free fatty acids have all been shown to participate
[696]. In cells IDE is mostly localized in the cytosol but its presence has
also been reported in peroxisomes, mitochondria, cell membranes and
extracellular fluids, including cerebrospinal fluid and plasma
[696,697].
IDE can be present as a monomer or multimer but it has been shown
that dimerization allosterically regulates its catalytic activity [697].
Dimerization and binding with cytoskeletal proteins and ATP enhances
the degradation of small peptides, like bradykinin. Aβ-bound IDE
structures reveal that the β-strand of amyloidogenic peptides interacts
with the door subdomain of IDE, which may explain the affinity of IDE
for amyloidogenic peptides.
Exposure of IDE to S-nitrosoglutathione can result in the modifica-
tion of IDE activity through S-nitrosylation of at least 5 of its 13
cysteine residues: Cys110, Cys178, Cys819, Cys789 and Cys966 [700].
S-nitrosylation of Cys819 promotes nitrosylation of Cys110, which is
near the catalytic site that is composed of two glutamates (residues 111
and 189) and a zinc ion coordinated by two histidines (residues 108 and
112). S-nitrosylation of Cys110 results in inactivation of IDE. Modifica-
tion of Cys178 prevents the nitrosothiol formation on Cys110 and
buffers the enzyme inhibition. S-nitrosylations at Cys789 and Cys966
induce a conformational change that triggers the aggregation of IDE
and its inhibition. S-nitrosylation of Cys178 protects all of the above
mentioned cysteine residues from nitrosylation. The oxidative modifi-
cations by H2O2 resulted in the modifications of the same residues with
equal effects on IDE activity. Although these results are from in vitro
studies, IDE was exposed to 10–100 µM S-nitrosoglutathione or H2O2,
which is in the concentration range of ROS/RNS released under
pathophysiological conditions [700]. These modifications were tested
for inhibition of Aβ hydrolysis. It has been proposed that the cysteines
of IDE act as sensors of environmental ROS/RNS levels through subtle
alterations of the protein structure and that IDE function is modulated
by the levels of oxidative/nitrosative stress. It is likely that the
oxidation of cysteine 178 may result in the protection of the active
site under moderate amounts of ROS, while severe oxidative stress
inhibits the enzyme. The decreased activity of IDE through S-nitrosyla-
tion could also reduce the degradation of both insulin and Aβ and
contribute to pathological disease conditions in type 2 diabetes and AD.
This is supported by findings demonstrating an altered redox state of
hippocampal and cortical neurons in both diseases. Indeed, increased
levels of glucose result in a significant rise in neuronal reactive nitrogen
species similar to the effects of oligomeric Aβ peptides. The high
glucose and Aβ oligomers were shown to increase neuronal Ca2+ and
NO levels in cortico-hippocampal brain slices and in cortical cultures to
the •NO levels that could potentially promote S-nitrosylation of specific
protein thiols in IDE resulting in a reduction or inhibition of its activity
[701]. Therefore, increased oxidative/nitrosative stress can contribute
to increased Aβ levels, an important pathologic hallmark of AD through
the S-nitrosylation of IDE. Although IDE is the best characterized
enzyme that degrades insulin, reduction in IDE activity in various
experimental models does not consistently increase insulin concentra-
tions. Recently the study with the IDE inhibitor that binds to its exosite
resulted in increased plasma levels of amylin, but not of insulin [697].
Other regulatory mechanisms and/or IDE substrates may also contri-
bute to glucose homeostasis, development of insulin resistance and
diabetes mellitus type 2.
9.4.3. Lipohormesis and lipotoxicity in pancreatic beta cells
Monounsaturated and polyunsaturated fatty acids (MUFA and
PUFA, respectively) promote adaptive responses and enhance cell
tolerance to lipid overload through induction of cellular defense
mechanisms (lipohormesis) that protect cells against lipotoxic effects.
Recent lipidomic analysis performed on pancreatic beta cells that were
exposed to increasing glucose and palmitic levels revealed extensive
remodeling of fatty acids in membrane phospholipids. Particularly, the
abundance of PUFA was decreased whereas the content of MUFA
increased. These changes were accompanied by non-enzymatic perox-
idation of the released PUFA and their transformation to bioactive 4-
hydroxyalkenals. This process in beta cells leads to the generation of 4-
hydroxynonenal, which activates PPARδ [702–704]. The latter aug-
ments the secretion of insulin, which promotes hepatic and peripheral
mechanisms that enhance glucose disposal and the incorporation of free
fatty acids into triglycerides and their storage in adipose tissues.
Excessive and prolonged nutrient overload often interferes with normal
cell functions and dysregulates hormonal-mediated inter- and intra-
organ metabolic communication networks. In beta cells, hyperglycemia
and hyperlipidemia synergistically compromise insulin synthesis, glu-
cose-stimulated insulin secretion and cell survival. The mechanisms
underlying these derangements, which characterize the etiology of type
2 diabetes and other manifestations of the metabolic syndrome, have
been thoroughly investigated [705]. A central hormetic mechanism is
redox-mediated release of KEAP1 from the KEAP1/NRF2 complex,
allowing nuclear translocation of NRF2 and its interaction with
Antioxidant Response Elements (ARE) in promoters of target genes
encoding antioxidant enzymes, ultimately resulting in their activated
transcription. Beyond the modification of dietary habits and life style in
addition to treatment of the underlying condition, it would be
theoretically sound to propose pharmacological approaches with potent
oral antioxidants, which are efficiently absorbed, reach the circulation
and affect cells, such as beta cells, and protect them against direct and
indirect effects of free radicals and lipid peroxidation. However, the
prevailing knowledge favors the notion that these oral antioxidants are
only effective when triggering intracellular physiological signals related
to endogenous protective pathways such as the aforementioned KEAP1/
NRF2-ARE axis.
9.4.4. Redox regulation of white adipose tissue remodeling
The white adipose organ features high metabolic activity and
endocrine function and regulates whole-body energy homeostasis
through the secretion of macronutrients (fatty acids) and adipokines
(e.g., adiponectin, resistin). White adipose tissue (WAT) can be
anatomically divided into visceral and subcutaneous. It is found
distributed broadly in the body and is subject to regulatory cues
throughout development and aging. Evolutionarily developed for
J. Egea et al. Redox Biology 13 (2017) 94–162
139
effective fat storage in the short periods of food access, as well as for
immune surveillance, dysfunctional obese WAT underlies metabolic
disorders in the modern era because food is readily and continuously
available [706].
In the fed state, insulin mediates the uptake of glucose by adipocytes
that is metabolized via the combined actions of glycolysis, TCA cycle
and fatty acid biosynthesis to produce precursors utilized for triglycer-
ide biosynthesis. Through these pathways, high nutrient oxidation
decreases the adipocyte NAD+/NADH ratio that attenuates the activity
of all NAD+ dependent enzymes, including the sirtuins. Sirtuins
deacetylate/deacylate both histone and non-histone target proteins
regulating their activity and cellular function. SIRT1 is the best studied
of all seven mammalian sirtuins. It provides a molecular link between
the cellular metabolic status and the adaptive transcriptional response.
In the WAT SIRT1 acts through repression of transcriptional activity of
the nuclear receptor PPARγ, the master regulator of both lipogenesis
and adipogenesis. Calorie restriction increases the adipocyte SIRT1
activity and promotes lipid mobilization, as well as insulin sensitivity
and glucose tolerance [707]. Therefore, the adipocyte NAD+/NADH
ratio, acts as an important indicator of cellular and whole body energy
status, and emerges as one of the key redox regulators of WAT function.
SIRT1 also has an important role in the browning of the WAT, a
metabolically beneficial WAT remodeling that promotes energy expen-
diture to combat obesity and diabetes, which might serve as a novel
strategy to improve metabolic health. A very recent study reveals that
capsaicin (a bioactive compound of red pepper) has the potential to
induce increased expression and phosphorylation of SIRT1 in the
subcutaneous WAT of mice fed a high fat diet. Activated SIRT1
deacetylates both PPARγ and positive regulatory domain containing
16 (PRDM-16), promotes WAT browning and prevents weight gain. The
effect of capsaicin on SIRT1 is mediated by the transient receptor
potential cation channel subfamily V 1 (TRPV1), Ca++/calmodulin
activated protein kinase II and adenosine monophosphate activated
kinase (AMPK). In parallel, an increased expression of mitochondrial
uncoupling protein 1 (UCP1) was found in the WAT of mice treated
with capsaicin, confirming the key role of UCP1 in the browning of
WAT [708].
Evolutionarily designed for effective fat storage (and release), the
WAT has developed an extraordinary ability for expansion, thus
preventing the metabolically detrimental ectopic fat accumulation. As
a consequence of nutrient overload, the existing adipocytes enlarge and
accumulate triglycerides (a process known as lipogenesis), and/or new
adipocytes differentiate from the multipotent mesenchymal stem cells
(MSC) to form mature adipocytes (adipogenesis). Adipogenesis, also
known as adipose tissue hyperplasia, leads to a metabolically healthy
obese WAT phenotype that is characterized by increased secretion of
adiponectin and insulin sensitivity, as well as decreased immune cell
recruitment, hypoxia and fibrosis. Among the many factors that initiate
and regulate adipogenesis, the contribution of ROS has been recognized
in the face of NOX4-generated H2O2. Importantly, ROS depletion with
N-acetyl-L-cysteine results in abrogation of in vitro adipogenesis [709].
Whereas adipocytes have an extraordinary capacity for fat accumula-
tion (lipogenesis), their growth above the critical volume (hypertrophy)
leads to necrotic death and pro-inflammatory remodeling linked to
macrophage infiltration and their phenotypic change from M2 (inflam-
mation resolving) to M1 (pro-inflammatory), appearance of crown-like
structures, increased angiogenesis and extracellular matrix production,
hypoxia, unbalanced production of pro- and anti-inflammatory cyto-
kines, and insulin resistance. Dysfunctional obese WAT exhibits sig-
nificantly increased protein carbonylation, indicating the central role of
excess ROS and oxidative stress in obesity induced insulin resistance
[710].
In contrast to the white adipocytes and their function for fat storage,
the adipocytes from the brown adipose tissue (BAT) are responsible for
energy dissipation in response to cold, exercise or excess calories. The
key player in energy dissipation is the inner mitochondrial membrane
protein UCP1 that uncouples the electron transport chain (ETC) from
ATP biosynthesis, thus dissipating the proton motive force, generating
heat, and increasing the rate of substrate oxidation. The recent
discovery of metabolically active BAT in human adults has attracted
much interest as a potential target for the development of anti-obesity
drugs. In addition to the classical white and brown adipocyte pheno-
type, beige adipocytes (also known as “brite” – short for brown in
white, or “brown-like”) have been identified as an inducible form of
thermogenic adipocytes. When induced they exhibit high UCP1 expres-
sion and energy expenditure. Beige adipocytes express unique genetic
signatures that distinguish them from both white and brown adipo-
cytes. In rodents, the brite adipocytes are most abundant in the
subcutaneous WAT and are responsible for its browning [711].
Intriguingly, a recent study reveals that UCP1-mediated thermo-
genesis depends on mitochondrial ROS production. It has been shown
in vivo that acute activation of BAT thermogenesis is associated with a
substantial increase in mitochondrial superoxide, lipid hydroperoxides
and hydrogen peroxide. Pharmacological depletion of mitochondrial
ROS inhibits the UCP1 dependent increase in whole-body energy
expenditure, confirming the essential role of ROS in the regulation of
adipocyte function and metabolism. At the same time, a substantial
oxidation and depletion of the cellular and mitochondrial glutathione
pool has been demonstrated, as well as an increased global protein
sulfenylation, and sulfenylation of UCP1 Cys253 as a redox sensitive
site related to thermogenesis [712]. The possible dependence of WAT
UCP1 activity on the cellular pro-oxidant state was studied in Nrf2-/-
mice. The NRF2 transcription factor is a critical regulator of genes
involved in detoxification and antioxidant defense. Therefore, Nrf2-/-
mice are more susceptible to toxicant- and oxidative stress-induced
diseases, as well as autoimmune diseases and cancer. Paradoxically,
they are also resistant to high fat diet-induced obesity, exhibit improved
metabolic profiles, and demonstrate increased energy expenditure in
comparison to the wild type mice fed a high fat diet. Such mice also
exhibit a concomitant decrease in the GSH/GSSG ratio and up-regula-
tion of UCP1 and other BAT markers in intra-abdominal fat pads [713].
Overall, balanced ROS levels are required for proper WAT function, and
both very high and very low levels impede its function and influence
whole-body energy homeostasis [714]. Therapeutic control of adipose
ROS therefore represents an attractive axis to regulate not only
adiposity, but also metabolic healthfulness.
9.5. Cardiovascular pathologies
The following subsections were composed by Andreas Daiber,
Vaclav Hampl, Jan Herget, Jaap Joles, Thomas Münzel, Isabel
Nguyen, and Olga Vajnerova.
9.5.1. Drug-induced oxidative stress – the case of nitroglycerin
Organic nitrate therapy is still a mainstay in the treatment of
patients with acute and chronic congestive heart failure, stable
coronary artery disease or acute coronary syndrome [715]. However,
despite the fact that members of this drug class have been clinically
used for more than a century, chronic organic nitrate therapy (espe-
cially in the case of nitroglycerin) is associated with a number of serious
side effects, including induction of oxidative stress [716] and endothe-
lial and autonomic dysfunction [717], with incomplete understanding
of the underlying pathomechanisms. The induction of reactive oxygen
and nitrogen species formation by chronic nitroglycerin therapy was
shown to largely depend on mitochondrial oxidative metabolism since
partial deficiency in MnSOD aggravated nitrate-induced oxidative stress
and also the degree of tolerance to the vasodilator activity of
nitroglycerin [718]. This was later shown to rely on complex I
dysfunction in response to nitroglycerin therapy [719]. The initial
formation of mitochondrial reactive oxygen and nitrogen species can
also activate secondary sources of oxidants in a crosstalk fashion
involving mitochondrial KATP channels and the permeability transition
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pore [61]. This leads to the activation of specific enzymatic “redox
switches” in NOXs and eNOS, as recently reviewed [60]. The formation
of mitochondrial reactive oxygen and nitrogen species may lead to
endothelial dysfunction by the activation of the vascular and phagocy-
tic NOXs through protein kinase C [720] as well as to the uncoupling of
eNOS by increased S-glutathionylation, inhibitory phosphorylation and
oxidative depletion of the eNOS cofactor tetrahydrobiopterin [478].
eNOS uncoupling and oxidative desensitization of the soluble guanylyl
cyclase are probably the major enzymatic mechanisms contributing to
endothelial dysfunction observed under nitroglycerin therapy, the latter
also accounting for impaired nitroglycerin-dependent vasodilation
(nitrate tolerance), all of them corrected by co-administration of an
activator of soluble guanylyl cyclase [721]. Nitroglycerin-induced
endothelial dysfunction but also nitrate tolerance may also rely on
direct oxidative break-down of nitric oxide by superoxide leading to the
formation of peroxynitrite and significantly increased levels of 3-
nitrotyrosine-positive proteins, an effect prevented by the peroxynitrite
scavenger hydralazine [722]. Finally, the bioactivation of nitroglycerin
largely depends on enzymatic conversion by mitochondrial aldehyde
dehydrogenase (ALDH-2) [723], which is a highly redox-regulated
enzyme and inactivated by oxidative stress [716]. Hence, nitroglycerin-
induced reactive oxygen and nitrogen species formation will ultimately
lead to inactivation of the thiol-based enzymatic activity of ALDH-2
contributing to impaired nitroglycerin bioactivation, loss of its vasodi-
lator activity and nitrate tolerance [724]. There is also clinical evidence
for nitroglycerin-induced vascular oxidative stress [725] and oxidative
DNA damage in patients under chronic nitrate therapy [726]. Very
recently, we were able to demonstrate persistent oxidative modifica-
tions of DNA and proteins in nitroglycerin-treated rats, even after a 3.5-
day nitrate-free interval, which was enough to normalize nitroglycerin
responsiveness but not endothelial dysfunction. The latter could be
related to endothelial cell death by pro-apoptotic stimuli such as 8-
oxoguanine lesions in DNA and 3-nitrotyrosine-positive proteins [727].
Other organic nitrates show similar side effects, such as the activation
of NADPH oxidases, increased vascular oxidative stress and severe
endothelial dysfunction by chronic isosorbide-5-mononitrate therapy,
which was associated with augmented endothelin-1 signaling and eNOS
uncoupling [728]. The only exception among the clinically used
organic nitrates is pentaerythritol tetranitrate [715,716], which over-
comes the typical side effects of nitrovasodilators by mechanisms that
are largely based on NRF2-dependent activation of antioxidant enzymes
such as heme oxygenase-1 and superoxide dismutase [729,730] as well
as beneficial effects on other transcription factor and epigenetic path-
ways [731,732].
In conclusion, the side effects of chronic therapy with organic
nitrates, especially with nitroglycerin, are largely based on oxidative
stress and adverse redox regulation. Antioxidant therapy (e.g. by ACE
inhibitors or statins) represents a pharmacological tool to overcome
these side effects [715–717]. These and other combination therapies
with specific antioxidants, inhibitors of relevant sources of oxidants
(e.g. inhibitors of NADPH oxidase isoforms) and drugs for repair of
oxidative damage (e.g. activators of soluble guanylyl cyclase) need to
be explored in the future to increase the therapeutic window of organic
nitrates, the oldest drug class in clinical use today.
9.5.2. Regulation of renal hemodynamics in chronic kidney disease
Hypertension and an increased renal vascular resistance (RVR) are
inherent to chronic kidney disease (CKD). There is accumulating
evidence that oxidative stress is involved in its pathogenesis [733].
Experimental induction of ROS (superoxide and H2O2) generation in
the renal medulla promotes hypertension [734]. Downregulation of the
antioxidant enzymes superoxide dismutase (SOD), catalase and glu-
tathione peroxidase in the kidney were found in experimental CKD
[735]. Hence, it has been suggested that antioxidant interventions may
have beneficial effects on renal hemodynamics in CKD.
Tempol, a SOD-mimetic, has been shown to reduce oxidative injury
in cells and animal models. It improved oxidative stress and lowered
arterial pressure and RVR in various models of hypertension. However
few studies have focused on the effects of Tempol in CKD. Rats
undergoing 5/6 renal mass reduction to induce CKD showed an
elevated arterial pressure and nitrotyrosine abundance, while urinary
NOx excretion was depressed [736]. The administration of Tempol for
one week ameliorated hypertension, reduced the nitrotyrosine abun-
dance and increased NOx excretion. In spontaneously hypertensive rats
(SHR), two weeks of Tempol administration decreased the elevated
mean arterial pressure (MAP) and renal excretion of 8-iso-prostaglandin
F2α and increased the glomerular filtration rate (GFR) [737], while it
had no significant effect on these variables in the normotensive Wistar-
Kyoto (WKY) control rats. These findings suggest that oxygen radicals
may be involved in the long-term maintenance of hypertension in SHR.
Another study found an elevated RVR in SHR compared to WKY rats
[738]. When SHR were treated with Tempol the baseline RVR was no
longer significantly different from the WKY rats. The additional use of
the NO-synthase inhibitor L-NAME did not influence the effects of
Tempol on the RVR, suggesting that it has a renal vasodilator effect and
that the elevated RVR is unlikely due to ROS-induced quenching of NO.
The two-kidney one-clip model showed an elevated MAP and 8-iso-
prostaglandin F2α excretion, which was significantly reduced by the
acute administration of Tempol [739]. In the clipped kidney, adding
Tempol increased GFR and effective renal plasma flow and reduced
RVR compared to their controls. The latter was also found in the non-
clipped kidney. This indicates that Tempol is able to have a vasodilating
effect via dismutation of the superoxide resulting from angiotensin
signaling that is independent of the local perfusion pressure. This
supports the role of superoxide during the early stage of renovascular
hypertension. In another study the acute effects of the SOD-mimetic on
renal hemodynamics were investigated in rats with long-established
CKD induced by bilateral 2/3 nephrectomy [740]. Tempol was not able
to reduce the increased MAP in the CKD rats, but did lower MAP in age-
matched controls with normal kidneys, suggesting that the maintenance
of hypertension in this CKD model does not appear to depend on
superoxide. As expected, RVR was higher in the CKD rats compared to
controls, but the administration of Tempol did not have any significant
effect on RVR. This proposes that renal resistance vessels are not
sensitive to the renal vasoconstrictor effects of ROS in this model.
These data suggest that although antioxidant therapy can reduce the
elevated arterial pressure in the early stages of experimental CKD, it
does not appear to be effective once CKD is established. The same
concept could be applied to the effects of Tempol on the RVR. In early
stages of experimental CKD, prior to the development of renal fibrosis,
Tempol can have a vasodilating effect independent of the local
perfusion pressure. However, when structural damage occurs to the
vascular beds and in their direct proximity, such as in established CKD,
the vasodilating effects of Tempol are lost. This suggests that ROS may
not be a driving force in the maintenance of disturbed renal hemody-
namics in established CKD.
9.5.3. Vascular effects related to chronic hypoxia of lungs and placenta
Oxidative tissue injury participates in the pathogenesis of chronic
hypoxic pulmonary hypertension (HPH) [741,742]. HPH is caused by
persistent lung hypoxia. It results in an increase in pulmonary vascular
resistance to blood flow as a consequence of the sustained increase in
the tone of the pulmonary vascular smooth muscle, decreased com-
pliance of pulmonary blood vessels due to fibrosis and muscularization
of prealveolar pulmonary arterioles. The severity of HPH is dose
dependent. After stabilization it does not progress further. It is fully
reversible after several weeks in normoxia. HPH typically appears in
residents at high altitudes. It is involved in the pathogenesis of
pulmonary hypertension in patients with various lung and heart
diseases with alveolar hypoxia.
Two basic mechanisms increase pulmonary vascular resistance in
HPH: structural remodeling of the peripheral pulmonary vessel walls
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and vasoconstriction. Vasoconstriction plays a pathogenetic role at the
onset of HPH and it is related to hypoxia-induced oxidant vascular
stress. Superoxide, hydroxyperoxide and peroxynitrite are important
vasoactive factors released at the beginning of exposure to chronic
hypoxia [743]. Oxidant tissue injury to the pulmonary vascular wall
induced by hypoxia is the primary mechanism that triggers vascular
remodeling in HPH. Antioxidant treatment at the beginning of hypoxia
is more effective in reducing HPH than antioxidant therapy applied in
later stages of developed pulmonary hypertension.
For the fetus, the placenta plays a role similar to that of the
pulmonary circulation in postnatal life - blood oxygenation and CO2
removal. For this reason, we speculated that the regulatory and
pathophysiological mechanisms of the fetoplacental and pulmonary
vessels were similar. Indeed, we showed that both acute and chronic
hypoxia elevate vascular resistance in the fetoplacental vascular bed,
which is similar to pulmonary and in contrast to systemic vascular beds
[744]. We have also demonstrated that a well-known state of high
oxidative stress, maternal diabetes, causes an increase similar to
chronic hypoxia in fetoplacental vascular resistance (preliminary
observations). As is the case in the pulmonary circulation, oxidative
stress also appears to be a major mechanism of vascular resistance
elevation in the fetoplacental circulation.
9.6. Conclusions
Redox signaling and oxidative stress constitute fundamental reg-
ulatory mechanisms not only in highly prevalent pathologies but also in
less explored areas of biomedicine such as those related to fibrosis, cell
migration and proliferation, hearing loss, schizophrenic disorders,
insulin resistance, drug metabolism, lung hypoxia or renal hemody-
namics. In some cases, the underlying molecular mechanisms of this
redox sensitivity have been deciphered, in others we are just beginning
to open the door. It is clear that the pervading nature of ROS reactivity
will continue to offer surprises-and explanations- of complex patholo-
gies such as the ones covered in this section.
10. Toxin and bacteria-mediated ROS formation and antioxidant
strategies in ROS-related diseases
Thomas Kietzmann (E-mail: Thomas. Kietzmann@oulu.fi) and
Kateryna Kubaichuk (E-mail: kateryna.kubaichuk@oulu.fi).
10.1. Introduction
Research during the last decade has shown that ROS are important
regulators of physiological and pathophysiological processes and not
only simply detrimental due to their chemical nature or by causing
oxidative stress. This is further supported by findings indicating that
redox active compounds are essential components of living organisms.
Thereby, recent advances in genomics and proteomics have led to the
identification of a “redoxome” consisting of hundreds of proteins
involved in redox systems. It comprises enzymes generating RONS such
as NADPH oxidases and nitric oxide synthases, redox relays such as
peroxiredoxins, thioredoxins and glutaredoxins, enzymes degrading
ROS such as superoxide dismutase or catalase, as well as numerous
proteins dependent on redox modifications, which are involved in the
defense against oxidant, inflammatory and/or proteotoxic stress [745].
Although a number of substances, factors, products of metabolism,
and nutrients are important for normal cell biology and redox signaling
of all species, toxins are rather important for causing deleterious effects.
Since toxins act universally on almost all species, it is conceivable that
their action may, at least in part, involve ROS or oxidative stress and
that antioxidant defense mechanisms could help to avoid the deleter-
ious effects of toxins.
10.2. A toxin and its action via ROS
João G. Costa and Nuno G. Oliveira, discuss how the well-known
nephrotoxic food contaminant and animal carcinogen, the mycotoxin
ochratoxin A (OTA), appears to act at least partially via ROS and
induction of oxidative stress, although different mechanisms of its
toxicity have also been pointed out. Furthermore, the OTA actions can
be overcome by antioxidant based approaches [746–748] (Fig. 10.1).
OTA increased ROS appear to precede the loss of cell viability
particularly in renal cells, indicating that these ROS may contribute to
OTA cytotoxicity rather than being a consequence of cell death
processes [746,749]. Concomitant with ROS induction, OTA also
increased lipid peroxidation, depleted antioxidant enzymes
[746–751], induced oxidative stress-related proteins, and caused DNA
damage. The latter has also been associated with oxidative DNA
damage, as assessed by the formation of 8-oxoguanine or using
modified versions of the comet assay (e.g. with FPG) [749,750].
Mechanistically, recent studies propose a pathway in which electro-
philic species that directly bind to DNA bases are generated during OTA
metabolism [752]. Further, OTA was found to be able to cause
nitrosative stress due to stimulation of iNOS-mediated NO formation,
which may contribute to the formation of peroxynitrite, nitrogen
dioxide, and hydroxyl radicals [753]. Several in vitro and in vivo
studies assessed the impact of different antioxidants on the OTA-
mediated toxicity and it was found that, in general, antioxidants
Fig. 10.1. Lines of evidence supporting the induction of oxidative stress by Ochratoxin A (OTA). Alterations in biomarkers related with oxidative stress and several antioxidant-based
approaches that provide protection against a plethora of OTA-induced toxic effects are indicated. Abbreviations: SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; GST,
glutathione S-transferase; GPx, glutathione peroxidase; GR, Glutathione reductase; AP-1, activator protein 1; NRF2, nuclear factor E2-related factor 2; PRDX4, peroxiredoxin-4; VDAC1,
voltage-dependent anion channel 1; HO-1, heme-oxygenase 1; DDAH, dimethylarginine dimethylaminohydrolase; TBARS, thiobarbituric acid reactive substances; MDA, malondialde-
hyde; 4-HNE, 4-hydroxynonenal; FPG, formamidopyrimidine DNA glycosylase.
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exerted protective effects [746,747,750,751,754].
10.3. Are ROS usage and antioxidant reactions conserved?
In order to avoid the life threatening effects of toxins and toxin-
induced oxidative stress, both exogenously taken up antioxidants and
trace molecules as well as endogenous defense mechanisms contribut-
ing to redox regulation with which nature has equipped not only
eukaryotes but also prokaryotes and plants, are important to maintain
redox status. These systems appear to be quite conserved and, together
with the ROS generator sites, they largely contribute to the tightly
controlled redox balance.
For example Brandán Pedre and Joris Messens discuss that,
Actinomycetes, a genus of gram-positive Actinobacteria, possess a low
molecular weight thiol molecule, mycothiol (MSH), which serves as a
glutathione surrogate [755,756], and they express a mycothiol perox-
idase (Mpx) - a glutathione peroxidase-like enzyme. Both, MSH and
Mpx are involved in reversibly protecting cysteines from oxidation
[130] and controlling the level of ROS [131]. Further, MSH in concert
with mycoredoxin-1 [757] and the thioredoxin reduction pathways are
alternative routes for the reduction of the different oxidative forms of
Mpx. Since thioredoxin can de-mycothiolate Mpx, this indicates the
interrelationship between the MSH/mycoredoxin-1 and thioredoxin
reduction pathways. Interestingly, this is also seen in the pathogenic
Actinobacteria family Corynebacterium diphtheriae (Cd), where MSH and
thioredoxin can deliver electrons to the methionine sulfoxide reductase
A (Cd-MsrA) which stereospecifically reduces Met-S-SO [132], thus
controlling sulfur oxidation repair. Thereby, the Cd-MsrA uses a unique
intramolecular mycothiol redox relay involving a MSH/mycoredoxin-1
monothiol mechanism, which keeps several MSH-dependent enzymes
on track [130–132,757,758]. Interestingly, Mycobacterium tuberculosis
1-Cys peroxiredoxin AhpE is reduced by a mycoredoxin-1 dithiol
mechanism in addition to the mycothiol/mycoredoxin-1 monothiol
mechanism, again indicating that mycothiol-dependent enzymes are
promiscuous in the pathway that they use for receiving electrons from
NADPH [758]. Overall, it appears that a number of conserved
mechanisms are in place to defend against oxidative stress.
Although a variety of microorganisms have well established defense
systems against oxidative stress, the gain of compartmentalization in
higher organisms created the need to develop an integrated system
allowing redox regulation and protection at the same time in each cell
compartment. As indicated by Afroditi Chatzi and Kostas Tokatlidis, an
excellent example of such cross-talk is the compartment‐specific import
and folding of proteins in the mitochondrial intermembrane space
(IMS) in Saccharomyces cerevisiae where potential antioxidant proteins
are involved.
The protein import and folding in the IMS relies on the Mia40
pathway [759–761] where Mia40 and Erv1 are key components.
Importantly these mechanisms are not restricted to yeast since Mia40
and Erv1 have homologs in almost all organisms including humans. In
that system Mia40 functions as a key import receptor in the IMS where
it exerts a chaperone-like role recognizing a specific hydrophobic signal
of Cys-rich IMS proteins and transfers a disulfide to the substrate [762].
Erv1, on the other hand, is a FAD-linked oxidoreductase that recycles
Mia40 to its oxidized state [763]. It was found that the Mia40 pathway
is influenced by hydrogen peroxide and that a fraction of Hyr1/Gpx3, a
thiol-peroxidase known to act as a redox-transducer in H2O2 signaling
via YAP1 in the cytosol, is localized in the IMS. Additional proteins
involved in the antioxidant response, like thioredoxin 1 and thioredoxin
reductase1, are also part of the IMS proteome in S. cerevisiae [764].
Although these data indicate that the Mia40 oxidative folding in the
IMS [765] is associated with antioxidant proteins, its putative links to
redox homeostasis and redox signaling are still elusive. However, it is
evident that a cross-talk between redox regulation and the oxidative
stress response and the IMS oxidative folding pathway exists in higher
eukaryotes.
10.4. Involvement of ROS and antioxidant mechanisms in human diseases
The existence of rather efficient, and conserved systems involved in
both the defense and maintenance of cell, tissue, or organism function-
ality, indicates that an imbalance in ROS homeostasis is connected with
the pathogenesis of frequently occurring diseases.
Fig. 10.2. SODm in cancer therapy. A. Model proposed to describe the opposite effects of intracellular H2O2 concentration on the proliferation of cancer and normal cells. B. SODm
generate additional intracellular H2O2, which leads to differential effects in cancer and normal cells. C. Potential applications of SODm in cancer treatment. SODm may protect normal
tissues from the adverse side effects of radio and chemotherapy and, conversely, increase the sensitivity of malignant cells to standard radio and chemotherapeutic agents. SODm have
also been used as mechanistic tools in the field of redox biology to evaluate the impact of ROS in cancer therapy and in carcinogenesis. (Modified from [768] and book chapter Fernandes
et al. Springer International Publishing (2016), Switzerland. DOI 10.1007/978-3-319–30705-3_18).
J. Egea et al. Redox Biology 13 (2017) 94–162
143
10.4.1. ROS and malignant disease
One example where ROS are considered to be involved is cancer.
However, ROS appear to have a dual role; they are often implicated in
being the cause of a carcinogenic process, but since the majority of
conventional therapies rely also on the increase of ROS they seem to be
also of therapeutical benefit causing cancer cell death [766,767].
The intracellular H2O2 concentration is an important factor for the
differential proliferation often observed when comparing cancer and
non-cancer cells (Fig. 10.2A) [768]. In general, normal cells do not
show high levels of ROS. In contrast, cancer cells with a reduced
antioxidant defense and higher instability have usually a higher ROS
concentration. This fact can be at least partially be explained by the
occurrence of mitochondrial dysfunction, which is associated with an
imbalance of the antioxidant defense and an increased production of
ROS.
Among the first defenses against ROS is the dismutation of super-
oxide radicals to hydrogen peroxide and molecular oxygen by SODs; in
mitochondria this task is carried out by MnSOD/SOD2. Since mito-
chondrial dysfunction is a hallmark of cancer, carcinogenesis may be
expected to be associated with a dysregulation in the expression of
MnSOD. Indeed, numerous reports show that reduced MnSOD con-
tributes to carcinogenesis in many solid tumors [769]. Kateryna
Kubaichuk and Thomas Kietzmann discuss the concept that loss of
MnSOD leads to a transformed cell type, which was recently supported
by findings from cells deficient in MnSOD and in hepatocyte-specific
MnSOD knockout mice [770]. The loss of MnSOD in cells caused
increased proliferation, reduced apoptosis, decreased contact inhibition
and cell adhesion as well as enhanced migration. This was in line with
the in vivo findings showing that hepatocyte-specific loss of MnSOD in
mice caused liver failure, and initiation of malignant transformation
and tumor formation [770].
Mechanistically, these findings could be linked to two pathways: the
Wnt/β-catenin pathway and the hypoxia signaling pathway. The Wnt/
β-catenin pathway is one of the most important pathways associated
with cancer, in particular liver cancer. The Wnt pathway components β-
catenin and APC were decreased in MnSOD-deficient HepG2 hepatoma
cells as well as in MnSOD deficient mouse livers [770]. This is in line
with findings from hepatocyte-specific β-catenin knockout mice, which
displayed an increased susceptibility to diethylnitrosamine-induced
carcinogenesis [771]. Indeed, induction of HIF-1α, a major regulator
of the hypoxia response pathway, was disrupted both in vitro and in
vivo due to the loss of MnSOD [770]. Although those data do not
unravel all mechanistic aspects of the carcinogenic process in response
to MnSOD deficiency, they indicate an intricate interplay between HIF-
1α and β–catenin.
Moreover, MnSOD can be regulated by the transcription factor
Nuclear factor (erythroid-derived 2)-like 2 (NRF2). As indicated by
Natalia Robledinos-Antón and Antonio Cuadrado, NRF2 is of utmost
importance and regulates the expression of about 250 genes with
homeostatic functions such as those involved in NADPH, glutathione
and thioredoxin metabolism, phase II detoxification reactions, inflam-
mation and proteostasis [772,773].
Considering the fact that cancer development is characterized by an
altered hypoxia response and malfunctioning of MnSOD, which both
can be affected by NRF2, superoxide dismutase mimics (SODm), as well
as NRF2 inhibitors, can be considered to be useful in cancer treatment
and in other diseases associated with enhanced ROS including cardio-
vascular, inflammatory, and neurodegenerative disorders [774].
Ana S. Fernandes and Nuno G. Oliveira point out that SODm are
synthetic compounds with low molecular weight that mimic the
Direct determinants:
• Nature of RONS
• Cellular site / organ system
• Time: early vs. late, acute 
vs. chronic
RONS sources:
• Mitochondria
• NADPH oxidases
• Xanthine oxidase
• Uncoupled eNOS
Indirect determinants:
• Interacon with other signaling pathways (e.g. H2S, 
phosphorylaon, Ca2+)
• Acvaon of intrinsic anoxidant defense (e.g. Nrf2, HIF1)
• Acvaon of inflammatory signaling pathways (e.g. NFκB)
• Changes of epigenec profiles and long-term reprogramming
Effects:
• Beneficial/essenal: cellular redox signaling, (ischemic) 
precondioning, anpathogenic defense
• Detrimental/harmful: oxidave stress, vicious circles, cellular 
damage, cell death
Fig. 11.1. Who's the bad guy – or which biological source of RONS formation is the most detrimental one? Likely candidates are mitochondrial RONS formation (mitochondrial
superoxide/hydrogen peroxide), NADPH oxidases (Nox1, Nox2, Nox4, in humans also Nox3), uncoupled eNOS (uc-eNOS) or xanthine oxidase (XO). The most challenging task for the
future is the discrimination between beneficial and detrimental effects of RONS formation and signaling, which is largely determined by the nature of the involved RONS, as well as the
time and place they are formed. This concept was put forward previously [18,21,28,32].
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functional properties of SOD enzymes [774,775]. Most SODm are
considered polyfunctional antioxidants, rather than specific O2•- sca-
vengers [775–777]. Along with the disproportionation of O2•-, SODm
may react with other reactive species (RS), including peroxynitrite,
CO3•-, H2O2, •NO2 radicals, peroxyl radicals, and alkoxyl radicals
[775,776]. Although many compounds with SOD-like activity with
distinct chemical structures have been reported, the search for SOD
mimics has been mostly focused on complexes that contain a redox-
active metal center and rich coordination chemistry [776]. This is the
case of Mn(III) porphyrins (MnPs), Mn(II) complexes with cyclic
polyamines (aza crown ethers), Mn(III) salen derivatives, and different
types of iron and copper complexes [775,776,778,779]. Some non-
metallic compounds, such as nitroxides and fullerenes have also been
explored as SODm [776,779].
The rationale underling the use of SODm as prospective drugs in
cancer treatment is presented in Fig. 10.2. SODm, which lead to an
additional amount of H2O2 (Fig. 10.2B), may reduce cell proliferation
and increase the efficacy of chemo- and radiotherapy treatments in
cancer cells (pro-oxidative effects).
Conversely, SODm may promote the survival/proliferation of
normal cells, protecting them against adverse side effects observed in
standard medical treatments for cancer (antioxidant effects)
[768,776,778,780]. Finally, SODm can be used to give further mechan-
istic insights namely to assess the involvement of ROS in carcinogenesis
or in cancer therapy (Fig. 10.2).
Mechanistically, SODm can affect redox-based cellular transcrip-
tional activity by affecting reactive thiols of transcription factors (e.g.
NF-κB or KEAP1/NRF2) [776,777,780]. In line with this and according
to Natalia Robledinos-Antón and Antonio Cuadrado, NRF2 inhibitors
are being developed for cancer therapy [781], though a wide range of
NRF2 activators is already known. Most activators identified so far
target KEAP1 by oxidation or adduct formation [782]. These molecules
include allyl sulfides, dithiolethiones, flavonoids, isothiocyanates,
polyphenols and terpenoids, etc. Moreover, many of these electrophilic
compounds may also react with redox sensitive cysteines located in the
catalytic center of several phosphatases, thus up-regulating signaling
pathways that further impinge on NRF2 activation. The most successful
case reported so far of a drug targeting NRF2 is the ester derivative of
fumaric acid, dimethyl fumarate, which is used for treatment of
multiple sclerosis.
Ana S. Fernandes and Nuno G. Oliveira explain that although the
development of SODm started long ago, none has reached clinical use
yet, however, some SODm have been entering phase I/II clinical trials,
especially in combination with chemotherapy or radiotherapy regi-
mens. Some examples include MnPs, which are currently being studied
for radioprotection in late-stage glioma patients treated with concur-
rent radiotherapy and temozolamide. In addition, both MnPs and Mn
macrocycles are being assessed as radioprotectors in head & neck cancer
patients. A different SODm, Mangafodipir, was studied as a protector
against oxaliplatin neurotoxicity and FOLFOX6 side effects, while its
analog calmangafodipir is being studied in combination with FOLFOX6
in advanced metastatic colorectal cancer [http://clinicaltrials.gov, as of
22nd June 2016].
In summary, there are several therapeutic opportunities for SODm
in oncology. These compounds can increase the therapeutic index of
chemo- and radiotherapy by boosting the efficacy of such treatments in
cancer cells, while counteracting major drug and radiation toxicity
issues.
10.4.2. ROS and non-malignant disease
Although the above-mentioned SODm may be beneficial in cancer
therapy, it is so far unknown whether their antioxidant effect could be
of use in other diseases where oxidative stress occurs without proper
malignancy. As indicated by Marios Phylactides and Marina
Kleanthous, such a disease is β-thalassemia – an autosomal recessive
red blood cell disorder characterized by a reduction or complete
absence of β-globin chain production, globin chain imbalance and the
accumulation of α-globins.
Precipitation and autoxidation of excess α-globins lead to the
generation of high levels of ROS as well as the release of free heme
and iron. Hemolysis, secondary iron overload, often the result of
regular blood transfusions and increased absorption of dietary iron in
the gut, as well as ineffective erythropoiesis overwhelm the patients'
antioxidant defense systems, giving rise to severe oxidative stress,
anemia and secondary complications [783].
Overall, Marios Phylactides and Marina Kleanthous mention that
the recurring theme seen in most of the trials involving β-thalassemia
patients is an improvement of the oxidant-antioxidant imbalance for the
duration of the trial with a decrease of oxidative stress markers (e.g.
ROS levels, RBC malondialdehyde concentration, lipid peroxidation)
and enhancement of the patients’ antioxidant status (e.g. RBC SOD,
glutathione peroxidase, reduced glutathione). However, with some rare
exceptions [784,785], there is no improvement of the patients' anemia,
and no effect on hemoglobin levels. Thus, antioxidant supplements
undoubtedly have a beneficial role in the management of β-thalasse-
mia; however, they do not substitute for blood transfusions and iron
chelation in patients with the most severe anemia, but they can feature
more prominently in milder, transfusion-independent forms of the
disease.
Given the central role of ROS in the pathophysiology of the disease,
Lidija Milković, and Višnja Stepanić indicate that the use of antiox-
idants as a means of reducing oxidative damage is an attractive
therapeutic option. A wide variety of compounds have been tested in
this context without, however, becoming established as an indispen-
sable part of the patients’ treatment regime. Some of the antioxidant
compounds under investigation are food products or herbal extracts,
which are used as supplements or form part of the normal diet (e.g.
vitamin E [784,786,787], resveratrol [788], curcuminoids [784,789],
N-acetylcysteine [785]), CoQ10 [790], green tea [791], fermented
papaya preparation [792], or the thistle Silybum marianum (L.) extract
silymarin [793,794].
The latter appears to be one of the most interesting and, as discussed
by Vladimir Kren and Katerina Valentova, silymarin's major active
constituent silybin (CAS no. 22888-70-6; syn. silibinin) is a typical
radical scavenger per se [795,796]. However, in addition to its radical
scavenging activity, this compound selectively interacts with various
specific receptors and signaling molecules such as the estrogen receptor
[797]. This effect was found to account for the proapoptotic activity of
silybin in MCF-7 breast cancer cells [798]. Silybin also targets p53, NF-
κB or Wnt/β-catenin signaling in various cancer cells, thus affecting
mitogenesis, cell cycle, apoptosis, autophagy, and angiogenesis. Its
ability to reverse the P-glycoprotein mediated multi-drug resistance in
small lung carcinoma [799] partially explains its chemopreventive and
chemoprotective activity [800,801]. Moreover, the ability of silybin to
bind to the α-amanitin binding site of RNA polymerase II is probably
responsible for its antidote effect in Amanita poisoning [802]. Alto-
gether, the role and the mode of action of this traditional and well
known chemoprotectant needs to be substantially revised in the future.
10.5. ROS, antioxidants and therapeutic options
In addition to the beneficial effects of antioxidant supplements in
mild β-thalassemia, their action may not always be a direct antiradical
(scavenging) action, as discussed by Lidija Milković and Višnja
Stepanić. Although the ability to reduce the amount of ROS in vitro
still remains to be an important stage in the evaluation of the
antioxidant potency of any new or known compounds [803], this
approach is challenged because: і) many known antioxidants do not
show direct antiradical activity in vivo and vice versa [31]; іі) proved
antioxidants (e.g. flavonoids, PUFAs as part of fish/plant oils) exhibit a
dual role acting as antiradical and prooxidant agents simultaneously
[804]; and ііі) effects of the known antioxidants are mostly related to
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their indirect action [31,805].
Hence, more specific therapeutic options need to be used and
accordingly first generations of specific compounds (e.g. NOX inhibi-
tors, NRF2 activators, myeloperoxidase inhibitors) are being developed
for application in a wide range of diseases including metabolic, fibrotic,
and neurodegenerative diseases as well as cancer [32]. The validation
of the specificity of these drugs is highly dependent on the availability
of specific target engagement and functional assays. Since the redox
reactions are complex and often redundant, the careful use of tools for
measuring ROS is important to select drugs, identify potential non-
specific effects and evaluate their mode of action [806].
Tamara Seredenina and Vincent Jaquet indicate that currently,
countless chemical probes are used to detect ROS, all with advantages
and limitations; it is therefore advisable to use several of them and it is
critical to control the types of ROS with which they react [807]. On this
matter, it is worth mentioning the innovative use of the cell-permeable
small molecule dihydroethidine as it allows detection of specific
oxidants and their quantification both in vitro [808] and in vivo
[809,810]. Genetically encoded probes are also great tools for detecting
intracellular H2O2 localization and real time monitoring [56] and may
prove essential for redox dynamics; they also allow visualization of the
redox state directly in paraformaldehyde fixed tissues [811].
The more specific design of redox active compounds together with
the selection of appropriate druggable biological targets should en-
compass different in silico approaches and in vitro assays for prediction
and measurement, respectively, of their various redox activities. In
addition to standard cell-free assays that allow evaluation of the
antioxidant properties of new compounds [e.g. DPPH scavenging
method, Trolox equivalent antioxidant capacity (TEAC) method,
ABTS radical cation decolorization assay, Ferric reducing-antioxidant
power (FRAP) assay or hydroxyl radical averting capacity (HORAC)
method], in vitro models of different cancer and normal cells should be
used [812]. In vivo, KO mouse models are to be used to prove the
specificity of action of a drug on a given target. They may, according to
Danylo Kaminskyy, Khrystyna Semen, and Olha Yelisyeyeva, enable
evaluation of a compounds’ cytotoxicity and possible selectivity (e.g.
toxic to cancer but not to normal cells), pro-oxidative activity (mea-
sured as ROS generation), as well as endogenous antioxidative
response; whether they are added alone or in combination with known
drugs to evaluate any possible synergistic effect.
Despite these advantages and a strong rationale for therapeutic
targeting of ROS and redox pathways, it is not known why the
antioxidants used so far in clinical trials/therapies did not exert the
expected effects [216]. Dose and combination regimen, or duration of
treatment, may be partial reasons. Indeed, in those studies high
antioxidant doses were usually applied, and some actions such as the
prooxidant action of some antioxidants as discussed above have been
neglected. Moreover, patients were usually not tested for antioxidant
deficiencies and/or compliance as in the EPIC clinical trial [813].
10.6. Conclusion
Altogether, in almost all living organisms ROS cannot simply be
considered as detrimental since they contribute to signaling, as well as
to maintenance of integrity and homeostasis in different organisms
ranging from bacteria to mammals. In the latter, disturbances of ROS
homeostasis can contribute to the pathogenesis of several chronic
diseases such as atherosclerosis, type II diabetes, and cancer via
modulation of diverse processes such as inflammation, and the immune
response. The common associated increase in ROS in these diseases
points to the therapeutic use of small molecules with antioxidant
function; however, so far little or no benefit could be observed from
the large scale studies with antioxidant supplementation. Overall, these
findings signify that further improvement is needed in our knowledge
about ROS, ROS-targets, antioxidants, measurement techniques, and
their connection to homeostasis and diseases.
11. Concluding remarks
Andreas Daiber and Fabio Di Lisa.
The last decade has witnessed intense research related to the
implications of ROS in cellular pathology with special emphasis on
the identification of sources, biochemical reactions and cellular effec-
tors responsible for final pathophysiological outcomes. The recognition
of RONS as conveyors of physiological signals has added a new level of
understanding to their function and has generated contradictory
observations regarding the effects of antioxidant molecules, which we
are only beginning to unravel. Studies in the context of whole organs
both in their healthy and diseased state have expanded the importance
of RONS regulation in unpredicted settings. The previous sections
highlight some interesting examples of these aspects and also reflects
the major achievements of the EU-ROS consortium, evidencing how
redox biology is slowly but inexorably evolving towards redox medi-
cine, a concept also put forward in [30,814].
Unfortunately, conclusive and precise answers are still needed and
the world of redox biology and medicine still has challenges. The
notions on the relevant sources might look obvious, yet it is not clear
which are the most important ones under physiological and pathologi-
cal conditions. In addition, it is not clear how much the various RONS
are compartmentalized, especially within a given cell. Thirdly, it is still
difficult to monitor RONS formation due to limitations that still affect
their assessment. Fourthly, the discussion is open on why and how the
same molecules might mediate physiological and pathological events. It
is likely that a threshold of RONS levels exists separating beneficial
effects from contribution to cell injury. The definition of this threshold,
that is likely to be different in healthy and diseased cells, requires
quantitative methods that are hardly available. The identification of
beneficial levels as opposed to detrimental ones should allow defining
and/or predicting the consequences of changes in RONS levels, and
how “good” RONS can change into “bad” ones. This last issue is
obviously crucial and necessary for the proper translation of experi-
mental findings into clinical settings. This applies not only to the
development of focused, if not personalized, therapeutic approaches,
but also to diagnostic procedures and disease monitoring. Although
providing the correct answers to the above defined questions seems
daunting, we hope that future studies and technological advances will
clarify the unsolved issues leading to an improved control of cardiac,
neurodegenerative, metabolic and inflammatory diseases. These con-
cepts have been laid down by members of the EU-ROS consortium
within 3 major coordinated collections of position papers, reviews and
original articles published by our members [1–4] (Fig. 11.1).
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